risperidone has been researched along with Weight Gain in 265 studies
Risperidone: A selective blocker of DOPAMINE D2 RECEPTORS and SEROTONIN 5-HT2 RECEPTORS that acts as an atypical antipsychotic agent. It has been shown to improve both positive and negative symptoms in the treatment of SCHIZOPHRENIA.
risperidone : A member of the class of pyridopyrimidines that is 2-methyl-6,7,8,9-tetrahydropyrido[1,2-a]pyrimidin-4-one carrying an additional 2-[4-(6-fluoro-1,2-benzoxazol-3-yl)piperidin-1-yl]ethyl group at position 2.
Weight Gain: Increase in BODY WEIGHT over existing weight.
| Excerpt | Relevance | Reference |
|---|---|---|
| "These results suggest that the antioxidant defense system may have predictive value for the weight gain of ANFE SCZ patients after risperidone treatment." | 9.51 | Antioxidant Enzymes and Weight Gain in Drug-naive First-episode Schizophrenia Patients Treated with Risperidone for 12 Weeks: A Prospective Longitudinal Study. ( Gao, Y; Guan, X; Li, X; Liu, H; Thomas, K; Xiu, M; Yu, R; Zhang, X, 2022) |
| "Paliperidone palmitate 3-monthly (PP3M) injectable formulation offers an advantage of improved medication adherence and lower relapse risk in patients with schizophrenia." | 9.27 | Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis. ( Alphs, L; Gopal, S; Hough, D; Mathews, M; Nuamah, I; Pei, H; Savitz, A, 2018) |
| "This study compares the efficacy and tolerability of olanzapine versus risperidone among patients with schizophrenia who are established in outpatient psychiatric care and entering supported employment." | 9.24 | Risperidone versus olanzapine among patients with schizophrenia participating in supported employment: Eighteen-month outcomes. ( Glynn, SM; Marder, SR; Noordsy, DL; O'Keefe, CD; Sugar, CA, 2017) |
| "Body iron stores are inversely related to risperidone-induced weight gain, even after extended treatment and despite adequate iron intake." | 9.22 | Serum Ferritin, Weight Gain, Disruptive Behavior, and Extrapyramidal Symptoms in Risperidone-Treated Youth. ( Arnold, LE; Calarge, CA; Murry, DJ; Ziegler, EE, 2016) |
| "We examine weight gain and metabolic consequences of risperidone monotherapy in children with autism spectrum disorder (ASD)." | 9.22 | Weight Gain and Metabolic Consequences of Risperidone in Young Children With Autism Spectrum Disorder. ( Aman, MG; Arnold, LE; Boorin, SJ; Caprio, S; Challa, SA; Deng, Y; Dziura, J; Jeon, S; McCracken, JT; McDougle, CJ; Nicol, G; Scahill, L; Vitiello, B, 2016) |
| "Risperidone has demonstrated efficacy for acute (8 week) and intermediate length (6 month) management of severe irritability and aggression in children and adolescents with autism." | 9.20 | Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial. ( Aman, M; Arnold, LE; Ghuman, J; Grados, M; Hellings, J; Hollway, JA; McCracken, J; McDougle, CJ; Nagaraja, HN; Posey, DJ; Rettiganti, M; Scahill, L; Shah, B; Swiezy, NB; Tierney, E; Vitiello, B, 2015) |
| "This randomized, double-blind study compared the efficacy and safety of blonanserin and risperidone to treat Chinese schizophrenia patients aged ≥18 and < 65 years." | 9.20 | Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial. ( Gu, N; Li, H; Li, J; Li, K; Li, L; Liu, C; Luo, X; Qi, S; Shi, J; Wang, C; Wang, L; Wang, Q; Yang, F; Yao, C; Zhang, H, 2015) |
| "This study was designed to investigate long-term clinical outcomes of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder." | 9.19 | A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea. ( Ahn, YM; Cho, SJ; Chung, YC; Jung, IK; Kim, CY; Kim, DH; Kim, SH; Kim, YS; Lee, DG; Lee, NY; Lee, YH; Lim, WJ; Na, YS; Shin, SE; Woo, JM; Yoon, BH; Yoon, JS, 2014) |
| "Antipsychotics, such as aripiprazole and risperidone, are often used to treat individuals with schizophrenia." | 9.19 | Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial. ( Gu, N; Kane, JM; Li, H; Luo, J; Wang, C; Wang, X; Xie, S; Xu, X; Yu, W, 2014) |
| "Riluzole add-on therapy shows several therapeutic outcomes, particularly for improving irritability, in children with autism." | 9.17 | Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial. ( Akhondzadeh, S; Ashrafi, M; Farokhnia, M; Ghaleiha, A; Hassanzadeh, E; Modabbernia, A; Mohammadi, E; Mohammadi, MR; Yekehtaz, H, 2013) |
| "The association between 5 ANKK1, 54 DRD2, and 11 HTR2C SNPs and weight change during 8 weeks of olanzapine treatment was assessed in 4 pooled studies of 205 white patients with diagnoses other than schizophrenia who were generally likely to have had limited previous antipsychotic exposure." | 9.16 | Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. ( Bishop, JR; Conley, RR; Ellingrod, VL; Fijal, BA; Houston, JP; Kohler, J; Ostbye, KM; Poole Hoffmann, V; Zhao, F, 2012) |
| "Eight patients with psychotic disorders (ages 11-17) who had started risperidone (mean: 1." | 9.14 | Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment. ( Maayan, LA; Vakhrusheva, J, 2010) |
| "The study aimed to evaluate the efficacy of long-acting injectable risperidone (LAR) in Asian patients with schizophrenia spectrum disorders." | 9.14 | Safety and efficacy of long-acting injectable risperidone in patients with schizophrenia spectrum disorders: a 6-month open-label trial in Asian patients. ( Abdin, E; Chong, SA; Lee, N; Sim, K; Su, A; Subramaniam, M; Verma, S, 2010) |
| "The objective of this study was to evaluate the efficacy and tolerability of blonanserin for the treatment of Korean patients with schizophrenia using a double-blind risperidone-compared design." | 9.14 | Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial. ( Bahk, WM; Cho, HS; Jeon, YW; Jon, DI; Jung, HY; Kim, CH; Kim, HC; Kim, SH; Kim, YH; Kim, YK; Kwon, JS; Lee, SH; Lee, SY; Yang, J; Yi, JS; Yoon, BH, 2010) |
| "Weight gain is an important adverse effect of risperidone, but predictors of significant weight gain have yet to be identified in pediatric patients." | 9.14 | Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene. ( Anderson, GM; Buitelaar, JK; Franke, B; Hoekstra, PJ; Lahuis, BE; Minderaa, RB; Mulder, EJ; Mulder, H; Scahill, L; Troost, PW, 2010) |
| "To evaluate the effect of metformin treatment on the risperidone-induced body weight gain in patients." | 9.13 | A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. ( Arman, S; Koleini, N; Nadi, M; Sadramely, MR, 2008) |
| "The aim of the study was to investigate safety, efficacy and tolerability of risperidone in comparison with haloperidol in the long-term treatment of autistic disorder." | 9.13 | Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. An open label maintenance study. ( Baykara, A; Baykara, B; Dirik, E; Emiroglu, FN; Gencer, O; Miral, S, 2008) |
| "To quantify the weight gain induced by first (haloperidol) and second generation antipsychotics (olanzapine and risperidone) in a cohort of drug-naïve subjects after 1 year of treatment." | 9.13 | Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population. ( Alvarez-Jimenez, M; Amado, JA; Crespo-Facorro, B; Garcia-Unzueta, MT; Martinez-Garcia, O; Pelayo-Teran, JM; Perez-Iglesias, R; Ramirez-Bonilla, ML; Vazquez-Barquero, JL, 2008) |
| "Newly diagnosed patients with first-episode schizophrenia treated with antipsychotic medication-olanzapine, risperidone, or haloperidol-and matched healthy controls were followed for 6 weeks." | 9.13 | Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. ( Akhtar, S; Ameen, S; Saddichha, S, 2008) |
| " The aim of this study was to investigate the phenomenology of SIB in a group of children with autistic disorder, and to test whether treatment with risperidone might reduce it." | 9.12 | Self injurious behavior in autism: clinical aspects and treatment with risperidone. ( Canitano, R, 2006) |
| " This study aimed to simultaneously explore the effects of multiple candidate genes and environment factors on body weight of schizophrenia patients who received risperidone, a commonly used atypical antipsychotic agent." | 9.12 | Risperidone-related weight gain: genetic and nongenetic predictors. ( Chang, WH; Chang, YC; Huang, CL; Lane, HY; Liu, YC; Lu, CT; Wu, PL, 2006) |
| "The authors compared 4-month treatment outcomes for olanzapine versus risperidone in patients with first-episode schizophrenia spectrum disorders." | 9.12 | Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. ( Gunduz-Bruce, H; Kane, JM; Khadivi, A; Lesser, ML; Lorell, BS; McCormack, J; Mendelowitz, A; Miller, R; Napolitano, B; Patel, RC; Robinson, DG; Schooler, NR; Sevy, SM; Soto-Perello, JM; Woerner, MG, 2006) |
| "In two double-blind studies, 552 adult and elderly patients with schizophrenia or schizoaffective disorder were randomly assigned to risperidone or olanzapine treatment for 8 weeks." | 9.11 | Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications. ( Gharabawi, G; Lasser, RA; Mao, L, 2004) |
| "The aim of the present study was to evaluate the effectiveness and tolerability of risperidone in children with autistic disorder and to examine the correlation between plasma levels of risperidone and its active metabolite 9-hydroxyrisperidone (9-OH-risperidone) and the clinical response." | 9.11 | Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. ( Calamoneri, F; D'Arrigo, C; Gagliano, A; Germanò, E; Impallomeni, C; Pustorino, G; Spina, E, 2004) |
| "Weight change was measured for 63 children and adolescents with autism treated with risperidone for 6 months." | 9.11 | Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. ( Aman, M; Anderson, GM; Arnold, LE; Chuang, S; Martin, A; McCracken, J; McDougle, CJ; Scahill, L; Tierney, E; Vitiello, B, 2004) |
| "Data on risperidone's efficacy and tolerability in adolescents with schizophrenia are scarce." | 9.10 | Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. ( Bensason, D; Carmon, E; Martin, A; Tyano, S; Weizman, A; Zalsman, G, 2003) |
| "The results suggest that risperidone treatment is not associated with weight gain among elderly persons with chronic psychosis." | 9.10 | No weight gain among elderly schizophrenia patients after 1 year of risperidone treatment. ( Barak, Y, 2002) |
| "Adding the atypical neuroleptic risperidone to a serotonin reuptake inhibitor (SRI) has benefited patients with treatment-refractory obsessive-compulsive disorder (OCD)." | 9.09 | Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. ( Elliott, MA; Koran, LM; Ringold, AL, 2000) |
| "Subjects (N=377) who met DSM-IV criteria for schizophrenia or schizoaffective disorder were randomly assigned to receive 2-6 mg/day of risperidone (mean modal dose=4." | 9.09 | A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. ( Conley, RR; Mahmoud, R, 2001) |
| "Clinical factors predicting weight change in patients with schizophrenia and related disorders during acute treatment with the antipsychotic drugs olanzapine, risperidone, and haloperidol were sought through retrospective analyses." | 9.09 | Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. ( Basson, BR; Gilmore, JA; Kinon, BJ; Szymanski, KA; Taylor, CC; Tollefson, GD, 2001) |
| "As part of an ongoing, prospective, ABA design, double-blind crossover study of risperidone versus placebo for the treatment of aggressive, destructive and self-injurious behavior in persons aged 6-65 years with mental retardation (MR) and autism, we measured the weight of 19 subjects at each study visit." | 9.09 | Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. ( Crandall, K; Hellings, JA; Schroeder, SR; Wallace, D; Zarcone, JR, 2001) |
| "Risperidone is more effective than placebo in the short-term treatment of symptoms of autism in adults." | 9.08 | A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. ( Carlson, DC; Cohen, DJ; Holmes, JP; McDougle, CJ; Pelton, GH; Price, LH, 1998) |
| "Between 40% and 70% of people with treatment-resistant schizophrenia do not respond to clozapine, despite adequate blood levels." | 8.95 | Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. ( Barber, S; Cipriani, A; Corsi, M; Olotu, U, 2017) |
| "To conduct meta-analyses of all published association studies on the HTR2C -759C/T (rs3813829) polymorphism and olanzapine-induced weight gain in schizophrenia patients and on the HTR2C -759C/T, -697G/C (rs518147) and rs1414334:C> G polymorphisms and olanzapine/clozapine/risperidone-induced metabolic syndrome in schizophrenia patients." | 8.90 | HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis. ( Gui, X; Hu, G; Ma, X; Maimaitirexiati, T; Xu, G; Zhang, R; Zhang, W, 2014) |
| "A systematic and comprehensive literature search was performed to determine the extent of weight gain induced by risperidone (RIS) treatment across the age span." | 8.82 | A comparison of risperidone-induced weight gain across the age span. ( Safer, DJ, 2004) |
| "This study aimed to assess weight changes following antipsychotic treatment in first-episode schizophrenia (FES) patients and make a comparison of aripiprazole, risperidone and olanzapine." | 8.31 | Weight changes following treatment with aripiprazole, risperidone and olanzapine: A 12-month study of first-episode schizophrenia patients in China. ( Cheng, Z; Gao, T; Huang, B; Huang, Z; Pu, C; Shi, C; Yu, X; Zhang, D; Zheng, Y; Zhou, E; Zhou, T, 2023) |
| "Atypical antipsychotics such as risperidone cause drug-induced metabolic syndrome." | 8.02 | The atypical antipsychotic risperidone targets hypothalamic melanocortin 4 receptors to cause weight gain. ( Arnold, AG; Birnbaum, SG; Chen, X; Jia, L; Li, L; Li, X; Liu, C; Sohn, JW; Wan, R; Wyler, SC; Yoo, ES, 2021) |
| "Many patients taking risperidone for the treatment of psychiatric disorders experience substantial body weight gain." | 7.96 | Risperidone stimulates food intake and induces body weight gain via the hypothalamic arcuate nucleus 5-HT2c receptor-NPY pathway. ( Huang, XF; Lin, S; Shi, YC; Wan, XQ; Wang, L; Yang, HQ; Zeng, F; Zhang, ZH, 2020) |
| "This study demonstrated that there was no significant difference in weight gain between risperidone and aripiprazole users during the first year of treatment." | 7.91 | No Differences in Weight Gain Between Risperidone and Aripiprazole in Children and Adolescents After 12 Months. ( Beex-Oosterhuis, MM; Dieleman, HG; Eussen, MLJM; Schoemakers, RJ; van Kesteren, C; van Rosmalen, J, 2019) |
| "The aim of this study was to explore the effectiveness and tolerability of long-acting paliperidone palmitate antipsychotic in adolescent first-episode schizophrenia patients while comparing the results with the oral antipsychotic risperidone." | 7.91 | Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First-Episode Schizophrenia Patients. ( Gačo, N; Graovac, M; Kaštelan, A; Petrić, D; Rački, V, 2019) |
| "To analyze weight gain, metabolic hormones, and homocysteine (Hcys) levels in children and adolescents on antipsychotics (AP) during a year-long follow-up." | 7.85 | The effects of antipsychotics on weight gain, weight-related hormones and homocysteine in children and adolescents: a 1-year follow-up study. ( Arango, C; Baeza, I; Calvo-Escalona, R; Castro-Fornieles, J; de la Serna, E; Merchán-Naranjo, J; Rodríguez-Latorre, P; Vigo, L, 2017) |
| "The atypical antipsychotic risperidone (RSP) is often associated with weight gain and cardiometabolic side effects." | 7.81 | Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children. ( Azcarate-Peril, MA; Bahr, SM; Burns, TL; Butcher, BD; Calarge, CA; Kirby, JR; Oltman, CL; Teesch, LM; Tyler, BC; Wooldridge, N, 2015) |
| "SLC6A4 might be susceptible gene for risperidone-induced weight gain within the Chinese Han population." | 7.81 | A pharmacogenomic study revealed an association between SLC6A4 and risperidone-induced weight gain in Chinese Han population. ( Du, B; Li, K; Liu, C; Lu, T; Lv, L; Ma, C; Ma, W; Mi, W; Wang, F; Wang, L; Yang, Y; Yue, W; Zhang, D; Zhang, H, 2015) |
| "Risperidone is a second-generation antipsychotic that causes weight gain." | 7.81 | Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure. ( Bahr, SM; Burnett, CM; Castro, AN; deLeon, O; Grobe, JL; Kirby, JR; Murry, DJ; Pearson, NA; Walsh, JW; Weidemann, BJ, 2015) |
| "The FTO gene polymorphisms, especially rs9939609, seem to be related to weight gain after risperidone treatment in Chinese Han patients with first episode schizophrenia." | 7.80 | Fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia. ( Fan, X; Feng, Y; Gao, J; Li, X; Lv, L; Nemani, K; Pang, L; Song, X; Zhang, H; Zhang, J; Zhang, W, 2014) |
| "This study assessed clinical and functional outcomes following a switch from risperidone to olanzapine in a 1-year naturalistic study of schizophrenia patients in Japan." | 7.78 | Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan. ( Ascher-Svanum, H; Fujikoshi, S; Nakahara, N; Ohmori, T; Takahashi, M; Ye, W, 2012) |
| "Weight gain and metabolic disturbances, such as dyslipidemia and hyperglycaemia, are common side effects of most antipsychotic drugs, including risperidone." | 7.77 | Overweight induced by chronic risperidone exposure is correlated with overexpression of the SREBP-1c and FAS genes in mouse liver. ( Bordet, R; Bouchaert, E; Cussac, D; Duriez, P; Helleboid, A; Hum, D; Lauressergues, E; Luc, G; Majd, Z; Martin, F; Staels, B, 2011) |
| "(1) To determine bone remodeling parameters and bone mass in patients with schizophrenia on long-term treatment with long-acting injectable risperidone (LAIR) in naturalistic settings, and (2) to evaluate the change in body weight, metabolic profile and neuroendocrine status in these patients." | 7.77 | Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone. ( Britvic, D; Damjanovic, A; Doknic, M; Jasovic Gasic, M; Maric, NP; Miljic, D; Pekic, S; Popovic, V; Radojicic, Z; Stojanovic, M, 2011) |
| "Despite the limited number of children included, our results confirm a strong link between prescription of risperidone in EOS and risk of obesity." | 7.76 | [Metabolic side effects of risperidone in early onset schizophrenia]. ( Bordet, R; Delion, P; Duhamel, A; Goeb, JL; Jardri, R; Kechid, G; Marco, S; Thomas, P, 2010) |
| "The long-term use of risperidone, especially when weight is above normal, is associated with a number of metabolic abnormalities but a low prevalence of the metabolic syndrome phenotype." | 7.75 | Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. ( Acion, L; Calarge, CA; Kuperman, S; Schlechte, JA; Tansey, M, 2009) |
| " We aimed to investigate the association between risperidone-induced weight gain, leptin concentration, and the leptin gene (LEP) -2548G/A variants in youths." | 7.75 | Leptin gene -2548G/A variants predict risperidone-associated weight gain in children and adolescents. ( Acion, L; Calarge, CA; Ellingrod, VL; Schlechte, JA; Sivitz, WI; Zimmerman, B, 2009) |
| "The aim of this study was to evaluate long-term weight gain associated with clozapine, olanzapine, and risperidone treatment and its clinical risk factors in children and adolescents." | 7.74 | Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone. ( Fleischhaker, C; Heiser, P; Hennighausen, K; Herpertz-Dahlmann, B; Holtkamp, K; Mehler-Wex, C; Rauh, R; Remschmidt, H; Schulz, E; Warnke, A, 2008) |
| "Risperidone has a relatively low risk of causing obesity and diabetes mellitus and is a first-line treatment for schizophrenia." | 7.74 | Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. ( Hosoda, H; Inoue, T; Itoh, K; Izumi, T; Kangawa, K; Koyama, T; Kusumi, I; Murashita, M; Nakagawa, S; Tanaka, T, 2007) |
| "We compared fasting lipids and other metabolic parameters in 211 normoglycemic patients meeting the DSM-IV diagnosis of schizophrenia or schizoaffective disorder undergoing continuous treatment with olanzapine, risperidone, or typical antipsychotics for at least 1 year." | 7.73 | Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics. ( Cavazzoni, P; Hardy, TA; Kryzhanovskaya, L; Marquez, E; Taylor, CC, 2006) |
| "Outpatients diagnosed of schizophrenia according to DSM-IV criteria and receiving a single antipsychotic (risperidone, olanzapine, quetiapine or haloperidol) for at least 4 weeks were consecutively recruited." | 7.72 | Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. ( Bobes, J; Fernández, I; Garcia-Garcia, M; García-Portilla, MP; Hernández, G; Rejas, J; Rico-Villademoros, F, 2003) |
| "Our results support the previously reported positive impact of atypical antipsychotics, particularly olanzapine, in patients with schizophrenia." | 7.72 | Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. ( Bitter, I; Boland, J; Dossenbach, M; el Mahfoud Kessaci, M; Erol, A; Hodge, A; O'Halloran, RA; Shaheen, MO; Sunbol, MM, 2004) |
| "Treatment with olanzapine was associated with significantly greater weight gain than treatment with risperidone in Chinese schizophrenia patients in Hong Kong." | 7.72 | Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone. ( Lee, E; Leung, CM; Wong, E, 2004) |
| "Olanzapine and risperidone use was associated with gaining weight in the first year, but only olanzapine was associated with developing diabetes mellitus." | 7.72 | Weight gain and new onset diabetes associated with olanzapine and risperidone. ( Farwell, WR; L'Italien, G; Stump, TE; Tafesse, E; Tierney, WM; Wang, J, 2004) |
| "The current investigation lends support to data that note weight gain with risperidone in adults with mental retardation." | 7.71 | Weight gain with risperidone among patients with mental retardation: effect of calorie restriction. ( Cohen, S; Glazewski, R; Khan, A; Khan, S, 2001) |
| " In order to determine whether newer antipsychotic agents differ from each other with respect to weight gain, we compared two cohorts of patients with DSM-IV schizophrenia who had newly started treatment with either risperidone or olanzapine." | 7.71 | Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone. ( Ayrton, Z; Brar, JS; Ganguli, R, 2001) |
| "To evaluate weight gain associated with olanzapine, risperidone, and haloperidol treatment and its clinical risk factors in adolescent patients." | 7.71 | Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. ( Apter, A; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Phillip, M; Ratzoni, G; Reidman, J; Weizman, R, 2002) |
| "Risperidone use has been associated with substantial weight gain in children and adolescents." | 7.70 | Risperidone-associated weight gain in children and adolescents: a retrospective chart review. ( Cicchetti, D; Landau, J; Leckman, JF; Leebens, P; Martin, A; Scahill, L; Ulizio, K, 2000) |
| " In the TDM group, physicians will receive dosing advice based on plasma levels of risperidone and aripiprazole and its metabolites at 4 and 10 weeks." | 7.11 | The effect of therapeutic drug monitoring of risperidone and aripiprazole on weight gain in children and adolescents: the SPACe 2: STAR (trial) protocol of an international multicentre randomised controlled trial. ( de Winter, BCM; Dierckx, B; Hermans, RA; Hillegers, MHJ; Kloosterboer, SM; Koch, BCP; Liang, K; Ringeling, LT, 2022) |
| "Weight gain is an important side effect of antipsychotic (AP) treatment." | 6.71 | The relationship of changes in leptin, neuropeptide Y and reproductive hormones to antipsychotic induced weight gain. ( de Castella, AR; Fitzgerald, PB; Kulkarni, J; Morris, MJ; Scaffidi, A, 2003) |
| "Risperidone doses were low (0." | 6.69 | Risperidone for young children with mood disorders and aggressive behavior. ( Schreier, HA, 1998) |
| "Weight gain is a serious side effect of antipsychotic therapy." | 6.69 | Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. ( Conley, RR; Horn, DS; Kelly, DL; Love, RC; Ushchak, CM, 1998) |
| "These results suggest that the antioxidant defense system may have predictive value for the weight gain of ANFE SCZ patients after risperidone treatment." | 5.51 | Antioxidant Enzymes and Weight Gain in Drug-naive First-episode Schizophrenia Patients Treated with Risperidone for 12 Weeks: A Prospective Longitudinal Study. ( Gao, Y; Guan, X; Li, X; Liu, H; Thomas, K; Xiu, M; Yu, R; Zhang, X, 2022) |
| "Risperidone was added to culture medium in clinically relevant doses of 0, 2." | 5.38 | Trabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gain. ( Baron, R; Bornstein, S; de Paula, FJ; Dick-de-Paula, I; Houseknecht, KL; Lotinun, S; Maloney, AE; Motyl, KJ; Rosen, CJ, 2012) |
| "Body weight gain was observed with both the drugs, although a sex-related differential response was noted." | 5.36 | Effect of lactational exposure of olanzapine on body weight of mice: a comparative study on neonates of both the sexes during post-natal development. ( Mishra, AC; Mohanty, B, 2010) |
| "Haloperidol patients were more often single and institutionalised, less educated, had more residual schizophrenia, were longer hospitalised in the previous year, took more corrective and psychotropic drugs and had more extrapyramidal symptoms (EPS) and gynaecomastia (all significantly)." | 5.35 | Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol. ( Albert, A; De Graeve, D; Gillain, B; Peuskens, J; Van Vleymen, B, 2009) |
| "Average weight gain was significantly higher for the olanzapine group (mean = 4." | 5.34 | Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents. ( Fleischhaker, C; Heiser, P; Hennighausen, K; Herpertz-Dahlmann, B; Holtkamp, K; Mehler-Wex, C; Rauh, R; Remschmidt, H; Schulz, E; Warnke, A, 2007) |
| "Risperidone was switched to another antipsychotic." | 5.34 | Risperidone-induced polydipsia and polyphagia associated with galactorrhea, abdominal pain, and rapid weight gain in an adolescent Hispanic female. ( Afzal, KI; Briones, DF; DeVargas, C, 2007) |
| "Risperidone treatment causes a greater increase in the body mass of patients than treatment with conventional antipsychotics, such as haloperidol." | 5.31 | Peripheral injection of risperidone, an atypical antipsychotic, alters the bodyweight gain of rats. ( Fujiwara, K; Itoh, M; Kaneko, YS; Mori, K; Nagasaka, A; Nakashima, A; Ota, A; Ota, M, 2002) |
| "Paliperidone palmitate 3-monthly (PP3M) injectable formulation offers an advantage of improved medication adherence and lower relapse risk in patients with schizophrenia." | 5.27 | Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis. ( Alphs, L; Gopal, S; Hough, D; Mathews, M; Nuamah, I; Pei, H; Savitz, A, 2018) |
| "This study compares the efficacy and tolerability of olanzapine versus risperidone among patients with schizophrenia who are established in outpatient psychiatric care and entering supported employment." | 5.24 | Risperidone versus olanzapine among patients with schizophrenia participating in supported employment: Eighteen-month outcomes. ( Glynn, SM; Marder, SR; Noordsy, DL; O'Keefe, CD; Sugar, CA, 2017) |
| "Body iron stores are inversely related to risperidone-induced weight gain, even after extended treatment and despite adequate iron intake." | 5.22 | Serum Ferritin, Weight Gain, Disruptive Behavior, and Extrapyramidal Symptoms in Risperidone-Treated Youth. ( Arnold, LE; Calarge, CA; Murry, DJ; Ziegler, EE, 2016) |
| "We examine weight gain and metabolic consequences of risperidone monotherapy in children with autism spectrum disorder (ASD)." | 5.22 | Weight Gain and Metabolic Consequences of Risperidone in Young Children With Autism Spectrum Disorder. ( Aman, MG; Arnold, LE; Boorin, SJ; Caprio, S; Challa, SA; Deng, Y; Dziura, J; Jeon, S; McCracken, JT; McDougle, CJ; Nicol, G; Scahill, L; Vitiello, B, 2016) |
| "Risperidone has demonstrated efficacy for acute (8 week) and intermediate length (6 month) management of severe irritability and aggression in children and adolescents with autism." | 5.20 | Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial. ( Aman, M; Arnold, LE; Ghuman, J; Grados, M; Hellings, J; Hollway, JA; McCracken, J; McDougle, CJ; Nagaraja, HN; Posey, DJ; Rettiganti, M; Scahill, L; Shah, B; Swiezy, NB; Tierney, E; Vitiello, B, 2015) |
| "This randomized, double-blind study compared the efficacy and safety of blonanserin and risperidone to treat Chinese schizophrenia patients aged ≥18 and < 65 years." | 5.20 | Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial. ( Gu, N; Li, H; Li, J; Li, K; Li, L; Liu, C; Luo, X; Qi, S; Shi, J; Wang, C; Wang, L; Wang, Q; Yang, F; Yao, C; Zhang, H, 2015) |
| "This study was designed to investigate long-term clinical outcomes of risperidone long-acting injectable (RLAI) in patients with schizophrenia or schizoaffective disorder." | 5.19 | A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea. ( Ahn, YM; Cho, SJ; Chung, YC; Jung, IK; Kim, CY; Kim, DH; Kim, SH; Kim, YS; Lee, DG; Lee, NY; Lee, YH; Lim, WJ; Na, YS; Shin, SE; Woo, JM; Yoon, BH; Yoon, JS, 2014) |
| "Antipsychotics, such as aripiprazole and risperidone, are often used to treat individuals with schizophrenia." | 5.19 | Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial. ( Gu, N; Kane, JM; Li, H; Luo, J; Wang, C; Wang, X; Xie, S; Xu, X; Yu, W, 2014) |
| "Riluzole add-on therapy shows several therapeutic outcomes, particularly for improving irritability, in children with autism." | 5.17 | Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial. ( Akhondzadeh, S; Ashrafi, M; Farokhnia, M; Ghaleiha, A; Hassanzadeh, E; Modabbernia, A; Mohammadi, E; Mohammadi, MR; Yekehtaz, H, 2013) |
| "Olanzapine and other second generation antipsychotics have been associated with weight gain, which may be related to changes in appetite and food intake." | 5.16 | Olanzapine and risperidone effects on appetite and ghrelin in chronic schizophrenic patients. ( Davis, JM; Dwivedi, S; Rachakonda, S; Smith, RC, 2012) |
| "From December 2004 through March 2008, adult outpatients with a Structured Clinical Interview for DSM-IV Axis I Disorders-Patient Edition diagnosis of schizophrenia or schizoaffective disorder who were taking haloperidol decanoate (n = 40) or fluphenazine decanoate (n = 22) were randomly assigned to stay on current long-acting injectable medication or switch to risperidone microspheres and followed for 6 months under study protocol and an additional 6 months naturalistic follow-up." | 5.16 | Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. ( Covell, NH; Essock, SM; Jackson, CT; McEvoy, JP; Rojas, IA; Schooler, NR; Stroup, TS, 2012) |
| "The association between 5 ANKK1, 54 DRD2, and 11 HTR2C SNPs and weight change during 8 weeks of olanzapine treatment was assessed in 4 pooled studies of 205 white patients with diagnoses other than schizophrenia who were generally likely to have had limited previous antipsychotic exposure." | 5.16 | Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia. ( Bishop, JR; Conley, RR; Ellingrod, VL; Fijal, BA; Houston, JP; Kohler, J; Ostbye, KM; Poole Hoffmann, V; Zhao, F, 2012) |
| " Patients, 13-17 years, with an acute episode of schizophrenia, randomised 1:1 to risperidone 1." | 5.14 | Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study. ( Augustyns, I; Eerdekens, M; Haas, M; Kushner, S; Kusumakar, V; Pandina, G; Quiroz, J; Singer, J, 2009) |
| "Eight patients with psychotic disorders (ages 11-17) who had started risperidone (mean: 1." | 5.14 | Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment. ( Maayan, LA; Vakhrusheva, J, 2010) |
| "The study aimed to evaluate the efficacy of long-acting injectable risperidone (LAR) in Asian patients with schizophrenia spectrum disorders." | 5.14 | Safety and efficacy of long-acting injectable risperidone in patients with schizophrenia spectrum disorders: a 6-month open-label trial in Asian patients. ( Abdin, E; Chong, SA; Lee, N; Sim, K; Su, A; Subramaniam, M; Verma, S, 2010) |
| "The objective of this study was to evaluate the efficacy and tolerability of blonanserin for the treatment of Korean patients with schizophrenia using a double-blind risperidone-compared design." | 5.14 | Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial. ( Bahk, WM; Cho, HS; Jeon, YW; Jon, DI; Jung, HY; Kim, CH; Kim, HC; Kim, SH; Kim, YH; Kim, YK; Kwon, JS; Lee, SH; Lee, SY; Yang, J; Yi, JS; Yoon, BH, 2010) |
| " We therefore examined the relationship between -141C Ins/Del (rs1799732), a functional promoter region polymorphism in DRD2, and antipsychotic-induced weight gain in 58 first episode schizophrenia patients enrolled in a randomized trial of risperidone versus olanzapine." | 5.14 | DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia. ( Goldman, D; Kane, JM; Lencz, T; Malhotra, AK; Napolitano, B; Robinson, DG; Sevy, S, 2010) |
| "Weight gain is an important adverse effect of risperidone, but predictors of significant weight gain have yet to be identified in pediatric patients." | 5.14 | Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene. ( Anderson, GM; Buitelaar, JK; Franke, B; Hoekstra, PJ; Lahuis, BE; Minderaa, RB; Mulder, EJ; Mulder, H; Scahill, L; Troost, PW, 2010) |
| "To evaluate the effect of metformin treatment on the risperidone-induced body weight gain in patients." | 5.13 | A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents. ( Arman, S; Koleini, N; Nadi, M; Sadramely, MR, 2008) |
| "The aim of the study was to investigate safety, efficacy and tolerability of risperidone in comparison with haloperidol in the long-term treatment of autistic disorder." | 5.13 | Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. An open label maintenance study. ( Baykara, A; Baykara, B; Dirik, E; Emiroglu, FN; Gencer, O; Miral, S, 2008) |
| "To quantify the weight gain induced by first (haloperidol) and second generation antipsychotics (olanzapine and risperidone) in a cohort of drug-naïve subjects after 1 year of treatment." | 5.13 | Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population. ( Alvarez-Jimenez, M; Amado, JA; Crespo-Facorro, B; Garcia-Unzueta, MT; Martinez-Garcia, O; Pelayo-Teran, JM; Perez-Iglesias, R; Ramirez-Bonilla, ML; Vazquez-Barquero, JL, 2008) |
| "Newly diagnosed patients with first-episode schizophrenia treated with antipsychotic medication-olanzapine, risperidone, or haloperidol-and matched healthy controls were followed for 6 weeks." | 5.13 | Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol. ( Akhtar, S; Ameen, S; Saddichha, S, 2008) |
| "There are several studies investigating the effects of risperidone on autism, but many of these studies are contradictory or inconclusive." | 5.12 | Effects of Risperidone in Autistic Children and Young Adults: A Systematic Review and Meta-Analysis. ( Alves, BC; Belo, VS; Chaves, VE; Duarte-Almeida, JM; Galduróz, JCF; Mano-Sousa, BJ; Pedrosa, AM, 2021) |
| " The aim of this study was to investigate the phenomenology of SIB in a group of children with autistic disorder, and to test whether treatment with risperidone might reduce it." | 5.12 | Self injurious behavior in autism: clinical aspects and treatment with risperidone. ( Canitano, R, 2006) |
| " This study aimed to simultaneously explore the effects of multiple candidate genes and environment factors on body weight of schizophrenia patients who received risperidone, a commonly used atypical antipsychotic agent." | 5.12 | Risperidone-related weight gain: genetic and nongenetic predictors. ( Chang, WH; Chang, YC; Huang, CL; Lane, HY; Liu, YC; Lu, CT; Wu, PL, 2006) |
| "The authors compared 4-month treatment outcomes for olanzapine versus risperidone in patients with first-episode schizophrenia spectrum disorders." | 5.12 | Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes. ( Gunduz-Bruce, H; Kane, JM; Khadivi, A; Lesser, ML; Lorell, BS; McCormack, J; Mendelowitz, A; Miller, R; Napolitano, B; Patel, RC; Robinson, DG; Schooler, NR; Sevy, SM; Soto-Perello, JM; Woerner, MG, 2006) |
| "In two double-blind studies, 552 adult and elderly patients with schizophrenia or schizoaffective disorder were randomly assigned to risperidone or olanzapine treatment for 8 weeks." | 5.11 | Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications. ( Gharabawi, G; Lasser, RA; Mao, L, 2004) |
| "The aim of the present study was to evaluate the effectiveness and tolerability of risperidone in children with autistic disorder and to examine the correlation between plasma levels of risperidone and its active metabolite 9-hydroxyrisperidone (9-OH-risperidone) and the clinical response." | 5.11 | Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications. ( Calamoneri, F; D'Arrigo, C; Gagliano, A; Germanò, E; Impallomeni, C; Pustorino, G; Spina, E, 2004) |
| "Weight change was measured for 63 children and adolescents with autism treated with risperidone for 6 months." | 5.11 | Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data. ( Aman, M; Anderson, GM; Arnold, LE; Chuang, S; Martin, A; McCracken, J; McDougle, CJ; Scahill, L; Tierney, E; Vitiello, B, 2004) |
| " The authors' goal was to assess the effects of clozapine, olanzapine, risperidone, and haloperidol on glucose and cholesterol levels in hospitalized patients with schizophrenia or schizoaffective disorder during a randomized double-blind 14-week trial." | 5.10 | Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. ( Chakos, M; Citrome, L; Cooper, TB; Czobor, P; Lieberman, JA; Lindenmayer, JP; McEvoy, JP; Sheitman, B; Volavka, J, 2003) |
| "We report on a 17-year-old girl who developed steatohepatitis and marked weight gain during risperidone treatment for paranoid psychosis." | 5.10 | Risperidone-associated steatohepatitis and excessive weight-gain. ( Bechtinger, E; Holtmann, M; Kopf, D; Mayer, M; Schmidt, MH, 2003) |
| "Data on risperidone's efficacy and tolerability in adolescents with schizophrenia are scarce." | 5.10 | Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study. ( Bensason, D; Carmon, E; Martin, A; Tyano, S; Weizman, A; Zalsman, G, 2003) |
| "The results suggest that risperidone treatment is not associated with weight gain among elderly persons with chronic psychosis." | 5.10 | No weight gain among elderly schizophrenia patients after 1 year of risperidone treatment. ( Barak, Y, 2002) |
| "We performed a retrospective analysis of 122 clinical records of 92 male patients with DSM-III-R schizophrenia to examine the relative weight gain liabilities of clozapine, risperidone, olanzapine, and sertindole compared with haloperidol." | 5.09 | Novel antipsychotics: comparison of weight gain liabilities. ( Berisford, MA; Goldstein, D; Kysar, L; Marder, SR; Mintz, J; Pashdag, J; Wirshing, DA; Wirshing, WC, 1999) |
| "Adding the atypical neuroleptic risperidone to a serotonin reuptake inhibitor (SRI) has benefited patients with treatment-refractory obsessive-compulsive disorder (OCD)." | 5.09 | Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder. ( Elliott, MA; Koran, LM; Ringold, AL, 2000) |
| "Subjects (N=377) who met DSM-IV criteria for schizophrenia or schizoaffective disorder were randomly assigned to receive 2-6 mg/day of risperidone (mean modal dose=4." | 5.09 | A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder. ( Conley, RR; Mahmoud, R, 2001) |
| "Clinical factors predicting weight change in patients with schizophrenia and related disorders during acute treatment with the antipsychotic drugs olanzapine, risperidone, and haloperidol were sought through retrospective analyses." | 5.09 | Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. ( Basson, BR; Gilmore, JA; Kinon, BJ; Szymanski, KA; Taylor, CC; Tollefson, GD, 2001) |
| "As part of an ongoing, prospective, ABA design, double-blind crossover study of risperidone versus placebo for the treatment of aggressive, destructive and self-injurious behavior in persons aged 6-65 years with mental retardation (MR) and autism, we measured the weight of 19 subjects at each study visit." | 5.09 | Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism. ( Crandall, K; Hellings, JA; Schroeder, SR; Wallace, D; Zarcone, JR, 2001) |
| "Risperidone is more effective than placebo in the short-term treatment of symptoms of autism in adults." | 5.08 | A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders. ( Carlson, DC; Cohen, DJ; Holmes, JP; McDougle, CJ; Pelton, GH; Price, LH, 1998) |
| " In an application, we examine the risk of excessive weight gain for patients with schizophrenia treated with the second-generation antipsychotics paliperidone, risperidone, or olanzapine in 14 clinical trials." | 5.01 | Bayesian Meta-analysis of Multiple Continuous Treatments with Individual Participant-Level Data: An Application to Antipsychotic Drugs. ( Horvitz-Lennon, M; Normand, ST; Spertus, J, 2019) |
| "Between 40% and 70% of people with treatment-resistant schizophrenia do not respond to clozapine, despite adequate blood levels." | 4.95 | Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia. ( Barber, S; Cipriani, A; Corsi, M; Olotu, U, 2017) |
| "There is some evidence that in the short term risperidone may reduce aggression and conduct problems in children and youths with disruptive behaviour disorders There is also evidence that this intervention is associated with significant weight gain." | 4.95 | Atypical antipsychotics for disruptive behaviour disorders in children and youths. ( Hetrick, SE; Loy, JH; Merry, SN; Stasiak, K, 2017) |
| "To conduct meta-analyses of all published association studies on the HTR2C -759C/T (rs3813829) polymorphism and olanzapine-induced weight gain in schizophrenia patients and on the HTR2C -759C/T, -697G/C (rs518147) and rs1414334:C> G polymorphisms and olanzapine/clozapine/risperidone-induced metabolic syndrome in schizophrenia patients." | 4.90 | HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis. ( Gui, X; Hu, G; Ma, X; Maimaitirexiati, T; Xu, G; Zhang, R; Zhang, W, 2014) |
| "Olanzapine, risperidone, and aripiprazole were all associated with statistically significant weight gain." | 4.89 | Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis. ( Aitchison, KJ; Almandil, NB; Besag, FM; Liu, Y; Murray, ML; Wong, IC, 2013) |
| "There is some limited evidence of efficacy of risperidone reducing aggression and conduct problems in children aged 5 to 18 with disruptive behaviour disorders in the short term." | 4.88 | Atypical antipsychotics for disruptive behaviour disorders in children and youths. ( Hetrick, SE; Loy, JH; Merry, SN; Stasiak, K, 2012) |
| " Olanzapine produced more weight gain than all other second-generation antipsychotics except for clozapine where no difference was found." | 4.86 | Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis. ( Davis, JM; Hunger, H; Kissling, W; Komossa, K; Leucht, S; Lobos, CA; Rummel-Kluge, C; Schmid, F; Schwarz, S, 2010) |
| " (2) Articles published between 2004 and 2008 were identified by a PubMed search with the keywords weight gain, metabolic, glucose, insulin, and lipid AND dose combined with amisulpride, aripiprazole, clozapine, quetiapine, risperidone, sertindole, and ziprasidone." | 4.85 | Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review. ( De Hert, M; Simon, V; van Winkel, R, 2009) |
| "A systematic and comprehensive literature search was performed to determine the extent of weight gain induced by risperidone (RIS) treatment across the age span." | 4.82 | A comparison of risperidone-induced weight gain across the age span. ( Safer, DJ, 2004) |
| " This reveals that the atypical antipsychotics are most likely to induce weight gain, in particular clozapine and olanzapine." | 4.82 | [Psychotropics and weight gain]. ( Bryois, Ch; Sahli, Ch, 2004) |
| " The newer atypical agents have a lower risk of EPS, but are associated in varying degrees with sedation, cardiovascular effects, anticholinergic effects, weight gain, sexual dysfunction, hepatic effects, lowered seizure threshold (primarily clozapine), and agranulocytosis (clozapine only)." | 4.80 | Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations. ( , 1998) |
| " Risperidone is associated with relatively few motor side effects compared with the traditional antipsychotics, and weight gain is less likely with risperidone than with either clozapine or olanzapine." | 4.80 | Risperidone side effects. ( Conley, RR, 2000) |
| " Compared with risperidone, olanzapine causes greater increases in weight gain and body mass index but less hyperprolactinemia." | 4.80 | Adverse events related to olanzapine. ( Conley, RR; Meltzer, HY, 2000) |
| " Clozapine seems to have the highest risk of weight gain, followed by olanzapine and quetiapine." | 4.80 | Atypical antipsychotics and weight gain--a systematic review. ( McAskill, R; Taylor, DM, 2000) |
| " Considering the impact of weight gain on global morbidity and mortality, physicians should closely monitor weight gain in young patients, especially children on risperidone." | 4.31 | Weight Gain During Antipsychotic Treatment in Children, Adolescents, and Adults: A Disproportionality Analysis in the Global Pharmacovigilance Database, Vigibase ( Chouchana, L; Delorme, R; Durrieu, G; Kaguelidou, F; Montastruc, F; Peyre, H; Treluyer, JM; Valtuille, Z, 2023) |
| "This study aimed to assess weight changes following antipsychotic treatment in first-episode schizophrenia (FES) patients and make a comparison of aripiprazole, risperidone and olanzapine." | 4.31 | Weight changes following treatment with aripiprazole, risperidone and olanzapine: A 12-month study of first-episode schizophrenia patients in China. ( Cheng, Z; Gao, T; Huang, B; Huang, Z; Pu, C; Shi, C; Yu, X; Zhang, D; Zheng, Y; Zhou, E; Zhou, T, 2023) |
| "Similar to older populations, risperidone treatment in preschoolers is associated with significant weight gain, with evidence for dose effects." | 4.02 | Body mass index increase in preschoolers with heterogeneous psychiatric diagnoses treated with risperidone. ( Avrahami, M; Balan-Moshe, L; Barzilay, R; Drapisz, A; Levy, T; Moore, T; Peskin, M; Segal-Gavish, H; Shachar, I; Taylor, J; Weizman, A, 2021) |
| "Atypical antipsychotics such as risperidone cause drug-induced metabolic syndrome." | 4.02 | The atypical antipsychotic risperidone targets hypothalamic melanocortin 4 receptors to cause weight gain. ( Arnold, AG; Birnbaum, SG; Chen, X; Jia, L; Li, L; Li, X; Liu, C; Sohn, JW; Wan, R; Wyler, SC; Yoo, ES, 2021) |
| " Olanzapine treatment was associated with the highest change in weight, with higher doses resulting in more weight gain." | 3.96 | Effects of long-term antipsychotics treatment on body weight: A population-based cohort study. ( Bazo-Alvarez, JC; Carpenter, JR; Hayes, JF; Morris, TP; Petersen, I, 2020) |
| "Many patients taking risperidone for the treatment of psychiatric disorders experience substantial body weight gain." | 3.96 | Risperidone stimulates food intake and induces body weight gain via the hypothalamic arcuate nucleus 5-HT2c receptor-NPY pathway. ( Huang, XF; Lin, S; Shi, YC; Wan, XQ; Wang, L; Yang, HQ; Zeng, F; Zhang, ZH, 2020) |
| " We Propose a text mining approach to detect adverse events and medication episodes from the clinical text to enhance our understanding of adverse effects related to Clozapine, the most effective antipsychotic drug for the management of treatment-resistant schizophrenia, but underutilised due to concerns over its side effects." | 3.96 | The side effect profile of Clozapine in real world data of three large mental health hospitals. ( Broadbent, M; Dobson, RJB; Dzahini, O; Govind, R; Ibrahim, ZM; Iqbal, E; Kim, CH; MacCabe, JH; Romero, A; Smith, T; Stewart, R; Werbeloff, N, 2020) |
| "The present study aimed to investigate the effect of bezafibrate on glucolipid abnormalities induced by antipsychotics in schizophrenia." | 3.91 | The effect of bezafibrate in preventing glucolipid abnormalities induced by the antipsychotic risperidone. ( Wei, XY; Yang, YJ; Zhu, XH, 2019) |
| "Children were at risk of weight gain more than adolescents, for both risperidone and, of note, aripiprazole." | 3.91 | Weight-Change Trajectories of Pediatric Outpatients Treated with Risperidone or Aripiprazole in a Naturalistic Setting. ( Bernardini, R; Biganzoli, E; Bravaccio, C; Capuano, A; Carnovale, C; Clementi, E; Marano, G; Molteni, M; Nobile, M; Pisano, S; Pozzi, M; Radice, S; Rafaniello, C; Rizzo, R; Rossi, F, 2019) |
| "This study demonstrated that there was no significant difference in weight gain between risperidone and aripiprazole users during the first year of treatment." | 3.91 | No Differences in Weight Gain Between Risperidone and Aripiprazole in Children and Adolescents After 12 Months. ( Beex-Oosterhuis, MM; Dieleman, HG; Eussen, MLJM; Schoemakers, RJ; van Kesteren, C; van Rosmalen, J, 2019) |
| "The aim of this study was to explore the effectiveness and tolerability of long-acting paliperidone palmitate antipsychotic in adolescent first-episode schizophrenia patients while comparing the results with the oral antipsychotic risperidone." | 3.91 | Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First-Episode Schizophrenia Patients. ( Gačo, N; Graovac, M; Kaštelan, A; Petrić, D; Rački, V, 2019) |
| " In this study, 264 Han Chinese inpatients diagnosed with schizophrenia or schizoaffective disorder initiated treatment with olanzapine (n=131) or risperidone (n=133) and were followed for 12weeks." | 3.88 | T ( Gao, M; Gao, Y; He, Y; Jiang, R; Li, J; Li, S; Li, WD; Lv, H; Wang, L; Wang, X; Xu, C; Zhang, M, 2018) |
| "The Treatment of Early-Onset Schizophrenia Spectrum Disorders (TEOSS) study randomized 119 youths (age 8-19 years) with schizophrenia or schizoaffective disorder to 8 weeks of antipsychotic treatment with molindone, risperidone, or olanzapine and assessed treatment response and side effects." | 3.88 | Predictors and Moderators of Antipsychotic-Related Weight Gain in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study. ( Bloch, MH; Gabriel, D; Jakubovski, E; Taylor, JH, 2018) |
| " However, after accounting for baseline weight, age, sex and diagnosis, olanzapine is still associated with greater weight gain over two years than risperidone or quetiapine." | 3.88 | Weight change over two years in people prescribed olanzapine, quetiapine and risperidone in UK primary care: Cohort study in THIN, a UK primary care database. ( Beckley, N; Hayes, J; Nazareth, I; Osborn, DP; Petersen, I; Walters, K, 2018) |
| "To analyze weight gain, metabolic hormones, and homocysteine (Hcys) levels in children and adolescents on antipsychotics (AP) during a year-long follow-up." | 3.85 | The effects of antipsychotics on weight gain, weight-related hormones and homocysteine in children and adolescents: a 1-year follow-up study. ( Arango, C; Baeza, I; Calvo-Escalona, R; Castro-Fornieles, J; de la Serna, E; Merchán-Naranjo, J; Rodríguez-Latorre, P; Vigo, L, 2017) |
| "Schizophrenia or schizoaffective disorder subjects (n = 218), treated mostly with clozapine and olanzapine for up to 14 weeks, were included." | 3.83 | Association of orexin receptor polymorphisms with antipsychotic-induced weight gain. ( Brandl, EJ; Chowdhury, NI; Freeman, N; Goncalves, VF; Kennedy, JL; Lieberman, JA; Meltzer, HY; Müller, DJ; Tiwari, AK; Zai, CC, 2016) |
| "A 17-year-old girl gained more than 25 kg in weight during treatment with risperidone and subsequently developed headache, diplopia and loss of vision due to IIH." | 3.81 | [Idiopathic intracranial hypertension and obesity]. ( Braakman, HM; Naarden, MT; Porro, GL; Schuitemaker, A; Straver, JS; van Doormaal, TP, 2015) |
| "Study 1: Between April 2004 and September 2007, participants were enrolled from outpatient settings in a prospective randomized clinical trial comparing the efficacy of risperidone monotherapy to the combination of risperidone and behavior therapy in targeting disruptive behavior in 4- to 13-year-old children with DSM-IV-TR-based autism spectrum disorder." | 3.81 | Iron homeostasis during risperidone treatment in children and adolescents. ( Aman, M; Arnold, LE; Calarge, CA; Del Castillo, N; McCracken, JT; McDougle, CJ; Scahill, L; Ziegler, EE, 2015) |
| "The atypical antipsychotic risperidone (RSP) is often associated with weight gain and cardiometabolic side effects." | 3.81 | Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children. ( Azcarate-Peril, MA; Bahr, SM; Burns, TL; Butcher, BD; Calarge, CA; Kirby, JR; Oltman, CL; Teesch, LM; Tyler, BC; Wooldridge, N, 2015) |
| "SLC6A4 might be susceptible gene for risperidone-induced weight gain within the Chinese Han population." | 3.81 | A pharmacogenomic study revealed an association between SLC6A4 and risperidone-induced weight gain in Chinese Han population. ( Du, B; Li, K; Liu, C; Lu, T; Lv, L; Ma, C; Ma, W; Mi, W; Wang, F; Wang, L; Yang, Y; Yue, W; Zhang, D; Zhang, H, 2015) |
| "Following several years of treatment, risperidone discontinuation is associated with a reversal of the excessive weight gain, mediated by a negative energy balance, and a corresponding improvement in cardiometabolic parameters." | 3.80 | Cardiometabolic outcomes in children and adolescents following discontinuation of long-term risperidone treatment. ( Burns, TL; Calarge, CA; Nicol, G; Schlechte, JA, 2014) |
| " The calorie-restricted diet was not significantly associated with a reduction in weight gain in participants who received any of the atypical antipsychotic agents except for olanzapine; therefore, findings indicate that the calorie-restricted diet may only be effective for patients receiving olanzapine." | 3.80 | The effect of a calorie-restricted diet on weight gain in short-term psychiatric inpatients receiving atypical antipsychotic medications. ( Derbabian, B; Jacobowitz, W; Saunders, A, 2014) |
| " The aims of this study were to investigate the antioxidative activity of paraoxonase and assess lipid profile as a cardiovascular risk factor in patients with schizophrenia under long-term clozapine or risperidone treatment." | 3.80 | A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics. ( Atanasiu, V; Delia, C; Gaman, L; Gilca, M; Iosif, L; Piriu, G; Stoian, I, 2014) |
| "The FTO gene polymorphisms, especially rs9939609, seem to be related to weight gain after risperidone treatment in Chinese Han patients with first episode schizophrenia." | 3.80 | Fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia. ( Fan, X; Feng, Y; Gao, J; Li, X; Lv, L; Nemani, K; Pang, L; Song, X; Zhang, H; Zhang, J; Zhang, W, 2014) |
| " Further, fewer preclinical adverse events were noted with 17m compared with risperidone in assays that measured prolactin secretion and weight gain." | 3.79 | Synthesis and biological investigation of coumarin piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics. ( Chen, Y; Liu, BF; Liu, S; Liu, X; Qiu, Y; Wang, S; Xu, X; Yu, M; Zhang, G; Zhang, T; Zhao, S, 2013) |
| "Risperidone-induced weight gain is associated with hyperphagia and a reduction in locomotor activity in C57BL/6J mice." | 3.79 | Effects of risperidone on energy balance in female C57BL/6J mice. ( Allison, DB; Johnson, MS; Kesterson, RA; Li, X; Li, Y; Nagy, TR; Smith, DL, 2013) |
| "This study assessed clinical and functional outcomes following a switch from risperidone to olanzapine in a 1-year naturalistic study of schizophrenia patients in Japan." | 3.78 | Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan. ( Ascher-Svanum, H; Fujikoshi, S; Nakahara, N; Ohmori, T; Takahashi, M; Ye, W, 2012) |
| "Compared with weight measured concurrently, the rate of weight gain in risperidone-treated children accounts for an equal or larger share of the variance in certain cardiometabolic outcomes (eg, HDL cholesterol [ΔR(2) = 8% vs ΔR(2) = 11%] and high-sensitivity C-reactive protein [ΔR(2) = 5% vs ΔR(2) = 9%]) and may serve as a treatment target." | 3.78 | Rate of weight gain and cardiometabolic abnormalities in children and adolescents. ( Burns, TL; Calarge, CA; Fiedorowicz, JG; Haynes, WG; Xie, D, 2012) |
| "Weight gain and metabolic disturbances, such as dyslipidemia and hyperglycaemia, are common side effects of most antipsychotic drugs, including risperidone." | 3.77 | Overweight induced by chronic risperidone exposure is correlated with overexpression of the SREBP-1c and FAS genes in mouse liver. ( Bordet, R; Bouchaert, E; Cussac, D; Duriez, P; Helleboid, A; Hum, D; Lauressergues, E; Luc, G; Majd, Z; Martin, F; Staels, B, 2011) |
| "To identify the factors associated with newly prescribed, first-line, second-generation antipsychotics (SgAs) associated with weight gain-olanzapine, risperidone, and quetiapine." | 3.77 | Factors associated with the prescribing of olanzapine, quetiapine, and risperidone in patients with bipolar and related affective disorders. ( Arndt, S; Chrischilles, EA; Coryell, WH; Ellingrod, VL; Fiedorowicz, JG; Haynes, WG; Miller, del D; Prabhakar, M; Warren, L, 2011) |
| "(1) To determine bone remodeling parameters and bone mass in patients with schizophrenia on long-term treatment with long-acting injectable risperidone (LAIR) in naturalistic settings, and (2) to evaluate the change in body weight, metabolic profile and neuroendocrine status in these patients." | 3.77 | Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone. ( Britvic, D; Damjanovic, A; Doknic, M; Jasovic Gasic, M; Maric, NP; Miljic, D; Pekic, S; Popovic, V; Radojicic, Z; Stojanovic, M, 2011) |
| "No difference in body weight gained during treatment was observed between risperidone and vehicle treated rats, but plasma risperidone levels positively correlated with visceral fat mass." | 3.76 | Risperidone treatment increases CB1 receptor binding in rat brain. ( Egerod, KL; Holst, B; Husum, H; Mellerup, E; Secher, A, 2010) |
| " To dissect the role of the dopamine D2 receptor (D2R), an important receptor in the pharmacology of antipsychotic drugs, we analyzed the effect of olanzapine, risperidone, and ziprasidone on changes in body weight and food intake in male wild-type (WT) and D2R knockout (D2R(-/-)) mice." | 3.76 | Effects of atypical antipsychotic drugs on body weight and food intake in dopamine D2 receptor knockout mice. ( Baik, JH; Choi, SY; Noh, JS; Yoon, S, 2010) |
| "Despite the limited number of children included, our results confirm a strong link between prescription of risperidone in EOS and risk of obesity." | 3.76 | [Metabolic side effects of risperidone in early onset schizophrenia]. ( Bordet, R; Delion, P; Duhamel, A; Goeb, JL; Jardri, R; Kechid, G; Marco, S; Thomas, P, 2010) |
| "Risperidone induces significant weight gain in female mice; however, the underlying mechanisms related to this effect are unknown." | 3.75 | Risperidone alters food intake, core body temperature, and locomotor activity in mice. ( Allison, DB; Cope, MB; DiCostanzo, CA; Jamison, WG; Jumbo-Lucioni, P; Kesterson, RA; Li, X; Nagy, TR, 2009) |
| "The long-term use of risperidone, especially when weight is above normal, is associated with a number of metabolic abnormalities but a low prevalence of the metabolic syndrome phenotype." | 3.75 | Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents. ( Acion, L; Calarge, CA; Kuperman, S; Schlechte, JA; Tansey, M, 2009) |
| "We investigated the relationships between functional genetic variants of the 5-HT(2C) receptor and multidrug-resistant protein (MDR1), coding for P-glycoprotein, and second generation antipsychotic (SDA)-induced weight gain among 108 female schizophrenic patients treated with olanzapine or risperidone for up to 4 months." | 3.74 | The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients. ( Bilusic, H; Bozina, N; Hotujac, L; Kuzman, MR; Medved, V; Sain, I, 2008) |
| "Risperidone has a relatively low risk of causing obesity and diabetes mellitus and is a first-line treatment for schizophrenia." | 3.74 | Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia. ( Hosoda, H; Inoue, T; Itoh, K; Izumi, T; Kangawa, K; Koyama, T; Kusumi, I; Murashita, M; Nakagawa, S; Tanaka, T, 2007) |
| " Data from a randomized, double-blind trial comparing treatment of schizophrenia with placebo and olanzapine were used to correlate weight change and change in psychopathology." | 3.73 | Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic. ( Ascher-Svanum, H; Kinon, BJ; Stensland, MD; Tollefson, GD, 2005) |
| " Role of ghrelin (RIA), resistin and TNF-alpha (ELISA) in weight gain and insulin resistance (fasting plasma insulin, HOMA, ELISA) was studied in Hungarian psychiatryic patients (n=60) treated with SGA (clozapine, olanzapine, risperidone, quetiapine, 15 each)." | 3.73 | [Possible connection between ghrelin, resistin and TNF-alpha levels and the metabolic syndrome caused by atypical antipsychotics]. ( Birkás Kováts, D; Cseh, K; Faludi, G; Palik, E, 2005) |
| "We compared fasting lipids and other metabolic parameters in 211 normoglycemic patients meeting the DSM-IV diagnosis of schizophrenia or schizoaffective disorder undergoing continuous treatment with olanzapine, risperidone, or typical antipsychotics for at least 1 year." | 3.73 | Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics. ( Cavazzoni, P; Hardy, TA; Kryzhanovskaya, L; Marquez, E; Taylor, CC, 2006) |
| " To investigate the possible mechanisms of antipsychotic-induced metabolic effects, we studied the impact of chronic administration of a typical antipsychotic drug (haloperidol) and an atypical antipsychotic (risperidone) to male rats on food intake, body weight, adiposity, and the circulating concentrations of hormones and metabolites that can influence energy homeostasis." | 3.73 | Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats. ( Dedova, I; Duffy, L; Herzog, H; Karl, T; Lee, NJ; Lin, EJ; Matsumoto, I; O'brien, E; Sainsbury, A; Slack, K, 2006) |
| "The study population comprised 56 patients with DSM-IV schizophrenia, who were divided into 4 treatment groups: quetiapine (N = 14), olanzapine (N = 14), risperidone (N = 14), or clozapine (N = 14) monotherapy, and a control group of 11 patients receiving no psychopharmacologic treatment." | 3.72 | Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. ( Atmaca, M; Kuloglu, M; Tezcan, E; Ustundag, B, 2003) |
| "Outpatients diagnosed of schizophrenia according to DSM-IV criteria and receiving a single antipsychotic (risperidone, olanzapine, quetiapine or haloperidol) for at least 4 weeks were consecutively recruited." | 3.72 | Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study. ( Bobes, J; Fernández, I; Garcia-Garcia, M; García-Portilla, MP; Hernández, G; Rejas, J; Rico-Villademoros, F, 2003) |
| "Our results support the previously reported positive impact of atypical antipsychotics, particularly olanzapine, in patients with schizophrenia." | 3.72 | Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol. ( Bitter, I; Boland, J; Dossenbach, M; el Mahfoud Kessaci, M; Erol, A; Hodge, A; O'Halloran, RA; Shaheen, MO; Sunbol, MM, 2004) |
| "Treatment with olanzapine was associated with significantly greater weight gain than treatment with risperidone in Chinese schizophrenia patients in Hong Kong." | 3.72 | Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone. ( Lee, E; Leung, CM; Wong, E, 2004) |
| "Olanzapine and risperidone use was associated with gaining weight in the first year, but only olanzapine was associated with developing diabetes mellitus." | 3.72 | Weight gain and new onset diabetes associated with olanzapine and risperidone. ( Farwell, WR; L'Italien, G; Stump, TE; Tafesse, E; Tierney, WM; Wang, J, 2004) |
| " The addition of risperidone to behavioral and psychopharmacologic treatments was observed to significantly increase oral intake and accelerate weight gain." | 3.72 | The effectiveness of risperidone in the treatment of three children with feeding disorders. ( Berger-Gross, P; Coletti, DJ; Hirschkorn, K; Simpser, EF; Terranova, E, 2004) |
| " However, accumulating evidence suggests that these agents, particularly clozapine and olanzapine, have serious side effects of their own, including weight gain and elevated glucose and triglyceride levels." | 3.71 | The effects of novel antipsychotics on glucose and lipid levels. ( Ballon, JS; Boyd, JA; Marder, SR; Meng, LR; Wirshing, DA; Wirshing, WC, 2002) |
| "The current investigation lends support to data that note weight gain with risperidone in adults with mental retardation." | 3.71 | Weight gain with risperidone among patients with mental retardation: effect of calorie restriction. ( Cohen, S; Glazewski, R; Khan, A; Khan, S, 2001) |
| " In order to determine whether newer antipsychotic agents differ from each other with respect to weight gain, we compared two cohorts of patients with DSM-IV schizophrenia who had newly started treatment with either risperidone or olanzapine." | 3.71 | Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone. ( Ayrton, Z; Brar, JS; Ganguli, R, 2001) |
| "To evaluate weight gain associated with olanzapine, risperidone, and haloperidol treatment and its clinical risk factors in adolescent patients." | 3.71 | Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study. ( Apter, A; Brand-Gothelf, A; Gal, G; Gothelf, D; Kikinzon, L; Phillip, M; Ratzoni, G; Reidman, J; Weizman, R, 2002) |
| "During clinical experience with the "atypical" neuroleptic drugs clozapine, risperidone, and zotepine, some patients have shown a marked weight gain." | 3.70 | Weight gain: side effect of atypical neuroleptics? ( Müssigbrodt, HE; Wetterling, T, 1999) |
| " Drug dosing followed U." | 2.90 | Pharmacotherapy of Autism Spectrum Disorder: Results from the Randomized BAART Clinical Trial. ( Abramson, RK; Bradley, C; Bragg, JE; Carpenter, LA; Charles, JM; DeVane, CL; Donovan, JL; Geesey, ME; Gwynette, F; Hall, AG; Kinsman, A; Kruesi, MJ; Powers, NR; Raven, S; Sherk, ST; Spratt, E; Stuck, CA; Williams, JE, 2019) |
| " The aims of this study were to investigate the effectiveness and adverse effects of LAIR in children and adolescents with conduct disorder, bipolar disorder, and schizophrenia." | 2.84 | Effectiveness, Adverse Effects and Drug Compliance of Long-Acting Injectable Risperidone in Children and Adolescents. ( Ceylan, MF; Cop, E; Erdogan, B; Tural Hesapcioglu, S, 2017) |
| "Average weight gain was 3." | 2.82 | Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial. ( Baruch, P; Beaulieu, S; Bond, DJ; da Cunha, A; Daigneault, A; Dias, R; Kapczinski, F; Kauer-Sant'Anna, M; Kunz, M; Lafer, B; Lam, RW; Milev, R; Parikh, SV; Qian, H; Quevedo, J; Schaffer, A; Sharma, V; Silverstone, PH; Walji, N; Wong, H; Yatham, LN; Young, LT, 2016) |
| "Risperidone was significantly more likely to be associated with elevation in serum prolactin levels in this population." | 2.75 | A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents. ( Black, VC; Bobier, CM; Buchan, JC; Craig, BJ; Pirwani, NZ; Swadi, HS, 2010) |
| " Adverse effects (n = 15), inadequate efficacy (n = 14), or study nonadherence (n = 8) were the most common reasons for discontinuation." | 2.75 | Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study. ( Findling, RL; Frazier, JA; Hamer, RM; Hlastala, S; Johnson, JL; Kaufman, EM; Lieberman, JA; Lingler, J; Maloney, AE; McClellan, J; McNamara, NK; Noyes, N; Pierson, L; Puglia, M; Ritz, L; Sikich, L; Vitiello, B, 2010) |
| "Weight gain was positively correlated with changes in insulin levels, insulin resistance index and triglyceride levels." | 2.74 | Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population. ( Amado, JA; Berja, A; Crespo-Facorro, B; Garcia-Unzueta, MT; Martinez-Garcia, O; Mata, I; Pelayo-Teran, JM; Perez-Iglesias, R; Vazquez-Barquero, JL, 2009) |
| "Risperidone was generally well tolerated." | 2.73 | Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents. ( Haas, M; Karcher, K; Pandina, GJ, 2008) |
| "Weight gain has become one of the most common and concerning side effects of antipsychotic treatment." | 2.73 | Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment. ( Amado, JA; Berja, A; Carrasco-Marín, E; Crespo-Facorro, B; Garcia-Unzueta, MT; Mata, I; Pelayo-Terán, JM; Perez-Iglesias, R; Vazquez-Barquero, JL, 2008) |
| "Risperidone has shown safety and efficacy for aggressive and destructive behaviors in short-term studies." | 2.72 | A crossover study of risperidone in children, adolescents and adults with mental retardation. ( Fleming, KK; Hellings, JA; Marquis, JG; Reese, RM; Schroeder, SR; Valdovinos, MG; Zarcone, JR, 2006) |
| "Preschool children tolerated low-dose risperidone well with no serious adverse effects observed over a 6-month treatment period." | 2.72 | Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy. ( Belden, A; Heffelfinger, A; Luby, J; Mrakotsky, C; Spitznagel, E; Stalets, MM; Williams, M, 2006) |
| "Weight gain is an important side effect of antipsychotic (AP) treatment." | 2.71 | The relationship of changes in leptin, neuropeptide Y and reproductive hormones to antipsychotic induced weight gain. ( de Castella, AR; Fitzgerald, PB; Kulkarni, J; Morris, MJ; Scaffidi, A, 2003) |
| "Amoxapine was associated with less EPS and less prolactin elevation than risperidone." | 2.71 | Amoxapine as an atypical antipsychotic: a comparative study vs risperidone. ( Apiquian, R; de la Fuente-Sandoval, C; Fresan, A; Herrera-Estrella, M; Kapur, S; Nicolini, H; Ulloa, RE; Vazquez, A, 2005) |
| "Patients aged > or = 18 years with schizoaffective disorder (DSM-IV), who required a change of medication, received risperidone long-acting injectable 25 mg (increased to 37." | 2.71 | Long-acting risperidone in stable patients with schizoaffective disorder. ( Benoit, M; Bräunig, P; Lex, A; Medori, R; Mohl, A; Opjordsmoen, S; Schreiner, A; Westlye, K, 2005) |
| "Risperidone doses were low (0." | 2.69 | Risperidone for young children with mood disorders and aggressive behavior. ( Schreier, HA, 1998) |
| "Weight gain is a serious side effect of antipsychotic therapy." | 2.69 | Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months. ( Conley, RR; Horn, DS; Kelly, DL; Love, RC; Ushchak, CM, 1998) |
| "Risperidone was given in daily doses ranging from 0." | 2.69 | Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior. ( Buitelaar, JK, 2000) |
| " The effect size, remission/response rate, and risk for discontinuation due to adverse events (AEs), weight gain (WG), nervous systems and gastrointestinal AEs were assessed and compared between two regions with Cohen's d or number needed to treat/harm." | 2.66 | Do Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics? ( Bai, Y; Chen, G; Gao, K; Yang, H, 2020) |
| "RLAI and OP show good short- and long-term safety when treating patients with schizophrenia, with uncommon discontinuation due to adverse effects." | 2.46 | Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review. ( Cañas, F; Möller, HJ, 2010) |
| "Five new antipsychotic drugs introduced in the United States in the last decade offer physicians the ability to treat patients with schizophrenia and bipolar mania without the adverse effects of the first-generation antipsychotics." | 2.42 | The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning. ( Citrome, L; Volavka, J, 2004) |
| " Considerable progress has been made in improving the motor side effect profile with the advent of clozapine and risperidone." | 2.39 | Side effect profiles of new antipsychotic agents. ( Casey, DE, 1996) |
| "It is possible that weight gain is mainly driven by APs." | 1.72 | Long-term treatment of antipsychotics and combined therapy with other psychotropic medications inducing weight gain in patients with non-affective psychotic disorder: Evidence from GROUP, a longitudinal study. ( Bartels-Velthuis, AA; Bruggeman, R; Burin, LM; Cahn, W; da Rocha, NS; de Haan, L; Hahn, MK; Schirmbeck, F; Simons, CJP; van Amelsvoort, T; van Os, J, 2022) |
| "Drug-induced weight gain is a profound side effect of numerous commonly used medications." | 1.72 | Drug-induced weight gain in the last 10 years: a descriptive study. ( Ahmed, NJ; Alahmari, A; Almalki, ZS; Alshehri, AM, 2022) |
| "Olanzapine (6 mg/kg) treatment significantly altered glucose and lipid homeostasis which was further accompanied by elevated levels of proinflammatory cytokines, ghrelin and leptin." | 1.51 | Modeling of antipsychotic-induced metabolic alterations in mice: An experimental approach precluding psychosis as a predisposing factor. ( Bansal, Y; Kuhad, A; Medhi, B; Saroj, P; Singh, R; Sodhi, RK, 2019) |
| "We examined 42 patients with paranoid schizophrenia." | 1.42 | [Lipid spectrum changes and ECG in patients with paranoid schizophrenia in the course of therapy with atypical antipsychotics]. ( Borodyuk, YN; Burdovitsina, TG; Kornetova, EG; Parshukova, DA; Semke, AV; Seregin, AA; Smirnova, LP; Tkacheva, GD, 2015) |
| "Weight gain was found to be lower in the elderly for antipsychotic drugs, in particular for olanzapine." | 1.39 | Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland. ( Baumann, P; Greil, W; Grohmann, R; Häberle, A; Schuhmann, T, 2013) |
| "Risperidone was added to culture medium in clinically relevant doses of 0, 2." | 1.38 | Trabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gain. ( Baron, R; Bornstein, S; de Paula, FJ; Dick-de-Paula, I; Houseknecht, KL; Lotinun, S; Maloney, AE; Motyl, KJ; Rosen, CJ, 2012) |
| "Weight gain is an undesirable side effect of second-generation antipsychotics (SGAs)." | 1.37 | Influence of resting energy expenditure on weight gain in adolescents taking second-generation antipsychotics. ( Arango, C; Bretón, I; Camblor, M; Cuerda, C; de Castro, MJ; Desco, M; Dulín, E; García-Peris, P; Giráldez, M; Gutierrez, A; Leiva, M; Merchan-Naranjo, J; Parellada, M; Sanz, I; Velasco, C, 2011) |
| "Body weight gain was observed with both the drugs, although a sex-related differential response was noted." | 1.36 | Effect of lactational exposure of olanzapine on body weight of mice: a comparative study on neonates of both the sexes during post-natal development. ( Mishra, AC; Mohanty, B, 2010) |
| "Haloperidol patients were more often single and institutionalised, less educated, had more residual schizophrenia, were longer hospitalised in the previous year, took more corrective and psychotropic drugs and had more extrapyramidal symptoms (EPS) and gynaecomastia (all significantly)." | 1.35 | Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol. ( Albert, A; De Graeve, D; Gillain, B; Peuskens, J; Van Vleymen, B, 2009) |
| "Treatment with aripiprazole, olanzapine, quetiapine, or risperidone for 12 weeks." | 1.35 | Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents. ( Correll, CU; Kane, JM; Malhotra, AK; Manu, P; Napolitano, B; Olshanskiy, V, 2009) |
| "Ziprasidone was without effect on indices of body weight and ingestive behaviour." | 1.35 | Investigation into the influence of a high fat diet on antipsychotic-induced weight gain in female rats. ( Anjum, N; Fell, MJ; Marshall, KM; Neill, JC; Peltola, LM, 2008) |
| "Weight gain is a risk factor for hypertension, diabetes, ischemic heart disease, respiratory illnesses, various forms of cancer, and the metabolic syndrome." | 1.35 | Weight gain due to long term antipsychotic treatment of persistent mental disorders. ( Melamed, Y; Tadger, S, 2008) |
| "Average weight gain was significantly higher for the olanzapine group (mean = 4." | 1.34 | Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents. ( Fleischhaker, C; Heiser, P; Hennighausen, K; Herpertz-Dahlmann, B; Holtkamp, K; Mehler-Wex, C; Rauh, R; Remschmidt, H; Schulz, E; Warnke, A, 2007) |
| "Significant weight gain is a serious side effect of many antipsychotic medications, yet successful strategies for significant weight loss are lacking." | 1.34 | Psychotic disorders, eating habits, and physical activity: who is ready for lifestyle changes? ( Akhtar-Danesh, N; Archie, SM; Goldberg, JO; Landeen, J; McColl, L; McNiven, J, 2007) |
| "Risperidone was switched to another antipsychotic." | 1.34 | Risperidone-induced polydipsia and polyphagia associated with galactorrhea, abdominal pain, and rapid weight gain in an adolescent Hispanic female. ( Afzal, KI; Briones, DF; DeVargas, C, 2007) |
| "Risperidone was the most commonly cited agent." | 1.33 | Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain? ( Pandurangi, A; Silverman, JJ; Sood, AB; Vieweg, WV, 2005) |
| "Drug-induced weight gain is a serious side effect of many commonly used drugs leading to noncompliance with therapy and to exacerbation of comorbid conditions related to obesity." | 1.33 | Drug-induced weight gain. ( Apovian, CM; Ness-Abramof, R, 2005) |
| "Olanzapine-treated patients had significantly higher plasma triglyceride concentrations (2." | 1.32 | Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics. ( Alméras, N; Bouchard, RH; Cadrin, C; Demers, MF; Després, JP; Mottard, JP; Roy, MA; Villeneuve, J, 2004) |
| "Risperidone treatment causes a greater increase in the body mass of patients than treatment with conventional antipsychotics, such as haloperidol." | 1.31 | Peripheral injection of risperidone, an atypical antipsychotic, alters the bodyweight gain of rats. ( Fujiwara, K; Itoh, M; Kaneko, YS; Mori, K; Nagasaka, A; Nakashima, A; Ota, A; Ota, M, 2002) |
| "Risperidone was used in combination with other psychotropic medications in 7 of the 8 children." | 1.31 | A case series of eight aggressive young children treated with risperidone. ( Cesena, M; DeMaso, DR; Gonzalez-Heydrich, J; Kohlenberg, TM; Szigethy, E, 2002) |
| "Weight gain was observed in 5 of 6 patients, with a median increase of 5." | 1.30 | Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up. ( Armenteros, J; Munoz-Silva, DM; Pataki, C; Perry, R; Silva, RR, 1997) |
| "Risperidone is an atypical antipsychotic drug that has been used in the treatment of numerous psychiatric disorders in children and adolescents." | 1.30 | Risperidone-induced hepatotoxicity in children and adolescents? A chart review study. ( Branicky, LA; Findling, RL; Maxwell, K; Szigethy, E; Wiznitzer, M, 1999) |
| "The sample included five patients with Tourette's syndrome and two with chronic motor tic disorder." | 1.29 | Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report. ( Chappell, PB; King, RA; Leckman, JF; Lombroso, PJ; Lynch, KA; McDougle, CJ; Peterson, BS; Scahill, L, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 17 (6.42) | 18.2507 |
| 2000's | 131 (49.43) | 29.6817 |
| 2010's | 102 (38.49) | 24.3611 |
| 2020's | 15 (5.66) | 2.80 |
| Authors | Studies |
|---|---|
| Kroeze, WK | 1 |
| Hufeisen, SJ | 1 |
| Popadak, BA | 1 |
| Renock, SM | 1 |
| Steinberg, S | 1 |
| Ernsberger, P | 1 |
| Jayathilake, K | 1 |
| Meltzer, HY | 4 |
| Roth, BL | 1 |
| Kim, SF | 1 |
| Huang, AS | 1 |
| Snowman, AM | 1 |
| Teuscher, C | 1 |
| Snyder, SH | 1 |
| Lange, JH | 1 |
| Reinders, JH | 1 |
| Tolboom, JT | 1 |
| Glennon, JC | 1 |
| Coolen, HK | 1 |
| Kruse, CG | 1 |
| Chen, Y | 2 |
| Wang, S | 1 |
| Xu, X | 2 |
| Liu, X | 2 |
| Yu, M | 1 |
| Zhao, S | 1 |
| Liu, S | 1 |
| Qiu, Y | 1 |
| Zhang, T | 1 |
| Liu, BF | 2 |
| Zhang, G | 2 |
| Gao, L | 1 |
| Hao, C | 1 |
| Chen, J | 1 |
| Ma, R | 1 |
| Zheng, L | 1 |
| Wu, Q | 1 |
| Jin, J | 1 |
| Liu, J | 1 |
| Wang, P | 1 |
| Sun, L | 1 |
| Guan, X | 2 |
| Xiu, M | 2 |
| Zhang, X | 2 |
| Liu, H | 1 |
| Yu, R | 1 |
| Gao, Y | 2 |
| Li, X | 5 |
| Thomas, K | 1 |
| Burin, LM | 1 |
| Hahn, MK | 1 |
| da Rocha, NS | 1 |
| van Amelsvoort, T | 1 |
| Bartels-Velthuis, AA | 1 |
| Bruggeman, R | 1 |
| de Haan, L | 1 |
| Schirmbeck, F | 1 |
| Simons, CJP | 1 |
| van Os, J | 2 |
| Cahn, W | 1 |
| Ahmed, NJ | 1 |
| Alshehri, AM | 1 |
| Almalki, ZS | 1 |
| Alahmari, A | 1 |
| Kaguelidou, F | 3 |
| Valtuille, Z | 3 |
| Durrieu, G | 3 |
| Delorme, R | 3 |
| Peyre, H | 3 |
| Treluyer, JM | 3 |
| Montastruc, F | 3 |
| Chouchana, L | 3 |
| Hermans, RA | 1 |
| Ringeling, LT | 1 |
| Liang, K | 1 |
| Kloosterboer, SM | 1 |
| de Winter, BCM | 1 |
| Hillegers, MHJ | 1 |
| Koch, BCP | 1 |
| Dierckx, B | 1 |
| Zhou, T | 1 |
| Pu, C | 1 |
| Huang, Z | 1 |
| Gao, T | 1 |
| Zhou, E | 1 |
| Zheng, Y | 1 |
| Zhang, D | 3 |
| Huang, B | 1 |
| Cheng, Z | 1 |
| Shi, C | 1 |
| Yu, X | 1 |
| Mustafa, S | 1 |
| Joober, R | 1 |
| Iyer, S | 1 |
| Shah, J | 1 |
| Lepage, M | 1 |
| Malla, A | 1 |
| Wei, XY | 1 |
| Yang, YJ | 1 |
| Zhu, XH | 1 |
| Bai, Y | 1 |
| Chen, G | 1 |
| Yang, H | 1 |
| Gao, K | 1 |
| Bazo-Alvarez, JC | 1 |
| Morris, TP | 1 |
| Carpenter, JR | 1 |
| Hayes, JF | 1 |
| Petersen, I | 2 |
| Wan, XQ | 1 |
| Zeng, F | 1 |
| Huang, XF | 2 |
| Yang, HQ | 1 |
| Wang, L | 5 |
| Shi, YC | 1 |
| Zhang, ZH | 1 |
| Lin, S | 1 |
| Mano-Sousa, BJ | 1 |
| Pedrosa, AM | 1 |
| Alves, BC | 1 |
| Galduróz, JCF | 1 |
| Belo, VS | 1 |
| Chaves, VE | 1 |
| Duarte-Almeida, JM | 1 |
| Iqbal, E | 1 |
| Govind, R | 1 |
| Romero, A | 1 |
| Dzahini, O | 1 |
| Broadbent, M | 1 |
| Stewart, R | 1 |
| Smith, T | 1 |
| Kim, CH | 2 |
| Werbeloff, N | 1 |
| MacCabe, JH | 1 |
| Dobson, RJB | 1 |
| Ibrahim, ZM | 1 |
| Avrahami, M | 1 |
| Peskin, M | 1 |
| Moore, T | 1 |
| Drapisz, A | 1 |
| Taylor, J | 1 |
| Segal-Gavish, H | 1 |
| Balan-Moshe, L | 1 |
| Shachar, I | 1 |
| Levy, T | 1 |
| Weizman, A | 2 |
| Barzilay, R | 1 |
| Li, L | 2 |
| Yoo, ES | 1 |
| Wyler, SC | 1 |
| Chen, X | 1 |
| Wan, R | 1 |
| Arnold, AG | 1 |
| Birnbaum, SG | 1 |
| Jia, L | 1 |
| Sohn, JW | 1 |
| Liu, C | 4 |
| Barber, S | 1 |
| Olotu, U | 1 |
| Corsi, M | 1 |
| Cipriani, A | 1 |
| Horska, K | 1 |
| Ruda-Kucerova, J | 1 |
| Karpisek, M | 1 |
| Suchy, P | 1 |
| Opatrilova, R | 1 |
| Kotolova, H | 1 |
| Mittal, K | 1 |
| Gonçalves, VF | 2 |
| Harripaul, R | 1 |
| Cuperfain, AB | 1 |
| Rollins, B | 1 |
| Tiwari, AK | 2 |
| Zai, CC | 2 |
| Maciukiewicz, M | 1 |
| Müller, DJ | 2 |
| Vawter, MP | 1 |
| Kennedy, JL | 2 |
| Ceylan, MF | 1 |
| Erdogan, B | 1 |
| Tural Hesapcioglu, S | 1 |
| Cop, E | 1 |
| Loy, JH | 2 |
| Merry, SN | 2 |
| Hetrick, SE | 2 |
| Stasiak, K | 2 |
| Noordsy, DL | 1 |
| Glynn, SM | 1 |
| Sugar, CA | 1 |
| O'Keefe, CD | 1 |
| Marder, SR | 3 |
| Li, S | 1 |
| Lv, H | 1 |
| Zhang, M | 1 |
| Jiang, R | 1 |
| Xu, C | 1 |
| Wang, X | 2 |
| Gao, M | 1 |
| He, Y | 2 |
| Li, J | 2 |
| Li, WD | 1 |
| Schoretsanitis, G | 1 |
| Drukker, M | 1 |
| Schruers, KRJ | 1 |
| Bak, M | 1 |
| Mathews, M | 2 |
| Pei, H | 1 |
| Savitz, A | 1 |
| Nuamah, I | 1 |
| Hough, D | 1 |
| Alphs, L | 1 |
| Gopal, S | 1 |
| Taylor, JH | 1 |
| Jakubovski, E | 1 |
| Gabriel, D | 1 |
| Bloch, MH | 1 |
| Osborn, DP | 1 |
| Beckley, N | 1 |
| Walters, K | 1 |
| Nazareth, I | 1 |
| Hayes, J | 1 |
| Pozzi, M | 1 |
| Pisano, S | 2 |
| Marano, G | 1 |
| Carnovale, C | 1 |
| Bravaccio, C | 1 |
| Rafaniello, C | 1 |
| Capuano, A | 1 |
| Rossi, F | 1 |
| Rizzo, R | 1 |
| Bernardini, R | 1 |
| Nobile, M | 1 |
| Molteni, M | 1 |
| Clementi, E | 1 |
| Biganzoli, E | 1 |
| Radice, S | 1 |
| Skonieczna-Żydecka, K | 1 |
| Łoniewski, I | 1 |
| Misera, A | 1 |
| Stachowska, E | 1 |
| Maciejewska, D | 1 |
| Marlicz, W | 1 |
| Galling, B | 1 |
| Bellavia, A | 1 |
| Centorrino, F | 1 |
| Jackson, JW | 1 |
| Fitzmaurice, G | 1 |
| Valeri, L | 1 |
| Schoemakers, RJ | 1 |
| van Kesteren, C | 1 |
| van Rosmalen, J | 1 |
| Eussen, MLJM | 1 |
| Dieleman, HG | 1 |
| Beex-Oosterhuis, MM | 1 |
| Petrić, D | 1 |
| Rački, V | 1 |
| Gačo, N | 1 |
| Kaštelan, A | 1 |
| Graovac, M | 1 |
| DeVane, CL | 1 |
| Charles, JM | 1 |
| Abramson, RK | 1 |
| Williams, JE | 1 |
| Carpenter, LA | 1 |
| Raven, S | 1 |
| Gwynette, F | 1 |
| Stuck, CA | 1 |
| Geesey, ME | 1 |
| Bradley, C | 1 |
| Donovan, JL | 1 |
| Hall, AG | 1 |
| Sherk, ST | 1 |
| Powers, NR | 1 |
| Spratt, E | 1 |
| Kinsman, A | 1 |
| Kruesi, MJ | 1 |
| Bragg, JE | 1 |
| Singh, R | 1 |
| Bansal, Y | 1 |
| Sodhi, RK | 1 |
| Saroj, P | 1 |
| Medhi, B | 1 |
| Kuhad, A | 1 |
| Spertus, J | 1 |
| Horvitz-Lennon, M | 1 |
| Normand, ST | 1 |
| Johnson, MS | 1 |
| Smith, DL | 1 |
| Li, Y | 1 |
| Kesterson, RA | 3 |
| Allison, DB | 3 |
| Nagy, TR | 3 |
| Ghate, SR | 1 |
| Porucznik, CA | 1 |
| Said, Q | 1 |
| Hashibe, M | 1 |
| Joy, E | 1 |
| Brixner, DI | 1 |
| Calarge, CA | 8 |
| Ziegler, EE | 3 |
| Gritti, A | 1 |
| Catone, G | 1 |
| Pascotto, A | 1 |
| Almandil, NB | 1 |
| Liu, Y | 1 |
| Murray, ML | 1 |
| Besag, FM | 1 |
| Aitchison, KJ | 1 |
| Wong, IC | 1 |
| Margari, L | 1 |
| Matera, E | 1 |
| Craig, F | 1 |
| Petruzzelli, MG | 1 |
| Palmieri, VO | 1 |
| Pastore, A | 1 |
| Margari, F | 1 |
| Nurmi, EL | 1 |
| Spilman, SL | 1 |
| Whelan, F | 1 |
| Scahill, LL | 1 |
| Aman, MG | 3 |
| McDougle, CJ | 10 |
| Arnold, LE | 6 |
| Handen, B | 1 |
| Johnson, C | 1 |
| Sukhodolsky, DG | 1 |
| Posey, DJ | 3 |
| Lecavalier, L | 1 |
| Stigler, KA | 2 |
| Ritz, L | 2 |
| Tierney, E | 3 |
| Vitiello, B | 5 |
| McCracken, JT | 3 |
| Yanik, T | 1 |
| Kursungoz, C | 1 |
| Sutcigil, L | 1 |
| Ak, M | 1 |
| Greil, W | 1 |
| Häberle, A | 1 |
| Schuhmann, T | 1 |
| Grohmann, R | 1 |
| Baumann, P | 1 |
| Ghaleiha, A | 1 |
| Mohammadi, E | 1 |
| Mohammadi, MR | 1 |
| Farokhnia, M | 1 |
| Modabbernia, A | 1 |
| Yekehtaz, H | 1 |
| Ashrafi, M | 1 |
| Hassanzadeh, E | 1 |
| Akhondzadeh, S | 1 |
| Schwarz, E | 1 |
| Steiner, J | 1 |
| Guest, PC | 1 |
| Bogerts, B | 1 |
| Bahn, S | 1 |
| Pérez-Iglesias, R | 5 |
| Martínez-García, O | 4 |
| Pardo-Garcia, G | 1 |
| Amado, JA | 5 |
| Garcia-Unzueta, MT | 5 |
| Tabares-Seisdedos, R | 1 |
| Crespo-Facorro, B | 5 |
| Wink, LK | 1 |
| Early, M | 1 |
| Schaefer, T | 1 |
| Pottenger, A | 1 |
| Horn, P | 1 |
| Erickson, CA | 2 |
| Lee, NY | 1 |
| Kim, SH | 3 |
| Cho, SJ | 1 |
| Chung, YC | 1 |
| Jung, IK | 1 |
| Kim, CY | 1 |
| Kim, DH | 1 |
| Lee, DG | 1 |
| Lee, YH | 1 |
| Lim, WJ | 1 |
| Na, YS | 1 |
| Shin, SE | 1 |
| Woo, JM | 1 |
| Yoon, JS | 1 |
| Yoon, BH | 2 |
| Ahn, YM | 1 |
| Kim, YS | 1 |
| Nicol, G | 2 |
| Schlechte, JA | 3 |
| Burns, TL | 3 |
| Jacobowitz, W | 1 |
| Derbabian, B | 1 |
| Saunders, A | 1 |
| Gilca, M | 1 |
| Piriu, G | 1 |
| Gaman, L | 1 |
| Delia, C | 1 |
| Iosif, L | 1 |
| Atanasiu, V | 1 |
| Stoian, I | 1 |
| Li, H | 2 |
| Luo, J | 1 |
| Wang, C | 3 |
| Xie, S | 1 |
| Yu, W | 1 |
| Gu, N | 2 |
| Kane, JM | 4 |
| Ma, X | 1 |
| Maimaitirexiati, T | 1 |
| Zhang, R | 1 |
| Gui, X | 1 |
| Zhang, W | 2 |
| Xu, G | 1 |
| Hu, G | 1 |
| Song, X | 1 |
| Pang, L | 1 |
| Feng, Y | 1 |
| Fan, X | 1 |
| Gao, J | 1 |
| Zhang, J | 2 |
| Nemani, K | 1 |
| Zhang, H | 6 |
| Lv, L | 3 |
| Ramsey, TL | 1 |
| Brennan, MD | 1 |
| Naarden, MT | 1 |
| Schuitemaker, A | 1 |
| Braakman, HM | 1 |
| van Doormaal, TP | 1 |
| Porro, GL | 1 |
| Straver, JS | 1 |
| Smirnova, LP | 1 |
| Parshukova, DA | 1 |
| Borodyuk, YN | 1 |
| Kornetova, EG | 1 |
| Tkacheva, GD | 1 |
| Seregin, AA | 1 |
| Burdovitsina, TG | 1 |
| Semke, AV | 1 |
| Meyer, JM | 1 |
| Mao, Y | 1 |
| Pikalov, A | 1 |
| Cucchiaro, J | 1 |
| Loebel, A | 1 |
| Aman, M | 3 |
| Rettiganti, M | 1 |
| Nagaraja, HN | 1 |
| Hollway, JA | 1 |
| McCracken, J | 2 |
| Scahill, L | 7 |
| Hellings, J | 1 |
| Swiezy, NB | 1 |
| Ghuman, J | 1 |
| Grados, M | 1 |
| Shah, B | 1 |
| Del Castillo, N | 1 |
| Yao, C | 1 |
| Shi, J | 1 |
| Yang, F | 1 |
| Qi, S | 1 |
| Wang, Q | 1 |
| Li, K | 3 |
| Luo, X | 1 |
| Ersland, KM | 1 |
| Skrede, S | 1 |
| Røst, TH | 1 |
| Berge, RK | 1 |
| Steen, VM | 1 |
| Bahr, SM | 2 |
| Tyler, BC | 1 |
| Wooldridge, N | 1 |
| Butcher, BD | 1 |
| Teesch, LM | 1 |
| Oltman, CL | 1 |
| Azcarate-Peril, MA | 1 |
| Kirby, JR | 2 |
| Brandl, EJ | 1 |
| Chowdhury, NI | 1 |
| Freeman, N | 1 |
| Lieberman, JA | 5 |
| Yatham, LN | 2 |
| Beaulieu, S | 2 |
| Schaffer, A | 1 |
| Kauer-Sant'Anna, M | 2 |
| Kapczinski, F | 1 |
| Lafer, B | 1 |
| Sharma, V | 1 |
| Parikh, SV | 1 |
| Daigneault, A | 1 |
| Qian, H | 1 |
| Bond, DJ | 2 |
| Silverstone, PH | 1 |
| Walji, N | 1 |
| Milev, R | 1 |
| Baruch, P | 1 |
| da Cunha, A | 1 |
| Quevedo, J | 1 |
| Dias, R | 1 |
| Kunz, M | 1 |
| Young, LT | 1 |
| Lam, RW | 2 |
| Wong, H | 1 |
| Wang, F | 2 |
| Mi, W | 2 |
| Ma, W | 2 |
| Ma, C | 2 |
| Yang, Y | 2 |
| Du, B | 2 |
| Lu, T | 2 |
| Yue, W | 2 |
| Weidemann, BJ | 1 |
| Castro, AN | 1 |
| Walsh, JW | 1 |
| deLeon, O | 1 |
| Burnett, CM | 1 |
| Pearson, NA | 1 |
| Murry, DJ | 2 |
| Grobe, JL | 1 |
| Jeon, S | 1 |
| Boorin, SJ | 1 |
| Dziura, J | 1 |
| Caprio, S | 1 |
| Deng, Y | 1 |
| Challa, SA | 1 |
| Baeza, I | 3 |
| Vigo, L | 1 |
| de la Serna, E | 3 |
| Calvo-Escalona, R | 1 |
| Merchán-Naranjo, J | 3 |
| Rodríguez-Latorre, P | 1 |
| Arango, C | 4 |
| Castro-Fornieles, J | 2 |
| Mennella, C | 1 |
| Dickstein, DP | 1 |
| Jahangard, L | 1 |
| Akbarian, S | 1 |
| Haghighi, M | 1 |
| Ahmadpanah, M | 1 |
| Keshavarzi, A | 1 |
| Bajoghli, H | 1 |
| Sadeghi Bahmani, D | 1 |
| Holsboer-Trachsler, E | 1 |
| Brand, S | 1 |
| Chang, KD | 1 |
| Arman, S | 1 |
| Sadramely, MR | 1 |
| Nadi, M | 1 |
| Koleini, N | 1 |
| Kuzman, MR | 1 |
| Medved, V | 1 |
| Bozina, N | 1 |
| Hotujac, L | 1 |
| Sain, I | 1 |
| Bilusic, H | 1 |
| Parellada, M | 3 |
| Soutullo, CA | 1 |
| Gonzalez-Pinto, A | 1 |
| Graell, M | 1 |
| Paya, B | 1 |
| Moreno, D | 1 |
| Haas, M | 2 |
| Karcher, K | 1 |
| Pandina, GJ | 2 |
| Fleischhaker, C | 2 |
| Heiser, P | 2 |
| Hennighausen, K | 2 |
| Herpertz-Dahlmann, B | 2 |
| Holtkamp, K | 2 |
| Mehler-Wex, C | 2 |
| Rauh, R | 2 |
| Remschmidt, H | 4 |
| Schulz, E | 2 |
| Warnke, A | 2 |
| Mata, I | 2 |
| Pelayo-Teran, JM | 3 |
| Berja, A | 2 |
| Vazquez-Barquero, JL | 4 |
| Cope, MB | 2 |
| Jumbo-Lucioni, P | 2 |
| DiCostanzo, CA | 1 |
| Jamison, WG | 1 |
| Gebhardt, S | 2 |
| Haberhausen, M | 2 |
| Heinzel-Gutenbrunner, M | 2 |
| Gebhardt, N | 1 |
| Krieg, JC | 2 |
| Hebebrand, J | 3 |
| Theisen, FM | 2 |
| Peuskens, J | 2 |
| Gillain, B | 1 |
| De Graeve, D | 1 |
| Van Vleymen, B | 1 |
| Albert, A | 1 |
| Mishra, AC | 1 |
| Mohanty, B | 1 |
| Eerdekens, M | 2 |
| Kushner, S | 1 |
| Singer, J | 1 |
| Augustyns, I | 1 |
| Quiroz, J | 1 |
| Pandina, G | 1 |
| Kusumakar, V | 1 |
| Acion, L | 2 |
| Kuperman, S | 1 |
| Tansey, M | 1 |
| Simon, V | 1 |
| van Winkel, R | 1 |
| De Hert, M | 2 |
| Swadi, HS | 1 |
| Craig, BJ | 1 |
| Pirwani, NZ | 1 |
| Black, VC | 1 |
| Buchan, JC | 1 |
| Bobier, CM | 1 |
| Secher, A | 1 |
| Husum, H | 1 |
| Holst, B | 1 |
| Egerod, KL | 1 |
| Mellerup, E | 1 |
| Correll, CU | 1 |
| Manu, P | 1 |
| Olshanskiy, V | 1 |
| Napolitano, B | 3 |
| Malhotra, AK | 2 |
| Ellingrod, VL | 3 |
| Zimmerman, B | 1 |
| Sivitz, WI | 1 |
| Park, S | 2 |
| Yoon, S | 1 |
| Noh, JS | 1 |
| Choi, SY | 1 |
| Baik, JH | 1 |
| Hong, SM | 1 |
| Ahn, IL | 1 |
| Kim, DS | 1 |
| Maayan, LA | 1 |
| Vakhrusheva, J | 1 |
| Gross, C | 1 |
| Blasey, CM | 1 |
| Roe, RL | 1 |
| Belanoff, JK | 1 |
| Verma, S | 1 |
| Subramaniam, M | 1 |
| Abdin, E | 1 |
| Sim, K | 1 |
| Su, A | 1 |
| Lee, N | 1 |
| Chong, SA | 1 |
| Hong, CJ | 3 |
| Liou, YJ | 3 |
| Bai, YM | 3 |
| Chen, TT | 1 |
| Wang, YC | 2 |
| Tsai, SJ | 3 |
| Moreno, C | 1 |
| Alvarez, M | 1 |
| Alda, JA | 1 |
| Martínez-Cantarero, C | 1 |
| Sánchez, B | 1 |
| Giráldez, M | 2 |
| Wehmeier, PM | 1 |
| Kühnau, W | 1 |
| Schmidtke, J | 1 |
| Findling, RL | 3 |
| Johnson, JL | 1 |
| McClellan, J | 1 |
| Frazier, JA | 1 |
| Hamer, RM | 2 |
| McNamara, NK | 1 |
| Lingler, J | 1 |
| Hlastala, S | 1 |
| Pierson, L | 1 |
| Puglia, M | 1 |
| Maloney, AE | 2 |
| Kaufman, EM | 1 |
| Noyes, N | 1 |
| Sikich, L | 2 |
| Goeb, JL | 1 |
| Marco, S | 1 |
| Duhamel, A | 1 |
| Kechid, G | 1 |
| Bordet, R | 2 |
| Thomas, P | 1 |
| Delion, P | 1 |
| Jardri, R | 1 |
| Yang, J | 1 |
| Bahk, WM | 1 |
| Cho, HS | 1 |
| Jeon, YW | 1 |
| Jon, DI | 1 |
| Jung, HY | 1 |
| Kim, HC | 1 |
| Kim, YK | 1 |
| Kim, YH | 1 |
| Kwon, JS | 1 |
| Lee, SY | 2 |
| Lee, SH | 1 |
| Yi, JS | 1 |
| Lencz, T | 1 |
| Robinson, DG | 2 |
| Sevy, S | 1 |
| Goldman, D | 1 |
| Cañas, F | 2 |
| Möller, HJ | 1 |
| Rummel-Kluge, C | 1 |
| Komossa, K | 1 |
| Schwarz, S | 1 |
| Hunger, H | 1 |
| Schmid, F | 1 |
| Lobos, CA | 1 |
| Kissling, W | 1 |
| Davis, JM | 2 |
| Leucht, S | 1 |
| Hung, GC | 1 |
| Kuo, CJ | 1 |
| Huang, MC | 1 |
| Kao, LH | 1 |
| Chen, YY | 1 |
| Mittoux, A | 1 |
| Park, MH | 1 |
| Patkar, AA | 1 |
| Pae, CU | 1 |
| Hoekstra, PJ | 1 |
| Troost, PW | 1 |
| Lahuis, BE | 1 |
| Mulder, H | 1 |
| Mulder, EJ | 1 |
| Franke, B | 1 |
| Buitelaar, JK | 2 |
| Anderson, GM | 2 |
| Minderaa, RB | 1 |
| Lauressergues, E | 1 |
| Martin, F | 1 |
| Helleboid, A | 1 |
| Bouchaert, E | 1 |
| Cussac, D | 1 |
| Hum, D | 1 |
| Luc, G | 1 |
| Majd, Z | 1 |
| Staels, B | 1 |
| Duriez, P | 1 |
| Cuerda, C | 1 |
| Velasco, C | 1 |
| Gutierrez, A | 1 |
| Leiva, M | 1 |
| de Castro, MJ | 1 |
| Bretón, I | 1 |
| Camblor, M | 1 |
| García-Peris, P | 1 |
| Dulín, E | 1 |
| Sanz, I | 1 |
| Desco, M | 1 |
| Adeneye, AA | 1 |
| Agbaje, EO | 1 |
| Olagunju, JA | 1 |
| Motyl, KJ | 1 |
| Dick-de-Paula, I | 1 |
| Lotinun, S | 1 |
| Bornstein, S | 1 |
| de Paula, FJ | 1 |
| Baron, R | 1 |
| Houseknecht, KL | 1 |
| Rosen, CJ | 1 |
| Demb, H | 1 |
| Valicenti-McDermott, M | 1 |
| Navarro, A | 1 |
| Ayoob, KT | 1 |
| Prabhakar, M | 1 |
| Haynes, WG | 2 |
| Coryell, WH | 1 |
| Chrischilles, EA | 1 |
| Miller, del D | 1 |
| Arndt, S | 1 |
| Warren, L | 1 |
| Fiedorowicz, JG | 2 |
| Tsai, A | 1 |
| Wu, CL | 2 |
| Huang, HH | 1 |
| Doknic, M | 2 |
| Maric, NP | 1 |
| Britvic, D | 1 |
| Pekic, S | 2 |
| Damjanovic, A | 2 |
| Miljic, D | 2 |
| Stojanovic, M | 1 |
| Radojicic, Z | 1 |
| Jasovic Gasic, M | 1 |
| Popovic, V | 2 |
| Smith, RC | 1 |
| Rachakonda, S | 1 |
| Dwivedi, S | 1 |
| Covell, NH | 1 |
| McEvoy, JP | 4 |
| Schooler, NR | 2 |
| Stroup, TS | 2 |
| Jackson, CT | 1 |
| Rojas, IA | 1 |
| Essock, SM | 1 |
| Ye, W | 1 |
| Fujikoshi, S | 1 |
| Nakahara, N | 1 |
| Takahashi, M | 1 |
| Ascher-Svanum, H | 2 |
| Ohmori, T | 1 |
| Ahmed, H | 1 |
| Ali, H | 1 |
| Xie, D | 1 |
| Houston, JP | 1 |
| Kohler, J | 1 |
| Bishop, JR | 1 |
| Ostbye, KM | 1 |
| Zhao, F | 1 |
| Conley, RR | 6 |
| Poole Hoffmann, V | 1 |
| Fijal, BA | 1 |
| Pai, N | 1 |
| Deng, C | 1 |
| Vella, SL | 1 |
| Castle, D | 1 |
| Hu, X | 1 |
| Jin, C | 1 |
| Li, W | 1 |
| Ota, M | 1 |
| Mori, K | 1 |
| Nakashima, A | 1 |
| Kaneko, YS | 1 |
| Fujiwara, K | 1 |
| Itoh, M | 1 |
| Nagasaka, A | 1 |
| Ota, A | 1 |
| Martin, A | 4 |
| L'Ecuyer, S | 1 |
| Wirshing, DA | 2 |
| Boyd, JA | 1 |
| Meng, LR | 1 |
| Ballon, JS | 1 |
| Wirshing, WC | 2 |
| Pavuluri, MN | 1 |
| Janicak, PG | 1 |
| Carbray, J | 1 |
| Lindenmayer, JP | 1 |
| Czobor, P | 1 |
| Volavka, J | 2 |
| Citrome, L | 2 |
| Sheitman, B | 1 |
| Cooper, TB | 1 |
| Chakos, M | 1 |
| Cesena, M | 1 |
| Gonzalez-Heydrich, J | 1 |
| Szigethy, E | 2 |
| Kohlenberg, TM | 1 |
| DeMaso, DR | 1 |
| McIntyre, RS | 2 |
| Gupta, S | 1 |
| Atmaca, M | 1 |
| Kuloglu, M | 1 |
| Tezcan, E | 1 |
| Ustundag, B | 1 |
| Bobes, J | 2 |
| Rejas, J | 2 |
| Garcia-Garcia, M | 1 |
| Rico-Villademoros, F | 1 |
| García-Portilla, MP | 1 |
| Fernández, I | 1 |
| Hernández, G | 1 |
| Goudie, AJ | 1 |
| Halford, JC | 1 |
| Cooper, GD | 1 |
| Dovey, T | 1 |
| Pickavance, LC | 1 |
| Wilding, JP | 1 |
| Mancini, DA | 1 |
| Basile, VS | 1 |
| Srinivasan, J | 1 |
| Kennedy, SH | 1 |
| Fitzgerald, PB | 1 |
| Scaffidi, A | 1 |
| Morris, MJ | 1 |
| de Castella, AR | 1 |
| Kulkarni, J | 1 |
| Holtmann, M | 1 |
| Kopf, D | 1 |
| Mayer, M | 1 |
| Bechtinger, E | 1 |
| Schmidt, MH | 1 |
| Garyfallos, G | 1 |
| Dimelis, D | 1 |
| Kouniakis, P | 1 |
| Sidiropoulos, N | 1 |
| Karastergiou, A | 1 |
| Lavrentiadis, G | 1 |
| Giouzepas, J | 1 |
| Fokas, K | 1 |
| Masi, G | 1 |
| Cosenza, A | 1 |
| Mucci, M | 1 |
| Brovedani, P | 1 |
| Kelly, DL | 2 |
| Kreyenbuhl, J | 1 |
| Love, RC | 2 |
| Van-Duong, Q | 1 |
| Zalsman, G | 1 |
| Carmon, E | 1 |
| Bensason, D | 1 |
| Tyano, S | 1 |
| Mosolov, SN | 1 |
| Kabanov, SO | 1 |
| Ziegenbein, M | 1 |
| Kropp, S | 1 |
| Lasser, RA | 1 |
| Mao, L | 1 |
| Gharabawi, G | 1 |
| Dossenbach, M | 1 |
| Erol, A | 1 |
| el Mahfoud Kessaci, M | 1 |
| Shaheen, MO | 1 |
| Sunbol, MM | 1 |
| Boland, J | 1 |
| Hodge, A | 1 |
| O'Halloran, RA | 1 |
| Bitter, I | 1 |
| Alméras, N | 1 |
| Després, JP | 1 |
| Villeneuve, J | 1 |
| Demers, MF | 1 |
| Roy, MA | 1 |
| Cadrin, C | 1 |
| Mottard, JP | 1 |
| Bouchard, RH | 1 |
| Gagliano, A | 1 |
| Germanò, E | 1 |
| Pustorino, G | 1 |
| Impallomeni, C | 1 |
| D'Arrigo, C | 1 |
| Calamoneri, F | 1 |
| Spina, E | 1 |
| Chuang, S | 1 |
| Lindsay, RL | 1 |
| Leone, S | 1 |
| Safer, DJ | 1 |
| Lee, E | 1 |
| Leung, CM | 1 |
| Wong, E | 1 |
| Fell, MJ | 2 |
| Neill, JC | 2 |
| Marshall, KM | 2 |
| Sahli, Ch | 1 |
| Bryois, Ch | 1 |
| Mackell, J | 1 |
| Farwell, WR | 1 |
| Stump, TE | 1 |
| Wang, J | 1 |
| Tafesse, E | 1 |
| L'Italien, G | 1 |
| Tierney, WM | 1 |
| Berger-Gross, P | 1 |
| Coletti, DJ | 1 |
| Hirschkorn, K | 1 |
| Terranova, E | 1 |
| Simpser, EF | 1 |
| Vieweg, WV | 1 |
| Sood, AB | 1 |
| Pandurangi, A | 1 |
| Silverman, JJ | 1 |
| Bakos, CD | 1 |
| Berecz, R | 1 |
| Degrell, I | 1 |
| Schooler, N | 1 |
| Rabinowitz, J | 2 |
| Davidson, M | 1 |
| Emsley, R | 2 |
| Harvey, PD | 1 |
| Kopala, L | 1 |
| McGorry, PD | 1 |
| Van Hove, I | 1 |
| Swyzen, W | 1 |
| De Smedt, G | 1 |
| Gasquet, I | 1 |
| Haro, JM | 1 |
| Novick, D | 1 |
| Edgell, ET | 1 |
| Kennedy, L | 1 |
| Lepine, JP | 1 |
| Apiquian, R | 1 |
| Fresan, A | 1 |
| Ulloa, RE | 1 |
| de la Fuente-Sandoval, C | 1 |
| Herrera-Estrella, M | 1 |
| Vazquez, A | 1 |
| Nicolini, H | 1 |
| Kapur, S | 1 |
| Canitano, R | 1 |
| Mohl, A | 1 |
| Westlye, K | 1 |
| Opjordsmoen, S | 1 |
| Lex, A | 1 |
| Schreiner, A | 1 |
| Benoit, M | 1 |
| Bräunig, P | 1 |
| Medori, R | 2 |
| Roerig, JL | 2 |
| Mitchell, JE | 2 |
| de Zwaan, M | 1 |
| Crosby, RD | 2 |
| Gosnell, BA | 2 |
| Steffen, KJ | 2 |
| Wonderlich, SA | 1 |
| Swartz, MS | 1 |
| Rosenheck, RA | 1 |
| Perkins, DO | 2 |
| Keefe, RS | 1 |
| Davis, SM | 1 |
| Davis, CE | 1 |
| Lebowitz, BD | 1 |
| Severe, J | 1 |
| Hsiao, JK | 1 |
| Lin, YH | 1 |
| Liu, CY | 1 |
| Hsiao, MC | 1 |
| Mou, XD | 1 |
| Zhang, ZJ | 1 |
| Yao, ZJ | 1 |
| Liu, W | 1 |
| Zhang, XR | 1 |
| Shi, JB | 1 |
| Sun, J | 1 |
| Stensland, MD | 1 |
| Kinon, BJ | 3 |
| Tollefson, GD | 2 |
| Ness-Abramof, R | 1 |
| Apovian, CM | 1 |
| Birkás Kováts, D | 1 |
| Palik, E | 1 |
| Faludi, G | 1 |
| Cseh, K | 1 |
| Reiss, JP | 1 |
| Sam, D | 1 |
| Sareen, J | 1 |
| Kostulski, A | 1 |
| Wyszogrodzka-Kucharska, A | 1 |
| Rabe-Jabłońska, J | 1 |
| Hellings, JA | 2 |
| Zarcone, JR | 2 |
| Reese, RM | 1 |
| Valdovinos, MG | 1 |
| Marquis, JG | 1 |
| Fleming, KK | 1 |
| Schroeder, SR | 2 |
| Lane, HY | 1 |
| Liu, YC | 1 |
| Huang, CL | 1 |
| Chang, YC | 1 |
| Wu, PL | 1 |
| Lu, CT | 1 |
| Chang, WH | 1 |
| Rondanelli, M | 1 |
| Sarra, S | 1 |
| Antoniello, N | 1 |
| Mansi, V | 1 |
| Govoni, S | 1 |
| Falvo, F | 1 |
| Solerte, SB | 1 |
| Ferrari, E | 1 |
| Hardy, TA | 1 |
| Marquez, E | 1 |
| Kryzhanovskaya, L | 1 |
| Taylor, CC | 2 |
| Cavazzoni, P | 2 |
| Lin, EJ | 1 |
| Lee, NJ | 1 |
| Slack, K | 1 |
| Karl, T | 1 |
| Duffy, L | 1 |
| O'brien, E | 1 |
| Matsumoto, I | 1 |
| Dedova, I | 1 |
| Herzog, H | 1 |
| Sainsbury, A | 1 |
| Theleritis, CG | 1 |
| Papadimitriou, GN | 1 |
| Papageorgiou, CC | 1 |
| Dikeos, DG | 1 |
| Masdrakis, V | 1 |
| Kostoulas, C | 1 |
| Psarros, C | 1 |
| Soldatos, CR | 1 |
| Lin, SK | 1 |
| Chen, CK | 1 |
| Baptista, T | 2 |
| Martinez, M | 1 |
| Lacruz, A | 1 |
| Arellano, A | 1 |
| Mendoza, S | 1 |
| Hernández, L | 1 |
| Contreras, Q | 1 |
| Galeazzi, T | 1 |
| Vargas, D | 1 |
| Luby, J | 1 |
| Mrakotsky, C | 1 |
| Stalets, MM | 1 |
| Belden, A | 1 |
| Heffelfinger, A | 1 |
| Williams, M | 1 |
| Spitznagel, E | 1 |
| Zhang, XY | 1 |
| Tan, YL | 1 |
| Zhou, DF | 1 |
| Cao, LY | 1 |
| Wu, GY | 1 |
| Xu, Q | 1 |
| Shen, Y | 1 |
| Haile, CN | 1 |
| Kosten, TA | 1 |
| Kosten, TR | 1 |
| Woerner, MG | 1 |
| Patel, RC | 1 |
| Sevy, SM | 1 |
| Gunduz-Bruce, H | 1 |
| Soto-Perello, JM | 1 |
| Mendelowitz, A | 1 |
| Khadivi, A | 1 |
| Miller, R | 1 |
| McCormack, J | 1 |
| Lorell, BS | 1 |
| Lesser, ML | 1 |
| Ruaño, G | 1 |
| Goethe, JW | 1 |
| Caley, C | 1 |
| Woolley, S | 1 |
| Holford, TR | 1 |
| Kocherla, M | 1 |
| Windemuth, A | 1 |
| de Leon, J | 1 |
| Walton, RG | 1 |
| Murashita, M | 1 |
| Inoue, T | 1 |
| Kusumi, I | 1 |
| Nakagawa, S | 1 |
| Itoh, K | 1 |
| Tanaka, T | 1 |
| Izumi, T | 1 |
| Hosoda, H | 1 |
| Kangawa, K | 1 |
| Koyama, T | 1 |
| Archie, SM | 1 |
| Goldberg, JO | 1 |
| Akhtar-Danesh, N | 1 |
| Landeen, J | 1 |
| McColl, L | 1 |
| McNiven, J | 1 |
| Hamilton, JD | 1 |
| Linden, M | 1 |
| Eich, FX | 1 |
| Pyrkosch, L | 1 |
| Khalili, H | 1 |
| Dashti-Khavidaki, S | 1 |
| Okhovatpour, H | 1 |
| Ghaeli, P | 1 |
| Strassnig, M | 1 |
| Miewald, J | 1 |
| Keshavan, M | 1 |
| Ganguli, R | 2 |
| Sahoo, S | 1 |
| Mishra, B | 1 |
| Akhtar, S | 2 |
| Siuciak, JA | 1 |
| McCarthy, SA | 1 |
| Martin, AN | 1 |
| Chapin, DS | 1 |
| Stock, J | 1 |
| Nadeau, DM | 1 |
| Kantesaria, S | 1 |
| Bryce-Pritt, D | 1 |
| McLean, S | 1 |
| Maric, N | 1 |
| Popovic, S | 1 |
| Miljic, N | 1 |
| Djurovic, M | 1 |
| Jasovic-Gasic, M | 1 |
| Dieguez, C | 1 |
| Casanueva, FF | 1 |
| Gu, H | 1 |
| Lazarus, A | 1 |
| Sweitzer, D | 1 |
| Olexy, C | 1 |
| Weiden, P | 1 |
| Strakowski, SD | 1 |
| Flanders, SC | 1 |
| Youngstrom, EA | 1 |
| Rupnow, MF | 1 |
| Jensik, SE | 1 |
| Carlson, GA | 1 |
| Muzina, DJ | 1 |
| Crocq, MA | 1 |
| Guillon, MS | 1 |
| Bailey, PE | 1 |
| Provost, D | 1 |
| Afzal, KI | 1 |
| Briones, DF | 1 |
| DeVargas, C | 1 |
| Winsberg, B | 1 |
| Usubiaga, H | 1 |
| Cooper, T | 1 |
| Gencer, O | 1 |
| Emiroglu, FN | 1 |
| Miral, S | 1 |
| Baykara, B | 1 |
| Baykara, A | 1 |
| Dirik, E | 1 |
| Carroll, BJ | 1 |
| Perlis, RH | 1 |
| Ramirez-Bonilla, ML | 2 |
| Gonzalez-Blanch, C | 1 |
| Alvarez-Jimenez, M | 1 |
| Saddichha, S | 1 |
| Ameen, S | 1 |
| Anjum, N | 1 |
| Peltola, LM | 1 |
| Koen, L | 1 |
| Oosthuizen, PP | 1 |
| Niehaus, DJ | 1 |
| Tadger, S | 1 |
| Melamed, Y | 1 |
| Carrasco-Marín, E | 1 |
| Friedel, RO | 1 |
| Jackson, WT | 1 |
| Huston, CS | 1 |
| May, RS | 1 |
| Kirby, NL | 1 |
| Stoves, A | 1 |
| Lombroso, PJ | 1 |
| King, RA | 1 |
| Lynch, KA | 1 |
| Chappell, PB | 1 |
| Peterson, BS | 1 |
| Leckman, JF | 2 |
| Penn, JV | 1 |
| Martini, J | 1 |
| Radka, D | 1 |
| Casey, DE | 1 |
| Crockford, DN | 1 |
| Fisher, G | 1 |
| Barker, P | 1 |
| Brecher, M | 1 |
| Geller, W | 1 |
| Perry, R | 1 |
| Pataki, C | 1 |
| Munoz-Silva, DM | 1 |
| Armenteros, J | 1 |
| Silva, RR | 1 |
| Schreier, HA | 1 |
| Holmes, JP | 2 |
| Carlson, DC | 1 |
| Pelton, GH | 1 |
| Cohen, DJ | 1 |
| Price, LH | 1 |
| Horrigan, JP | 1 |
| Horn, DS | 1 |
| Ushchak, CM | 1 |
| Dartnall, NA | 1 |
| Morgan, SN | 1 |
| Aquila, R | 1 |
| Emanuel, M | 1 |
| Kysar, L | 1 |
| Berisford, MA | 1 |
| Goldstein, D | 1 |
| Pashdag, J | 1 |
| Mintz, J | 1 |
| Wetterling, T | 1 |
| Müssigbrodt, HE | 1 |
| Wiznitzer, M | 1 |
| Branicky, LA | 1 |
| Maxwell, K | 1 |
| Masand, PS | 1 |
| Taylor, DM | 1 |
| McAskill, R | 1 |
| Koran, LM | 1 |
| Ringold, AL | 1 |
| Elliott, MA | 1 |
| Newman-Toker, J | 1 |
| Landau, J | 1 |
| Leebens, P | 1 |
| Ulizio, K | 1 |
| Cicchetti, D | 1 |
| Jones, B | 1 |
| Basson, BR | 2 |
| Walker, DJ | 1 |
| Crawford, AM | 1 |
| Cohen, S | 1 |
| Glazewski, R | 1 |
| Khan, S | 1 |
| Khan, A | 1 |
| Mahmoud, R | 1 |
| Brar, JS | 1 |
| Ayrton, Z | 1 |
| Szymanski, KA | 1 |
| Gilmore, JA | 1 |
| Crandall, K | 1 |
| Wallace, D | 1 |
| Simpson, MM | 1 |
| Goetz, RR | 1 |
| Devlin, MJ | 1 |
| Goetz, SA | 1 |
| Walsh, BT | 1 |
| Barak, Y | 1 |
| Ratzoni, G | 1 |
| Gothelf, D | 1 |
| Brand-Gothelf, A | 1 |
| Reidman, J | 1 |
| Kikinzon, L | 1 |
| Gal, G | 1 |
| Phillip, M | 1 |
| Apter, A | 1 |
| Weizman, R | 1 |
| Sowell, MO | 1 |
| Mukhopadhyay, N | 1 |
| Shankar, S | 1 |
| Steinberg, HO | 1 |
| Breier, A | 1 |
| Beasley, CM | 1 |
| Dananberg, J | 1 |
| Webster, D | 1 |
| Devarajan, S | 1 |
| Gallant, J | 1 |
| Harris, A | 1 |
| Kopala, LC | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Orally-Disintegrating vs. Regular Olanzapine Tablets: Effects on Weight and GI Hormones[NCT00384332] | Phase 4 | 20 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| A Randomized, Multicenter, Double-Blind, Non-inferiority Study of Paliperidone Palmitate 3 Month and 1 Month Formulations for the Treatment of Subjects With Schizophrenia[NCT01515423] | Phase 3 | 1,429 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| Treatment of Schizophrenia and Related Disorders in Children and Adolescents[NCT00053703] | Phase 4 | 116 participants (Actual) | Interventional | 2002-02-28 | Completed | ||
| Biomarkers in Autism of Aripiprazole and Risperidone Treatment[NCT01333072] | Phase 4 | 80 participants (Actual) | Interventional | 2011-07-31 | Completed | ||
| A Feasibility and Acceptability Study of Elevated Protein Dietary Intake for Children Diagnosed With Autism Spectrum Disorder (ASD) While on Atypical Antipsychotic Medication[NCT03708614] | 10 participants (Anticipated) | Interventional | 2018-12-07 | Recruiting | |||
| A Prospective, Open-Label Study to Evaluate Symptomatic Remission in Schizophrenia With Long Acting Risperidone Microspheres (Risperdal Consta)[NCT00216528] | Phase 4 | 527 participants (Actual) | Interventional | 2005-07-31 | Completed | ||
| Emotion Awareness and Skills Enhancement (EASE) Program: A Clinical Trial[NCT03432832] | 113 participants (Actual) | Interventional | 2018-01-30 | Completed | |||
| Risperidone and Behavioral Therapy in Treatment of Children and Adolescents With Autistic Disorder[NCT00080145] | 124 participants (Actual) | Interventional | 2004-02-29 | Completed | |||
| Atypical Antipsychotics for Continuation and Maintenance Treatment After an Acute Manic Episode[NCT01977300] | Phase 3 | 159 participants (Actual) | Interventional | 2003-01-31 | Completed | ||
| The Efficacy and Safety of Risperidone in Adolescents With Schizophrenia: a Comparison of Two Dose Ranges of Risperidone[NCT00034749] | Phase 3 | 279 participants (Actual) | Interventional | 2001-04-30 | Completed | ||
| A Community-based, Family Navigator Intervention to Improve Cardiometabolic Health of Medicaid-insured Youth Identified Through an Antipsychotic Medication Preauthorization Program[NCT02877823] | 302 participants (Actual) | Interventional | 2016-08-31 | Completed | |||
| 1/2-MC4R Genotype and Pediatric Antipsychotic Drug- Induced Weight Gain[NCT01844700] | Phase 4 | 14 participants (Actual) | Interventional | 2013-07-31 | Terminated (stopped due to very slow recruitment, no sufficient results) | ||
| Monitoring of Metabolic Adverse Events of Second Generation Antipsychotics in a Naive Pediatric Population Followed in Mental Health Outpatient and Inpatient Clinical Settings (MEMAS Prospective Study)[NCT04395326] | 120 participants (Anticipated) | Observational | 2017-01-01 | Recruiting | |||
| Efficacy and Safety of Add-on Topiramate vs Metformin on Cardio-Metabolic Profile in Patients With Schizophrenia on Atypical Antipsychotics With Metabolic Syndrome: a Randomized Controlled Trial[NCT05663749] | Phase 4 | 60 participants (Actual) | Interventional | 2022-09-20 | Completed | ||
| Sertindole Versus Risperidone Safety Outcome Study: a Randomised, Partially-blinded, Parallel-group, Active-controlled, Post-marketing Study[NCT00856583] | Phase 3 | 9,809 participants (Actual) | Interventional | 2002-07-31 | Completed | ||
| Independent Investigator Grant Study-Comparative Effects of Chronic Treatment With Olanzapine and Risperidone on Glucose and Lipid Metabolism[NCT00287820] | Phase 4 | 46 participants (Anticipated) | Interventional | 2004-02-29 | Completed | ||
| Effectiveness of Switching Antipsychotic Medications[NCT00044655] | Phase 4 | 219 participants (Actual) | Interventional | 2001-07-31 | Completed | ||
| Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Double-Blind Comparison With Placebo[NCT00088036] | Phase 3 | 450 participants | Interventional | 2004-02-29 | Completed | ||
| Olanzapine Versus Divalproex and Placebo in the Treatment of Mild to Moderate Mania Associated With Bipolar I Disorder[NCT00094549] | Phase 4 | 500 participants | Interventional | 2004-10-31 | Completed | ||
| The Study of Olanzapine Plus Fluoxetine in Combination for Treatment-Resistant Depression Without Psychotic Features[NCT00035321] | Phase 3 | 600 participants | Interventional | 2002-04-30 | Completed | ||
| Efficacy and Safety of Olanzapine in Patients With Borderline Personality Disorder: A Randomized Flexible Dose Double-Blind Comparison With Placebo[NCT00091650] | Phase 3 | 300 participants | Interventional | 2004-03-31 | Completed | ||
| Transcranial Magnetic Stimulation for Individuals With Tourette's Syndrome[NCT00529308] | Phase 2 | 20 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| Aripiprazole for Clozapine Associated Medical Morbidity[NCT00345033] | Phase 4 | 38 participants (Actual) | Interventional | 2005-03-31 | Completed | ||
| Outcome Evaluation of Solutions for Wellness and Team Solutions Program in Patients With Severe Mental Illness[NCT00661869] | 295 participants (Actual) | Interventional | 2006-09-30 | Completed | |||
| A Comparison of the Effects of Modafinil on Olanzapine Associated Eating Behaviors in Normal Human Subjects[NCT00636896] | 50 participants (Actual) | Interventional | 2006-07-31 | Completed | |||
| Relative Effectiveness of Schizophrenia Therapy (REST) Study[NCT01245348] | 1,110 participants (Actual) | Observational | 2010-12-31 | Completed | |||
| Comparative Effectiveness of Antipsychotic Medications in Patients With Schizophrenia (CATIE Schizophrenia Trial)[NCT00014001] | Phase 4 | 1,600 participants | Interventional | 2000-12-31 | Completed | ||
| Feasibility of Using Holographic Memory Resolution® (HMR) in Patients/Clients With Pain[NCT05001399] | 60 participants (Actual) | Interventional | 2021-10-25 | Completed | |||
| Clinical Utility of Pharmacogenomics of Psychotropic Medications[NCT03907124] | Phase 4 | 0 participants (Actual) | Interventional | 2019-06-03 | Withdrawn (stopped due to PI left institution prior to recruitment.) | ||
| A Phase IIA, Prospective, Randomized, Double-blind, Multiple-dose Study of NW-3509A in Chronic Schizoprhenia Patients Not Responding to Their Current Anti-psychotic Medication[NCT02624167] | Phase 2 | 90 participants (Actual) | Interventional | 2015-12-31 | Completed | ||
| Pharmacologic Augmentation of Neurocognition and Cognitive Training in Psychosis[NCT02634684] | Phase 2 | 82 participants (Actual) | Interventional | 2014-07-01 | Completed | ||
| Reducing Cardiovascular Risk in Adults With Serious Mental Illness Using an Electronic Medical Record-based Clinical Decision Support[NCT02451670] | 10,347 participants (Actual) | Interventional | 2016-01-20 | Completed | |||
| A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Evaluate Efficacy and Safety Study of Iloperidone Virus Risperidone to Treat Schizophrenia[NCT01623713] | Phase 2 | 260 participants (Actual) | Interventional | 2012-06-30 | Completed | ||
| DNA Diagnostics for Minimizing Metabolic Side-Effects of Antipsychotics[NCT00752960] | 1,000 participants (Anticipated) | Observational | 2007-01-31 | Recruiting | |||
| Efficacy and Tolerability of Olanzapine, Quetiapine and Risperidone in the Treatment of First Episode Psychosis: A Randomized Double Blind 52-Week Comparison[NCT00034892] | Phase 3 | 0 participants | Interventional | 2002-03-31 | Completed | ||
| A Placebo-Controlled, Cross-Over Trial of Aripiprazole Added to Obese Olanzapine-Treated Patients With Schizophrenia[NCT00351936] | Phase 4 | 16 participants (Actual) | Interventional | 2005-12-31 | Completed | ||
| Reduction of Body Weight in Olanzapine Treated Schizophrenia Patients by Adjunctive Supplementation of Antioxidants (Vitamins E + C) Plus Omega-3 Fatty Acids[NCT00211562] | Phase 3 | 20 participants (Actual) | Interventional | 2005-10-31 | Terminated | ||
| A Clinical Trial Of Weight Reduction in Schizophrenia[NCT00158366] | 261 participants (Actual) | Interventional | 2004-05-31 | Completed | |||
| Effects of Atypical Antipsychotics on Appetite and Eating Behavior of Schizophrenia Patients: Analysis for Three Drugs, Olanzapine, Risperidone, and Aripiprazole, Known to Induce Different Degrees of Weight Gain[NCT01043250] | 81 participants (Actual) | Observational | 2009-05-31 | Completed | |||
| Severe Aberrant Behavior Among Persons With Mental Retardation. Project III: Behavioral Selectivity of Atypical Neuroleptic Drugs: Effects on Cognitive and Social Behaviors[NCT00065273] | Phase 3 | 50 participants | Interventional | 1998-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Montgomery Asberg Depression Rating Scale (MADRS) total score. Construct: Depression severity. Scores below represent mean change scores, endpoint minus baseline. Minimum total score: 0 (no depression). Maximum total score: 60 (severe depression). Lower (more negative) scores indicate a better outcome. There are no subscales. (NCT00384332)
Timeframe: 10 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Arm 1 | -15.5 |
| Arm 2 | -15.5 |
Change in weight from baseline to endpoint in kilograms. Reported as weight in Kilograms at Baseline, Weeks 1, 4, 6, and 8 (NCT00384332)
Timeframe: 10 weeks
| Intervention | kilograms (Mean) | ||||
|---|---|---|---|---|---|
| Baseline | Week 1 | Week 4 | Week 6 | Week 8 | |
| Arm 1- ODT | 76.0 | 77.4 | 77.8 | 78.9 | 79.1 |
| Arm 2- SOT | 76.1 | 77.6 | 78.3 | 79.4 | 80.1 |
Symptomatic remission criterion was defined as having a simultaneous score of mild or less on all selected PANSS items (P1, P2, P3, N1, N4, N6, G5, and G9). Symptomatic remission was defined for the last 6 months of the Double-blind Phase as meeting the remission criterion during the 6 months prior to the End of study visit during the Double-blind Phase, with one excursion allowed. (NCT01515423)
Timeframe: Weeks 41 to 65
| Intervention | Percentage of Participants (Number) |
|---|---|
| Double Blind: Paliperidone Palmitate 3 Month Formulation | 58.4 |
| Double Blind: Paliperidone Palmitate 1 Month Formulation | 59.2 |
Relapse defined as: Psychiatric hospitalization;participant had an increase of 25 percent in total PANSS score from randomization for 2 consecutive assessments separated by 3-7 days if score at randomization was greater than (>) 40; had a 10 point increase in total PANSS score from randomization for 2 consecutive assessments separated by 3-7 days if score at randomization was less than or equal to (<=) 40; deliberate self-injury or exhibited violent behavior resulting in suicide, clinically significant injury;suicidal or homicidal ideation and aggressive behavior;For PANSS items-had a score of greater than or equal to (>=) 5 after randomization for 2 consecutive assessments separated by 3-7 days on any of above items if maximum score for these above PANSS items was <=3 at randomization; had a score of >=6 after randomization for 2 consecutive assessments separated by 3-7 days on any of above items if maximum score for these above PANSS items was 4 at randomization. (NCT01515423)
Timeframe: Up to 48 weeks
| Intervention | Percentage of Participants (Number) |
|---|---|
| Double Blind: Paliperidone Palmitate 3 Month Formulation | 91.5 |
| Double Blind: Paliperidone Palmitate 1 Month Formulation | 90.0 |
5 PANSS Marder factor scores (positive symptoms [range:8 to 56], negative symptoms [range: 7 to 49], disorganized thoughts [range: 7 to 49], uncontrolled hostility/excitement [range: 4 to 28], and anxiety/depression [range: 4 to 28]) were examined to gain insight into the symptoms affected by treatment with the study drug. Negative change from baseline in subscales score for positive symptoms, negative symptoms, disorganized thoughts, uncontrolled hostility/excitement, and anxiety/depression indicates improvement in various symptoms of schizophrenia. (NCT01515423)
Timeframe: DB Baseline (Week 17) and 48 week or DB Endpoint
| Intervention | Units on a scale (Mean) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Positive symptoms factor: Baseline | Positive symptoms factor:Change at Endpoint | Negative symptoms factor: Baseline | Negative symptoms factor : Change at Endpoint | Disorganized thoughts factor :Baseline | Disorganized thoughts factor:Change at Endpoint | Uncontrolled hostility Factor:Baseline | Uncontrolled hostility Factor:Change at Endpoint | Anxiety/depression factor:Baseline | Anxiety/depression factor:Change at Endpoint | |
| Double Blind: Paliperidone Palmitate 1 Month Formulation | 15.8 | -1.4 | 16.3 | -1.3 | 14.3 | -1.2 | 5.4 | -0.2 | 6.3 | -0.2 |
| Double Blind: Paliperidone Palmitate 3 Month Formulation | 15.7 | -1.1 | 16.2 | -1.4 | 14.2 | -1.2 | 5.2 | 0.2 | 6.1 | -0.0 |
The neuropsychiatric symptoms of schizophrenia were assessed by means of the 30-item Positive and Negative Syndrome Scale (PANSS). The PANSS provides a total score (sum of the scores of all 30 items) ranging from 30 to 210, higher scores indicate more severe neuropsychiatric symptoms of schizophrenia. Scores for 3 subscales, that is, for positive subscale (sum of the scores of all 7 items) and negative subscale (sum of the scores of all 7 items) ranges from 7 (absent) to 49 (extreme psychopathology), and for the general psychopathology subscale (sum of the scores of all 16 items) score ranges from 16 (absent) to 112 (extreme psychopathology). (NCT01515423)
Timeframe: DB Baseline (Week 17) and 48 week or DB Endpoint
| Intervention | Units on a scale (Mean) | |||||
|---|---|---|---|---|---|---|
| Positive subscale: Baseline | Positive subscale:Change at Endpoint | Negative subscale: Baseline | Negative subscale:Change at Endpoint | General psychopathology : Baseline | General psychopathology : Change at Endpoint | |
| Double Blind: Paliperidone Palmitate 1 Month Formulation | 12.0 | -0.9 | 17.3 | -1.4 | 28.8 | -2.0 |
| Double Blind: Paliperidone Palmitate 3 Month Formulation | 11.9 | -0.6 | 17.3 | -1.4 | 28.2 | -1.4 |
"The Clinical Global Impression Severity (CGI-S) rating scale is a 7 point global assessment that measures the clinician's impression of the severity of illness exhibited by a participant. A rating of 1 is equivalent to Normal, not at all ill and a rating of 7 is equivalent to Among the most extremely ill participants. Higher scores indicate worsening." (NCT01515423)
Timeframe: DB Baseline (Week 17) and 48 week or DB Endpoint
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at DB End point | |
| Double Blind: Paliperidone Palmitate 1 Month Formulation | 2.9 | -0.1 |
| Double Blind: Paliperidone Palmitate 3 Month Formulation | 2.9 | -0.1 |
The Personal and Social Performance (PSP) scale assesses degree of a participant's dysfunction within 4 domains of behavior: socially useful activities, personal and social relationships, self-care, and disturbing and aggressive behavior. Score ranges from 1 to 100. Participants with a score of 71 to 100 have mild degree of difficulty; from 31 to 70, varying degrees of disability; less than or equal to 30, functioning so poorly as to require intensive supervision. (NCT01515423)
Timeframe: DB Baseline (Week 17) and 48 week or DB Endpoint
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at DB End point | |
| Double Blind: Paliperidone Palmitate 1 Month Formulation | 65.0 | 1.9 |
| Double Blind: Paliperidone Palmitate 3 Month Formulation | 65.5 | 1.3 |
The neuropsychiatric symptoms of schizophrenia were assessed by means of the 30-item Positive and Negative Syndrome Scale (PANSS). The PANSS provides a total score (sum of the scores of all 30 items) ranging from 30 to 210, higher scores indicate more severe neuropsychiatric symptoms of schizophrenia. Scores for 3 subscales, that is, for positive subscale (sum of the scores of all 7 items) and negative subscale (sum of the scores of all 7 items) ranges from 7 (absent) to 49 (extreme psychopathology), and for the general psychopathology subscale (sum of the scores of all 16 items) score ranges from 16 (absent) to 112 (extreme psychopathology). (NCT01515423)
Timeframe: DB Baseline (Week 17) and 48 week or DB Endpoint
| Intervention | Units on a scale (Mean) | |
|---|---|---|
| Baseline | Change from Baseline at DB End point | |
| Double Blind: Paliperidone Palmitate 1 Month Formulation | 58.1 | -4.3 |
| Double Blind: Paliperidone Palmitate 3 Month Formulation | 57.4 | -3.5 |
Barnes Akathisia Scale is a clinician rated scale which considers information based on observation of the participant as well as participant report. The scale includes 3 items rated between 0- none to 3 severe and 1 summary item rated between 0 none to 5 severe. All items are summed to obtain the total score. The minimal total score is 0 and the maximal score is 14 with higher scores reflecting more severe akathisia. A score of 4 or more is clinically significant. (NCT00053703)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Olanzapine | 0.19 |
| Risperidone | 0.41 |
| Molindone | 1.23 |
Change from baseline in Body Mass Index Change, kg/m2, at week 8, last observation was carried forward for individuals who withdrew from treatment early. (NCT00053703)
Timeframe: 8 weeks
| Intervention | kg/m2 (Mean) |
|---|---|
| Olanzapine | 1.27 |
| Risperidone | 2.20 |
| Molindone | 0.15 |
The PANSS (described above) includes 7 items that reflect negative psychotic symptoms such as amotivation and social withdrawal. As are all items within the PANSS, items are categorically rated by the clinician between 0 - no symptoms to 7 extreme symptoms. The minimal score is 0 reflecting no positive symptoms to 49 reflecting that all items were extreme. Higher scores reflect more severe symptoms. Scores above 18 are usually clinically significant. (NCT00053703)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Olanzapine | -5.3 |
| Risperidone | -5.1 |
| Molindone | -5.8 |
The PANSS (described above) includes 7 items that reflect positive psychotic symptoms such as hallucinations and delusions. As are all items within the PANSS, items are categorically rated by the clinician between 0 - no symptoms to 7 extreme symptoms. The minimal score is 0 reflecting no positive symptoms to 49 reflecting that all items were extreme. Higher scores reflect more severe symptoms. Scores above 18 are usually clinically significant. (NCT00053703)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Olanzapine | -8.9 |
| Risperidone | -8.4 |
| Molindone | -8.8 |
Assessed with the Positive and Negative Syndrome Scale in which a clinician rates various psychotic symptoms on the basis of observation of the participant, interview with the participant, and review of all other available information including informant reports. The scale consists of 30 items which are rated categorically between 1 - no symptoms to 7 - extreme symptoms. The minimal score is 0 and the maximal score is 210, with higher scores reflecting more symptoms. Typically scores > that 60 are considered clinically significant. (NCT00053703)
Timeframe: 8 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Olanzapine | -26.6 |
| Risperidone | -23.7 |
| Molindone | -27.0 |
change in weight from baseline to week 8 in kg (NCT00053703)
Timeframe: 8 weeks
| Intervention | Kg (Mean) |
|---|---|
| Olanzapine | 6.12 |
| Risperidone | 3.64 |
| Molindone | 0.34 |
"Multi-center, blinded clinical trial to evaluate biomarkers as predictors of efficacy and safety in children with autistic disorder to risperidone, an atypical antipsychotic drug and aripiprazole, an antipsychotic having a unique clinical and receptor-binding profile.~The major outcome measure was the score on the Irritability subscale of the Aberrant Behavior Checklist (ABC-I) . The ABC has 58 items describing some aspect of behavior and the Irritability sub-scale has 15 items, each completed by a parent or caregiver under the supervision of an investigator. Scores on each item range from 0 = no problem and 3 = severe problem (range of total scores 0 to 45). A fall in scores indicates behavioral improvement." (NCT01333072)
Timeframe: baseline to 10 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Risperidone | 12.7 |
| Aripiprazole | 14.1 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | percentage of weight change (Mean) |
|---|---|
| Ziprasidone | 11.58 |
| Aripiprazole, Quetiapine, Risperidone | 5.66 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI percentile (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | 37.67 | 62.5 |
| Ziprasidone | 32 | 59 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | BMI z-score (Mean) | |
|---|---|---|
| baseline | week 12 (n=1, n=2) | |
| Aripiprazole, Quetiapine, Risperidone | -0.37 | 0.38 |
| Ziprasidone | -0.51 | 0.22 |
(NCT01844700)
Timeframe: baseline to week 12
| Intervention | lbs (Mean) | |
|---|---|---|
| baseline | week 12 (n=1,2) | |
| Aripiprazole, Quetiapine, Risperidone | 118.5 | 141 |
| Ziprasidone | 120.5 | 151 |
"The analysis was based on all deaths from the WRT+30 days period using the classification performed by the ISC.~The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide." (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 31 |
| Risperidone | 12 |
The analysis was based on all deaths from the WRT+30 days period using the classification based upon the Medical Dictionary for Regulatory Activities (MedDRA) terminology, that is, as reported by the investigator (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 17 |
| Risperidone | 8 |
"The analysis was based on all deaths from the WRT+30 days period using the classification performed by the ISC.~The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide." (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 14 |
| Risperidone | 21 |
The analysis was based on all deaths from the WRT+30 days period using the classification based upon MedDRA terminology, that is, as reported by the investigator (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 13 |
| Risperidone | 21 |
"The analysis was based on all deaths from the WRT+30 days period using the classification performed by the ISC.~The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide." (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 19 |
| Risperidone | 28 |
The analysis was based on all deaths from the WRT+30 days period using the classification based upon MedDRA terminology, that is, as reported by the investigator (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 34 |
| Risperidone | 32 |
The analysis was based on time from start of study drug until stop of study drug for any reason other than sponsor closure of the study (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 3136 |
| Risperidone | 2597 |
The analysis was based on time from start of study drug to first hospitalisation during the WRT+30 days period (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 174 |
| Risperidone | 149 |
"The analysis was based on all suicides and suicide attempts from the WRT+30 days period using the classification performed by the ISC.~The ISC reviewed and classified those adverse events which resulted in death or hospitalisation or were possible suicide attempts and this review was blinded to exposure. The definition of cardiac death was intentionally wide; sudden or unexplained deaths were assumed to be cardiac if there was no non-cardiac explanation. To ensure consistent evaluation and classification, the ISC decided a priori to classify all instances of self harm as possible suicide." (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 68 |
| Risperidone | 76 |
The analysis was based on all suicides and suicide attempts from the WRT+30 days period using the classification based upon MedDRA terminology, that is, as reported by the investigator (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 43 |
| Risperidone | 65 |
Second primary endpoint: a serious adverse event where the patient was hospitalised and for which the Independent Safety Committee (ISC) classified the event as a cardiac event with documented arrhythmia. The analysis of this outcome was not performed due to low number of events. The presented analysis is a replacement analysis using all cardiac events, including arrhythmias, that required hospitalisation (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) |
|---|---|
| Sertindole | 10 |
| Risperidone | 6 |
The analysis was based on all deaths from the Whole Randomised Treatment (WRT)+30 days period and the Only Randomised Treatment (ORT) period, respectively (NCT00856583)
Timeframe: As study design allowed patients to continue study drug until the study was closed, many patients were followed for several years, with an overall median time period of approximately 14 months
| Intervention | participants (Number) | |
|---|---|---|
| Number of deaths (WRT+30 days) | Number of deaths (ORT) | |
| Risperidone | 61 | 44 |
| Sertindole | 64 | 40 |
(NCT00044655)
Timeframe: Measured at Six Months
| Intervention | participants (Number) |
|---|---|
| Stay | 11 |
| Switch | 23 |
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 2 |
| Sham | 8 |
"The CGI-I is a clinician-rated scales that have been used in clinical trials for over 25 years. Clinicians rate patient improvement compared to baseline. By convention, 4 = No Change; scores of 5, 6, and 7 move in the direction of worsening; scores of 3, 2, and 1 correspond to Minimal Improvement, Much Improved or Very Much Improved, respectively. CGI-I ratings of Much or Very Much Improved at post-treatment are used to identify treatment responders." (NCT00529308)
Timeframe: 3 weeks
| Intervention | participants (Number) |
|---|---|
| Active | 1 |
| Sham | 0 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56.5 |
| Sham | 63.8 |
Motor Threshold (MT) is thought to be a measure of membrane excitability in pyramidal neurons. MT is defined as the minimum magnetic flux needed to elicit a threshold EMG response (50 µV in peak to peak amplitude) in a resting target muscle in 5 out of 10 trials using single pulse TMS administered to the contralateral primary motor cortex. MT for both right and left hand are determined, and the lowest is used to select the intensity for rTMS. (NCT00529308)
Timeframe: 3 weeks
| Intervention | µV (Mean) |
|---|---|
| Active | 56 |
| Sham | 59.8 |
Y-GTSS is a clinician-rated scale used to assess tic severity. Motor and phonic tics are rated separately from 0 to 5 on several scales including number, frequency, intensity, complexity, and interference. Thus Motor and Phonic Tic scores can range from 0 to 25; the combined Total Tic Score ranges from 0 to 50. There is also an Impairment score that rates the overall burden due to tics. The Impairment scale yields a single score from 0 to 50 with higher scores indicating higher levels of overall impairment associated with tics. (NCT00529308)
Timeframe: 3 weeks
| Intervention | units on a scale (Mean) |
|---|---|
| Active | 29.5 |
| Sham | 31.5 |
A comparison between aripiprazole group and placebo group of change in Body Mass Index (BMI) measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | kg/m^2 (Mean) |
|---|---|
| Aripiprazole | -0.52 |
| Placebo | 0.03 |
A comparison between the aripiprazole group and placebo group in change in glucose metabolism measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | min^-1 (Mean) |
|---|---|
| Aripiprazole | 0.003 |
| Placebo | -0.005 |
A comparison between aripiprazole group and placebo group of change in insulin resistance measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | HOMA score (Mean) |
|---|---|
| Aripiprazole | 0.6 |
| Placebo | 0.65 |
A comparison of aripiprazole group and placebo group in change in total cholesterol measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -15.3 |
| Placebo | 5.6 |
(NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -5.9 |
| Placebo | -7.3 |
A comparison between aripiprazole group and placebo group in change in weight measured at Baseline and Week 8. (NCT00345033)
Timeframe: Measured at Baseline and Week 8
| Intervention | kg (Mean) |
|---|---|
| Aripiprazole | -1.5 |
| Placebo | 0.3 |
The T-score indicates the performance on a neurocognitive battery of tests. Higher score reflects better performance. (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | standardized T-score (Mean) | |
|---|---|---|
| placebo | amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | 57.870 | 56.000 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 54.476 | 55.476 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | 39.895 | 38.105 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | 31.895 | 33.842 |
"PPI was assessed with 42 trials of 6 types: 118 dB 40 ms pulse alone (P) & the same P preceded 10, 20, 30, 60, or 120 ms by a prepulse (pp) 16 dB over background. Startle magnitude (SM), habituation, latency & latency facilitation were measured to interpret changes in PPI.~%PPI = 100 x [(SM on P trials) - (SM on pp+P trials)] / SM on P trials. Example:~SM on P trials = 80 units SM on pp+P trials = 30 units %PPI = 100 x (80-30)/80 = 100 x 50/80 = 62.5%~Greater %PPI mean the reflex has been inhibited to a greater extent in the presence of a pp.~%PPI can't exceed 100: when SM on pp+P trials = 0, then %PPI = 100 x (SM on P trials - 0)/SM on P trials = 100 x 1 = 100%.~However, %PPI can theoretically be infinitely negative since SM on pp+P trials could be infinitely large (prepulse facilitiation (PPF)), i.e. SM is potentiated in the presence of a pp. PPF is normal at very short & very long pp intervals, but not within a species-specific physiological range of intervals." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | % inhibition of startle (Mean) | |
|---|---|---|
| Placebo | Amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | 50.626 | 53.029 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 50.626 | 45.822 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | 41.162 | 39.545 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | 22.629 | 32.656 |
"Auditory discrimination learning: Subjects identify direction (up vs. down) of 2 consecutive sound sweeps. Parameters (e.g. inter-sweep interval, sweep duration) are established for subjects to maintain 80% correct responses. On screen and test days, subjects complete 1h of TCT. Analytic software yields the key measures: auditory processing speed (APS) and APS learning. APS is the shortest inter-stimulus interval at which a subject performs to criteria and APS learning is the difference (ms) between the first APS and the best APS of the subsequent trials. A smaller APS reflects better discrimination (i.e., subject correctly identified frequency sweep direction despite a smaller ms gap between stimuli) and a larger ms value for APS learning reflects more learning, i.e., faster APS with repeated trials. Limits for APS are capped at 0-to-1000 ms; values for APS learning are capped at (-) 1000-to-APS." (NCT02634684)
Timeframe: two visits, 1 week apart, each visit lasting approximately 6 hours
| Intervention | msec (Mean) | |
|---|---|---|
| placebo | amphetamine | |
| Healthy Subjects: 10 mg Amphetamine 1st, Then Placebo | -2.113 | 29.190 |
| Healthy Subjects: Placebo 1st, Then 10 mg Amphetamine | 5.911 | 35.905 |
| Subjects With Schizophrenia: 10 mg Amphetamine 1st, Then Placebo | -50.158 | 101.000 |
| Subjects With Schizophrenia: Placebo 1st, Then 10 mg Amphetamine | -15.118 | 52.647 |
A modifiable risk component for each cardiovascular risk factor not at optimal goal at the time of each encounter was calculated as the difference between total 10-year atherosclerotic cardiovascular disease risk with the patient's actual values and the goal value. Total modifiable cardiovascular risk was calculated by summing the modifiable cardiovascula risk components across cardiovascular risk factors not at optimal goal at the time of the encounter, and was calculated for each enrolled patient at the index visit and each subsequent encounter during the intervention period. Annual rate of change in modifiable cardiovascular risk was estimated from all patient encounters. A comparison of the difference in model-estimated rate of change in modifiable cardiovascular risk at 12 months post-index tested the primary efficacy hypothesis. (NCT02451670)
Timeframe: Index to 12 months post index visit
| Intervention | percentage of annual rate of change (Number) |
|---|---|
| Prioritized Clinical Decision Support | 14.2 |
| Usual Care | 20.8 |
Evaluating change in Body Mass Index (BMI) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | kg/m^2 (Mean) |
|---|---|
| Aripiprazole | -0.4 |
| Placebo | 0.3 |
Evaluating change in fasting total cholesterol between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -3 |
| Placebo | 9 |
Evaluating change in high-density lipoprotein cholesterol (HDL-C) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | 0.4 |
| Placebo | 0.6 |
Evaluating change in low-density lipoprotein (LDL) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -0.2 |
| Placebo | 3.1 |
Evaluating change in triglyceride levels between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | mg/dL (Mean) |
|---|---|
| Aripiprazole | -51.7 |
| Placebo | 47.6 |
Evaluating change in waist-hip ratio (WHR) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | cm (Mean) |
|---|---|
| Aripiprazole | 0.0 |
| Placebo | 0.0 |
Evaluating change in weight (lbs) between Baseline and Week 4, comparing subjects treated with aripiprazole for 4 weeks to subjects treated with placebo for 4 weeks. (NCT00351936)
Timeframe: baseline, week 4
| Intervention | lbs (Mean) |
|---|---|
| Aripiprazole | -2.9 |
| Placebo | 2.1 |
31 reviews available for risperidone and Weight Gain
| Article | Year |
|---|---|
Do Asian and North American patients with bipolar disorder have similar efficacy, tolerability, and safety profile during clinical trials with atypical antipsychotics?
Topics: Adult; Antipsychotic Agents; Aripiprazole; Asian People; Bipolar Disorder; Female; Humans; North Ame | 2020 |
Effects of Risperidone in Autistic Children and Young Adults: A Systematic Review and Meta-Analysis.
Topics: Adolescent; Antipsychotic Agents; Autistic Disorder; Child; Female; Humans; Male; Risperidone; Treat | 2021 |
Clozapine combined with different antipsychotic drugs for treatment-resistant schizophrenia.
Topics: Adult; Amisulpride; Antipsychotic Agents; Aripiprazole; Clozapine; Dibenzothiazepines; Drug Resistan | 2017 |
Atypical antipsychotics for disruptive behaviour disorders in children and youths.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety Disorders; Attention Deficit and Disruptive Be | 2017 |
No differences in olanzapine- and risperidone-related weight gain between women and men: a meta-analysis of short- and middle-term treatment.
Topics: Adult; Aged; Antipsychotic Agents; Body Mass Index; Drug-Related Side Effects and Adverse Reactions; | 2018 |
Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Gastrointestinal Microbiome; Humans; Hyperglycemia; | 2019 |
Bayesian Meta-analysis of Multiple Continuous Treatments with Individual Participant-Level Data: An Application to Antipsychotic Drugs.
Topics: Adult; Antipsychotic Agents; Bayes Theorem; Dose-Response Relationship, Drug; Female; Humans; Male; | 2019 |
Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: a systematic review and meta-analysis.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Humans; Olanzapine; Piperazi | 2013 |
HTR2C polymorphisms, olanzapine-induced weight gain and antipsychotic-induced metabolic syndrome in schizophrenia patients: a meta-analysis.
Topics: Alleles; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Genetic Association Studies; Huma | 2014 |
The use of atypical antipsychotics in pediatric bipolar disorder.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; | 2008 |
Are weight gain and metabolic side effects of atypical antipsychotics dose dependent? A literature review.
Topics: Adolescent; Adult; Antipsychotic Agents; Child; Clozapine; Controlled Clinical Trials as Topic; Dose | 2009 |
[Neuroleptic adverse effects with emphasis on weight gain].
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Brain; Cardiomyopathies; Child; Clozapine; Dyskin | 2009 |
Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.
Topics: Administration, Oral; Antipsychotic Agents; Benzodiazepines; Delayed-Action Preparations; Dyslipidem | 2010 |
Head-to-head comparisons of metabolic side effects of second generation antipsychotics in the treatment of schizophrenia: a systematic review and meta-analysis.
Topics: Amisulpride; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Blood Glucose; Cholesterol; Clinic | 2010 |
Atypical antipsychotics for disruptive behaviour disorders in children and youths.
Topics: Adolescent; Aggression; Antipsychotic Agents; Anxiety Disorders; Attention Deficit and Disruptive Be | 2012 |
Are there different neural mechanisms responsible for three stages of weight gain development in anti-psychotic therapy: temporally based hypothesis.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Nervous System Physiological Phenomena; Ol | 2012 |
Safety in treating bipolar disorder.
Topics: Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Clozapine; Diabetes Melli | 2003 |
[The appearance of metabolic syndrome in treatment with atypical antipsychotics].
Topics: Adolescent; Adult; Age Factors; Aged; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body W | 2003 |
A comparison of risperidone-induced weight gain across the age span.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Aging; Child; Child, Preschool; Humans; Ris | 2004 |
[Psychotropics and weight gain].
Topics: Adolescent; Adult; Amisulpride; Antidepressive Agents; Antimanic Agents; Antipsychotic Agents; Aripi | 2004 |
The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus, Type 2; Dibenzoth | 2004 |
Risperidone in pervasive developmental disorders.
Topics: Antipsychotic Agents; Child; Child Development Disorders, Pervasive; Diabetes Mellitus; Expert Testi | 2005 |
[Mechanisms of the body weight gain induced by novel antipsychotic drugs and concomitant lipid abnormalities].
Topics: Antipsychotic Agents; Body Weight; Clozapine; Dibenzothiazepines; Humans; Hyperlipidemias; Leptin; P | 2005 |
Atypical antipsychotics: new drugs, new challenges.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Diabetes Mellitus; Humans; Olanzapine; Psychotic D | 2007 |
Treatment of bipolar disorder: the evolving role of atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Arrhythmias, Cardiac; Benzodiazepines; Bipolar Disorder; Diabete | 2007 |
Side effect profiles of new antipsychotic agents.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Clozapine; Dyskinesia, Drug-Induced; | 1996 |
Adverse effects of the atypical antipsychotics. Collaborative Working Group on Clinical Trial Evaluations.
Topics: Agranulocytosis; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Central Nervous Syst | 1998 |
Risperidone side effects.
Topics: Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Humans; Hyperprolactinemia; Inc | 2000 |
Adverse events related to olanzapine.
Topics: Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Mass In | 2000 |
Atypical antipsychotics and weight gain--a systematic review.
Topics: Amisulpride; Antipsychotic Agents; Benzodiazepines; Clozapine; Dibenzothiazepines; Dibenzothiepins; | 2000 |
Weight change and atypical antipsychotic treatment in patients with schizophrenia.
Topics: Antipsychotic Agents; Behavior Therapy; Benzodiazepines; Dose-Response Relationship, Drug; Follow-Up | 2001 |
81 trials available for risperidone and Weight Gain
| Article | Year |
|---|---|
The association between BDNF levels and risperidone-induced weight gain is dependent on the BDNF Val66Met polymorphism in antipsychotic-naive first episode schizophrenia patients: a 12-week prospective study.
Topics: Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Genotype; Humans; Polymorphism, Genetic; Po | 2021 |
Antioxidant Enzymes and Weight Gain in Drug-naive First-episode Schizophrenia Patients Treated with Risperidone for 12 Weeks: A Prospective Longitudinal Study.
Topics: Antioxidants; Antipsychotic Agents; Case-Control Studies; Humans; Longitudinal Studies; Oxidative St | 2022 |
The effect of therapeutic drug monitoring of risperidone and aripiprazole on weight gain in children and adolescents: the SPACe 2: STAR (trial) protocol of an international multicentre randomised controlled trial.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Drug Monitoring; Humans; Multicenter Studies | 2022 |
Early Stabilization of Weight Changes Following Treatment With Olanzapine, Risperidone, and Aripiprazole: A 12-Month Naturalistic Study of First Episode Psychosis.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Body Mass Index; Female; Humans; Male; Olanzapine; Prospe | 2019 |
Effectiveness, Adverse Effects and Drug Compliance of Long-Acting Injectable Risperidone in Children and Adolescents.
Topics: Adolescent; Antipsychotic Agents; Bipolar Disorder; Child; Conduct Disorder; Delayed-Action Preparat | 2017 |
Risperidone versus olanzapine among patients with schizophrenia participating in supported employment: Eighteen-month outcomes.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Employment, Supported; Female; Hu | 2017 |
Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Disor | 2018 |
The role of weight gain in explaining the effects of antipsychotic drugs on positive and negative symptoms: An analysis of the CATIE schizophrenia trial.
Topics: Adult; Antipsychotic Agents; Body-Weight Trajectory; Female; Humans; Male; Middle Aged; Olanzapine; | 2019 |
Pharmacotherapy of Autism Spectrum Disorder: Results from the Randomized BAART Clinical Trial.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Autism Spectrum Disorder; Child; Double-Blind Method | 2019 |
Riluzole as an adjunctive therapy to risperidone for the treatment of irritability in children with autistic disorder: a double-blind, placebo-controlled, randomized trial.
Topics: Antipsychotic Agents; Appetite; Autistic Disorder; Child; Child, Preschool; Double-Blind Method; Dru | 2013 |
Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Haloperidol; Humans; Male; Metabolic Disea | 2014 |
A prospective, open-label study to evaluate symptomatic remission in schizophrenia with risperidone long-acting injectable in Korea.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Diagnostic and Statistical Manual of Mental Disorders | 2014 |
Efficacy and safety of aripiprazole in Chinese Han schizophrenia subjects: a randomized, double-blind, active parallel-controlled, multicenter clinical trial.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Asian People; Blood Pressure; China; Diagnostic and Stati | 2014 |
Glucagon-like peptide 1 receptor (GLP1R) haplotypes correlate with altered response to multiple antipsychotics in the CATIE trial.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Biomarkers, Pharmacological; Dibenzothiazepines; Femal | 2014 |
Tolerability, Safety, and Benefits of Risperidone in Children and Adolescents with Autism: 21-Month Follow-up After 8-Week Placebo-Controlled Trial.
Topics: Adolescent; Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child, Preschool; Double-Bli | 2015 |
Comparative study of the efficacy and safety between blonanserin and risperidone for the treatment of schizophrenia in Chinese patients: A double-blind, parallel-group multicenter randomized trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Asian People; China; Double-Blind Method; Drug Admini | 2015 |
Optimal duration of risperidone or olanzapine adjunctive therapy to mood stabilizer following remission of a manic episode: A CANMAT randomized double-blind trial.
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Combined Modality | 2016 |
Serum Ferritin, Weight Gain, Disruptive Behavior, and Extrapyramidal Symptoms in Risperidone-Treated Youth.
Topics: Adolescent; Attention Deficit Disorder with Hyperactivity; Basal Ganglia Diseases; Bone Density; Cal | 2016 |
Weight Gain and Metabolic Consequences of Risperidone in Young Children With Autism Spectrum Disorder.
Topics: Antipsychotic Agents; Autism Spectrum Disorder; Child; Child, Preschool; Female; Humans; Insulin Res | 2016 |
Children with ADHD and symptoms of oppositional defiant disorder improved in behavior when treated with methylphenidate and adjuvant risperidone, though weight gain was also observed - Results from a randomized, double-blind, placebo-controlled clinical t
Topics: Adjuvants, Pharmaceutic; Attention Deficit and Disruptive Behavior Disorders; Attention Deficit Diso | 2017 |
A randomized, double-blind, placebo-controlled trial of metformin treatment for weight gain associated with initiation of risperidone in children and adolescents.
Topics: Antipsychotic Agents; Child; Double-Blind Method; Humans; Hypoglycemic Agents; Metformin; Risperidon | 2008 |
Antipsychotic treatment in child and adolescent first-episode psychosis: a longitudinal naturalistic approach.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Child; Dibenzothiazepines; Female; Follow-Up Stud | 2008 |
Treating disruptive behavior disorders with risperidone: a 1-year, open-label safety study in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Basal Ganglia | 2008 |
Glucose and lipid disturbances after 1 year of antipsychotic treatment in a drug-naïve population.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cholesterol; Cholesterol, H | 2009 |
Efficacy, safety and tolerability of two dosing regimens in adolescent schizophrenia: double-blind study.
Topics: Acute Disease; Adolescent; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Meth | 2009 |
A trial of quetiapine compared with risperidone in the treatment of first onset psychosis among 15- to 18-year-old adolescents.
Topics: Adolescent; Adolescent Behavior; Antipsychotic Agents; Dibenzothiazepines; Female; Humans; Hyperprol | 2010 |
Risperidone associated weight, leptin, and anthropometric changes in children and adolescents with psychotic disorders in early treatment.
Topics: Adolescent; Anthropometry; Antidepressive Agents, Second-Generation; Body Mass Index; Body Size; Bod | 2010 |
Mifepristone reduces weight gain and improves metabolic abnormalities associated with risperidone treatment in normal men.
Topics: Adolescent; Adult; Analysis of Variance; Antipsychotic Agents; Double-Blind Method; Hormone Antagoni | 2010 |
Safety and efficacy of long-acting injectable risperidone in patients with schizophrenia spectrum disorders: a 6-month open-label trial in Asian patients.
Topics: Adult; Asian People; Blood Glucose; Delayed-Action Preparations; Female; Humans; Injections, Intramu | 2010 |
Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.
Topics: Adolescent; Akathisia, Drug-Induced; Benzodiazepines; Child; Double-Blind Method; Female; Humans; Lo | 2010 |
Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.
Topics: Adolescent; Akathisia, Drug-Induced; Benzodiazepines; Child; Double-Blind Method; Female; Humans; Lo | 2010 |
Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.
Topics: Adolescent; Akathisia, Drug-Induced; Benzodiazepines; Child; Double-Blind Method; Female; Humans; Lo | 2010 |
Double-blind maintenance safety and effectiveness findings from the Treatment of Early-Onset Schizophrenia Spectrum (TEOSS) study.
Topics: Adolescent; Akathisia, Drug-Induced; Benzodiazepines; Child; Double-Blind Method; Female; Humans; Lo | 2010 |
Efficacy and tolerability of Blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trial.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind Method | 2010 |
DRD2 promoter region variation predicts antipsychotic-induced weight gain in first episode schizophrenia.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Drug Administration Schedule; Female; Huma | 2010 |
A head-to-head comparison of sertindole and risperidone on metabolic parameters.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Cholesterol; Female; Humans; Imidazoles; Indoles; Lipi | 2010 |
Risperidone-induced weight gain in referred children with autism spectrum disorders is associated with a common polymorphism in the 5-hydroxytryptamine 2C receptor gene.
Topics: Adolescent; Age Factors; Analysis of Variance; Antipsychotic Agents; Body Mass Index; Child; Child D | 2010 |
TNF-α -308 G>A polymorphism and weight gain in patients with schizophrenia under long-term clozapine, risperidone or olanzapine treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Genotype; Humans; Male; Middle Aged | 2011 |
Olanzapine and risperidone effects on appetite and ghrelin in chronic schizophrenic patients.
Topics: Adult; Antipsychotic Agents; Appetite; Benzodiazepines; Body Weight; Female; Ghrelin; Humans; Male; | 2012 |
Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.
Topics: Antipsychotic Agents; Connecticut; Delayed-Action Preparations; Drug Substitution; Female; Fluphenaz | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Pharmacogenomic associations with weight gain in olanzapine treatment of patients without schizophrenia.
Topics: Adult; Alleles; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Borderline Personality Diso | 2012 |
Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cholesterol; Clozapine; Double-Bl | 2003 |
Antipsychotic-induced weight gain: bipolar disorder and leptin.
Topics: Adolescent; Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Body M | 2003 |
The relationship of changes in leptin, neuropeptide Y and reproductive hormones to antipsychotic induced weight gain.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Female; Gonadal Steroid Hormones; Humans; Leptin; Midd | 2003 |
Risperidone-associated steatohepatitis and excessive weight-gain.
Topics: Adolescent; Antipsychotic Agents; Fatty Liver; Female; Humans; Paranoid Disorders; Risperidone; Weig | 2003 |
Effectiveness, safety, and tolerability of risperidone in adolescents with schizophrenia: an open-label study.
Topics: Adolescent; Akathisia, Drug-Induced; Antipsychotic Agents; Basal Ganglia Diseases; Dyskinesia, Drug- | 2003 |
Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Female; Humans; Male; Middle Aged | 2004 |
Risperidone treatment of children with autistic disorder: effectiveness, tolerability, and pharmacokinetic implications.
Topics: Autistic Disorder; Child; Child, Preschool; Drug Tolerance; Female; Humans; Isoxazoles; Male; Palipe | 2004 |
Weight and leptin changes among risperidone-treated youths with autism: 6-month prospective data.
Topics: Adolescent; Age Factors; Antipsychotic Agents; Autistic Disorder; Body Mass Index; Body Weight; Chil | 2004 |
Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain.
Topics: Antipsychotic Agents; Benzodiazepines; Cost-Benefit Analysis; Dyskinesia, Drug-Induced; Follow-Up St | 2004 |
Risperidone and haloperidol in first-episode psychosis: a long-term randomized trial.
Topics: Adult; Antipsychotic Agents; Double-Blind Method; Drug Administration Schedule; Dyskinesia, Drug-Ind | 2005 |
Amoxapine as an atypical antipsychotic: a comparative study vs risperidone.
Topics: Adolescent; Adult; Amoxapine; Antipsychotic Agents; Dose-Response Relationship, Drug; Double-Blind M | 2005 |
Self injurious behavior in autism: clinical aspects and treatment with risperidone.
Topics: Antipsychotic Agents; Autistic Disorder; Brain; Brain Chemistry; Child; Dopamine; Dose-Response Rela | 2006 |
Long-acting risperidone in stable patients with schizoaffective disorder.
Topics: Adult; Aged; Antipsychotic Agents; Body Weight; Delayed-Action Preparations; Female; Humans; Injecti | 2005 |
A comparison of the effects of olanzapine and risperidone versus placebo on eating behaviors.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Double-Blind Method; Energy Intake; Feedin | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
Effectiveness of antipsychotic drugs in patients with chronic schizophrenia.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Chronic Disease; Dibenzothiazepines; Double-Blind Meth | 2005 |
A crossover study of risperidone in children, adolescents and adults with mental retardation.
Topics: Adolescent; Adult; Aggression; Antipsychotic Agents; Autistic Disorder; Child; Cross-Over Studies; D | 2006 |
Risperidone-related weight gain: genetic and nongenetic predictors.
Topics: Adolescent; Adult; Age Factors; Antipsychotic Agents; Brain-Derived Neurotrophic Factor; China; Cyto | 2006 |
Insulin resistance index and counter-regulatory factors during olanzapine or risperidone administration in subjects with schizophrenia.
Topics: Adult; Antipsychotic Agents; Appetite; Benzodiazepines; Blood Glucose; Chronic Disease; Delayed-Acti | 2007 |
Risperidone in preschool children with autistic spectrum disorders: an investigation of safety and efficacy.
Topics: Antipsychotic Agents; Anxiety; Autistic Disorder; Behavior Therapy; Child Behavior Disorders; Child, | 2006 |
Randomized comparison of olanzapine versus risperidone for the treatment of first-episode schizophrenia: 4-month outcomes.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Body Mass Index; Female; Follo | 2006 |
Physiogenomic comparison of weight profiles of olanzapine- and risperidone-treated patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Analysis of Variance; Antipsychotic Agents; Apolipoprote | 2007 |
Effects of risperidone on lipid profile.
Topics: Adult; Aged; Antipsychotic Agents; Body Mass Index; Cholesterol; Cross-Sectional Studies; Female; Hu | 2007 |
Changes in neuroendocrine and metabolic hormones induced by atypical antipsychotics in normal-weight patients with schizophrenia.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Body Weight; Clozapine; Femal | 2007 |
Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Double-Blind Method; D | 2007 |
Ghrelin and leptin response to oral glucose challenge among antipsychotic drug-treated children.
Topics: Administration, Oral; Adolescent; Age Factors; Analysis of Variance; Antipsychotic Agents; Aripipraz | 2007 |
Comparison of long-term efficacy and safety of risperidone and haloperidol in children and adolescents with autistic disorder. An open label maintenance study.
Topics: Adolescent; Adolescent Behavior; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior; Dos | 2008 |
A 12-week randomized clinical trial to evaluate metabolic changes in drug-naive, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone.
Topics: Adolescent; Adult; Anthropometry; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass In | 2007 |
Weight gain induced by haloperidol, risperidone and olanzapine after 1 year: findings of a randomized clinical trial in a drug-naïve population.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Chronic Disease; Cohort S | 2008 |
A comparison of the effects of olanzapine and risperidone versus placebo on ghrelin plasma levels.
Topics: Adult; Antipsychotic Agents; Area Under Curve; Benzodiazepines; Double-Blind Method; Feeding Behavio | 2008 |
Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Double-Blind Method; Female; Haloperi | 2008 |
Long-acting injectable risperidone in the treatment of subjects with recent-onset psychosis: a preliminary study.
Topics: Adolescent; Adult; Antidepressive Agents; Blood Glucose; Body Mass Index; Cholesterol; Delayed-Actio | 2008 |
Effect of antipsychotics on peptides involved in energy balance in drug-naive psychotic patients after 1 year of treatment.
Topics: Adiponectin; Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Composition; Body Mass I | 2008 |
Risperidone for young children with mood disorders and aggressive behavior.
Topics: Adolescent; Aggression; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Child; | 1998 |
A double-blind, placebo-controlled study of risperidone in adults with autistic disorder and other pervasive developmental disorders.
Topics: Adolescent; Adult; Age Factors; Aggression; Antipsychotic Agents; Autistic Disorder; Child Developme | 1998 |
Weight gain in adolescents treated with risperidone and conventional antipsychotics over six months.
Topics: Adolescent; Antipsychotic Agents; Body Mass Index; Central Nervous System Stimulants; Drug Interacti | 1998 |
Novel antipsychotics: comparison of weight gain liabilities.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Haloperidol; Humans; I | 1999 |
Open-label treatment with risperidone of 26 psychiatrically-hospitalized children and adolescents with mixed diagnoses and aggressive behavior.
Topics: Adolescent; Aggression; Antipsychotic Agents; Child; Female; Hospitalization; Humans; Intellectual D | 2000 |
Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
Topics: Adult; Benzodiazepines; Drug Administration Schedule; Drug Therapy, Combination; Fluoxetine; Humans; | 2000 |
A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Benzodiazepines; Double-Blind Method; Drug Admi | 2001 |
Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.
Topics: Adult; Age Factors; Antipsychotic Agents; Appetite; Benzodiazepines; Body Mass Index; Body Weight; B | 2001 |
Weight gain in a controlled study of risperidone in children, adolescents and adults with mental retardation and autism.
Topics: Adolescent; Adult; Aged; Aggression; Antipsychotic Agents; Autistic Disorder; Child; Cross-Over Stud | 2001 |
No weight gain among elderly schizophrenia patients after 1 year of risperidone treatment.
Topics: Age Factors; Aged; Aged, 80 and over; Analysis of Variance; Antipsychotic Agents; Dose-Response Rela | 2002 |
Hyperglycemic clamp assessment of insulin secretory responses in normal subjects treated with olanzapine, risperidone, or placebo.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Female; Glucose Clamp Technique; Huma | 2002 |
153 other studies available for risperidone and Weight Gain
| Article | Year |
|---|---|
H1-histamine receptor affinity predicts short-term weight gain for typical and atypical antipsychotic drugs.
Topics: Animals; Antipsychotic Agents; Discriminant Analysis; Drug Evaluation, Preclinical; Forecasting; Hum | 2003 |
From the Cover: Antipsychotic drug-induced weight gain mediated by histamine H1 receptor-linked activation of hypothalamic AMP-kinase.
Topics: Adenylate Kinase; Animals; Antipsychotic Agents; Enzyme Activation; Hypothalamus; Immunohistochemist | 2007 |
Principal component analysis differentiates the receptor binding profiles of three antipsychotic drug candidates from current antipsychotic drugs.
Topics: Antipsychotic Agents; Basal Ganglia Diseases; Benzoxazines; Biogenic Monoamines; Humans; Hyperprolac | 2007 |
Synthesis and biological investigation of coumarin piperazine (piperidine) derivatives as potential multireceptor atypical antipsychotics.
Topics: Animals; Antipsychotic Agents; Avoidance Learning; Biological Availability; Coumarins; ERG1 Potassiu | 2013 |
Discovery of a new class of multi-target heterocycle piperidine derivatives as potential antipsychotics with pro-cognitive effect.
Topics: Animals; Antipsychotic Agents; Behavior, Animal; Cognition; Dopamine; Drug Design; Humans; Hyperprol | 2021 |
Long-term treatment of antipsychotics and combined therapy with other psychotropic medications inducing weight gain in patients with non-affective psychotic disorder: Evidence from GROUP, a longitudinal study.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Longitudinal Studies; Olanzapine; Psychoti | 2022 |
Drug-induced weight gain in the last 10 years: a descriptive study.
Topics: Adalimumab; Adverse Drug Reaction Reporting Systems; Aripiprazole; Databases, Factual; Drug-Related | 2022 |
Weight Gain During Antipsychotic Treatment in Children, Adolescents, and Adults: A Disproportionality Analysis in the Global Pharmacovigilance Database, Vigibase
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Child; Humans; Pha | 2023 |
Weight Gain During Antipsychotic Treatment in Children, Adolescents, and Adults: A Disproportionality Analysis in the Global Pharmacovigilance Database, Vigibase
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Child; Humans; Pha | 2023 |
Weight Gain During Antipsychotic Treatment in Children, Adolescents, and Adults: A Disproportionality Analysis in the Global Pharmacovigilance Database, Vigibase
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Child; Humans; Pha | 2023 |
Weight Gain During Antipsychotic Treatment in Children, Adolescents, and Adults: A Disproportionality Analysis in the Global Pharmacovigilance Database, Vigibase
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Child; Humans; Pha | 2023 |
Weight changes following treatment with aripiprazole, risperidone and olanzapine: A 12-month study of first-episode schizophrenia patients in China.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Weight; Humans; Olanzapine; Risperidone; S | 2023 |
The effect of bezafibrate in preventing glucolipid abnormalities induced by the antipsychotic risperidone.
Topics: Adolescent; Adult; Antipsychotic Agents; Bezafibrate; Blood Glucose; Body Weight; Drug Therapy, Comb | 2019 |
Effects of long-term antipsychotics treatment on body weight: A population-based cohort study.
Topics: Adolescent; Adult; Age Factors; Aged; Aged, 80 and over; Antipsychotic Agents; Body Weight; Cohort S | 2020 |
Risperidone stimulates food intake and induces body weight gain via the hypothalamic arcuate nucleus 5-HT2c receptor-NPY pathway.
Topics: Animals; Arcuate Nucleus of Hypothalamus; Body Weight; Eating; Female; Mice; Mice, Inbred C57BL; Neu | 2020 |
The side effect profile of Clozapine in real world data of three large mental health hospitals.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Databases, Factual; Female; Hospitals, Psyc | 2020 |
Body mass index increase in preschoolers with heterogeneous psychiatric diagnoses treated with risperidone.
Topics: Age Factors; Antipsychotic Agents; Body Mass Index; Child, Preschool; Dose-Response Relationship, Dr | 2021 |
The atypical antipsychotic risperidone targets hypothalamic melanocortin 4 receptors to cause weight gain.
Topics: alpha-MSH; Animals; Antipsychotic Agents; Female; Hyperphagia; Hypothalamus; Male; Metabolic Syndrom | 2021 |
Depot risperidone-induced adverse metabolic alterations in female rats.
Topics: Adipokines; Animals; Antipsychotic Agents; Female; Leptin; Lipids; Rats; Rats, Sprague-Dawley; Rispe | 2017 |
A comprehensive analysis of mitochondrial genes variants and their association with antipsychotic-induced weight gain.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; DNA, Mitochondrial; Female; Genes, Mitochondrial; Geno | 2017 |
T
Topics: Adult; Antipsychotic Agents; Asian People; Benzodiazepines; Biomarkers, Pharmacological; Body Mass I | 2018 |
Predictors and Moderators of Antipsychotic-Related Weight Gain in the Treatment of Early-Onset Schizophrenia Spectrum Disorders Study.
Topics: Adolescent; Antipsychotic Agents; Female; Humans; Male; Olanzapine; Psychiatric Status Rating Scales | 2018 |
Weight change over two years in people prescribed olanzapine, quetiapine and risperidone in UK primary care: Cohort study in THIN, a UK primary care database.
Topics: Adult; Aged; Aged, 80 and over; Antipsychotic Agents; Body Weight; Cohort Studies; Databases, Factua | 2018 |
Weight-Change Trajectories of Pediatric Outpatients Treated with Risperidone or Aripiprazole in a Naturalistic Setting.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Body Mass Index; Body Weight; Child; Female; Humans; | 2019 |
No Differences in Weight Gain Between Risperidone and Aripiprazole in Children and Adolescents After 12 Months.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Autism Spectrum Disorder; Body Mass Index; Child; Fe | 2019 |
Retrospective Analysis of the Effectiveness and Tolerability of Long-Acting Paliperidone Palmitate Antipsychotic in Adolescent First-Episode Schizophrenia Patients.
Topics: Adolescent; Antipsychotic Agents; Brief Psychiatric Rating Scale; Female; Hospitalization; Humans; H | 2019 |
Modeling of antipsychotic-induced metabolic alterations in mice: An experimental approach precluding psychosis as a predisposing factor.
Topics: Animals; Antipsychotic Agents; Body Weight; Female; Ghrelin; Hyperglycemia; Leptin; Mice; Mice, Inbr | 2019 |
Effects of risperidone on energy balance in female C57BL/6J mice.
Topics: Adipose Tissue, Brown; Animals; Antipsychotic Agents; Basal Metabolism; Brain-Derived Neurotrophic F | 2013 |
Association between second-generation antipsychotics and changes in body mass index in adolescents.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Confidence Intervals; Dibenzothi | 2013 |
Iron deficiency in pediatric patients in long-term risperidone treatment.
Topics: Adolescent; Antipsychotic Agents; Central Nervous System Stimulants; Child; Cross-Sectional Studies; | 2013 |
Antipsychotic-induced dyslipidemia treated with omega 3 fatty acid supplement in an 11-year-old psychotic child: a 1-year follow-up.
Topics: Antipsychotic Agents; Child; Dietary Supplements; Dyslipidemias; Fatty Acids, Omega-3; Follow-Up Stu | 2013 |
Tolerability and safety profile of risperidone in a sample of children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Body Composit | 2013 |
Moderation of antipsychotic-induced weight gain by energy balance gene variants in the RUPP autism network risperidone studies.
Topics: Adolescent; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Amidohydrolases; Antipsychotic Agents; Bo | 2013 |
Weight gain in risperidone therapy: investigation of peripheral hypothalamic neurohormone levels in psychotic patients.
Topics: alpha-MSH; Antipsychotic Agents; Appetite Regulation; Body Mass Index; Case-Control Studies; Humans; | 2013 |
Age and adverse drug reactions from psychopharmacological treatment: data from the AMSP drug surveillance programme in Switzerland.
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Age Factors; Aged; Aged, 80 and over; An | 2013 |
Investigation of molecular serum profiles associated with predisposition to antipsychotic-induced weight gain.
Topics: Adult; Antipsychotic Agents; Body Mass Index; Clozapine; Disease Susceptibility; ErbB Receptors; Fem | 2015 |
Body mass index change in autism spectrum disorders: comparison of treatment with risperidone and aripiprazole.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Body Mass Index; Child; Child Development Disorders, | 2014 |
Cardiometabolic outcomes in children and adolescents following discontinuation of long-term risperidone treatment.
Topics: Adolescent; Cardiovascular Diseases; Child; Female; Follow-Up Studies; Humans; Male; Metabolic Syndr | 2014 |
The effect of a calorie-restricted diet on weight gain in short-term psychiatric inpatients receiving atypical antipsychotic medications.
Topics: Adult; Age Factors; Antipsychotic Agents; Benzodiazepines; Caloric Restriction; Education, Nursing, | 2014 |
A study of antioxidant activity in patients with schizophrenia taking atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Aryldialkylphosphatase; Cardiovascular Diseases; Clozapine; Female; Hum | 2014 |
Fat-mass and obesity-associated gene polymorphisms and weight gain after risperidone treatment in first episode schizophrenia.
Topics: Adult; Alleles; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Antipsychotic Agents; Female; Genetic | 2014 |
[Idiopathic intracranial hypertension and obesity].
Topics: Adolescent; Antipsychotic Agents; Female; Headache; Humans; Obesity; Pseudotumor Cerebri; Risperidon | 2015 |
[Lipid spectrum changes and ECG in patients with paranoid schizophrenia in the course of therapy with atypical antipsychotics].
Topics: Adult; Antipsychotic Agents; Atherosclerosis; Benzodiazepines; Dibenzothiazepines; Electrocardiograp | 2015 |
Weight change during long-term treatment with lurasidone: pooled analysis of studies in patients with schizophrenia.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Body Mass Index; Delayed-Action Preparations; Dose-Re | 2015 |
Iron homeostasis during risperidone treatment in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit and Disruptive Behavior Disorders; Autism Spectr | 2015 |
Antipsychotic-induced metabolic effects in the female rat: Direct comparison between long-acting injections of risperidone and olanzapine.
Topics: Animals; Antipsychotic Agents; Benzodiazepines; Body Weight; Female; Half-Life; Olanzapine; Rats; Ra | 2015 |
Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children.
Topics: Adolescent; Antipsychotic Agents; Bacteroidetes; Child; Cross-Sectional Studies; Female; Firmicutes; | 2015 |
Association of orexin receptor polymorphisms with antipsychotic-induced weight gain.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Female; Genetic Association Studies; Humans | 2016 |
A pharmacogenomic study revealed an association between SLC6A4 and risperidone-induced weight gain in Chinese Han population.
Topics: Adult; Antipsychotic Agents; Asian People; China; Female; Follow-Up Studies; Genetic Association Stu | 2015 |
Risperidone-induced weight gain is mediated through shifts in the gut microbiome and suppression of energy expenditure.
Topics: Animals; Antipsychotic Agents; Energy Metabolism; Fecal Microbiota Transplantation; Female; Gastroin | 2015 |
The effects of antipsychotics on weight gain, weight-related hormones and homocysteine in children and adolescents: a 1-year follow-up study.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Body Weight; Child; Child, Preschool; Female; Fol | 2017 |
Metformin-Induced Type 1 Hypersensitivity in a Child with Antipsychotic-Induced Weight Gain.
Topics: Antipsychotic Agents; Bipolar Disorder; Child; Drug Hypersensitivity; Humans; Hypersensitivity, Imme | 2017 |
The influence of 5-HT(2C) and MDR1 genetic polymorphisms on antipsychotic-induced weight gain in female schizophrenic patients.
Topics: Adult; Antipsychotic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Benzodiazepine | 2008 |
Weight gain in children and adolescents during 45 weeks treatment with clozapine, olanzapine and risperidone.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Child; Clozapine; Female; Hospit | 2008 |
Risperidone alters food intake, core body temperature, and locomotor activity in mice.
Topics: Analysis of Variance; Animals; Antipsychotic Agents; Appetite Regulation; Body Temperature Regulatio | 2009 |
Antipsychotic-induced body weight gain: predictors and a systematic categorization of the long-term weight course.
Topics: Adolescent; Adult; Age Factors; Analysis of Variance; Antipsychotic Agents; Benzodiazepines; Body Ma | 2009 |
Belgian Schizophrenia Outcome Survey - results of a 2-year naturalistic study in patients stabilised on monotherapy with olanzapine, risperidone or haloperidol.
Topics: Adult; Antipsychotic Agents; Basal Ganglia Diseases; Belgium; Benzodiazepines; Brief Psychiatric Rat | 2009 |
Effect of lactational exposure of olanzapine on body weight of mice: a comparative study on neonates of both the sexes during post-natal development.
Topics: Animals; Animals, Newborn; Animals, Suckling; Antipsychotic Agents; Benzodiazepines; Body Weight; Fe | 2010 |
Weight gain and metabolic abnormalities during extended risperidone treatment in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Body Mass Index; Child; Cholesterol, HDL; Drug Administration Sche | 2009 |
Risperidone treatment increases CB1 receptor binding in rat brain.
Topics: Adiponectin; Animals; Antipsychotic Agents; Brain; Cyclohexanols; Dopamine Antagonists; Eating; Ghre | 2010 |
Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Composition; Child; Child, Pre | 2009 |
Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Composition; Child; Child, Pre | 2009 |
Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Composition; Child; Child, Pre | 2009 |
Cardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Composition; Child; Child, Pre | 2009 |
Leptin gene -2548G/A variants predict risperidone-associated weight gain in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Base Sequence; Child; DNA Primers; Female; Humans; Leptin; Male; P | 2009 |
Weight gain, obesity, and metabolic indices following a first manic episode: prospective 12-month data from the Systematic Treatment Optimization Program for Early Mania (STOP-EM).
Topics: Adult; Antimanic Agents; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Blood Glucose; Bod | 2010 |
Olanzapine, not resperidone, exacerbates beta-cell function and mass in ovariectomized diabetic rats and estrogen replacement reverses them.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Benzodiazepines; Blotting, Western; Cell Separation; | 2010 |
Effects of atypical antipsychotic drugs on body weight and food intake in dopamine D2 receptor knockout mice.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Benzodiazepines; Body Weight; Eating; Male; Mice; Mic | 2010 |
Estrogen replacement reverses olanzapine-induced weight gain and hepatic insulin resistance in ovariectomized diabetic rats.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Benzodiazepines; Diabetes Mellitus, Type 2; Eating; E | 2010 |
Second-generation antipsychotics cause weight gain in youths.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Child, Preschool; Dibenzothi | 2010 |
Dopamine receptor D2 gene is associated with weight gain in schizophrenic patients under long-term atypical antipsychotic treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Weight; Clozapine; Female; Genes; Genotype; Haplo | 2010 |
Metabolic effects of second-generation antipsychotics in bipolar youth: comparison with other psychotic and nonpsychotic diagnoses.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Biomarkers; Bipolar Disorder; Body Mass Index; Ch | 2010 |
Body weight gain induced by atypical antipsychotics: an extension of the monozygotic twin and sib pair study.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; Cross-Sectio | 2010 |
[Metabolic side effects of risperidone in early onset schizophrenia].
Topics: Adolescent; Age Factors; Antipsychotic Agents; Body Mass Index; Child; Female; Humans; Hypercholeste | 2010 |
Sex differences in the association of weight gain and risperidone efficacy among schizophrenic patients.
Topics: Adult; Female; Humans; Male; Middle Aged; Retrospective Studies; Risperidone; Schizophrenia; Sex Cha | 2010 |
A retrospective comparison of BMI changes and the potential risk factors among schizophrenic inpatients treated with aripiprazole, olanzapine, quetiapine or risperidone.
Topics: Age Factors; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Body Mass Index; Body Weight; Dibe | 2011 |
Overweight induced by chronic risperidone exposure is correlated with overexpression of the SREBP-1c and FAS genes in mouse liver.
Topics: Animals; Antipsychotic Agents; Cells, Cultured; Disease Models, Animal; Fatty Acid Synthases; Female | 2011 |
Influence of resting energy expenditure on weight gain in adolescents taking second-generation antipsychotics.
Topics: Adiponectin; Adolescent; Adolescent Development; Antipsychotic Agents; Basal Metabolism; Benzodiazep | 2011 |
Metformin: an effective attenuator of risperidone-induced insulin resistance hyperglycemia and dyslipidemia in rats.
Topics: Animals; Antipsychotic Agents; Blood Glucose; Disease Models, Animal; Dyslipidemias; Glyburide; Huma | 2011 |
Trabecular bone loss after administration of the second-generation antipsychotic risperidone is independent of weight gain.
Topics: Adiposity; Administration, Oral; Animals; Antipsychotic Agents; Bone Density; Bone Resorption; Cell | 2012 |
The effect of long-term use of risperidone on body weight of children with an autism spectrum disorder.
Topics: Antipsychotic Agents; Body Weight; Child; Child Development Disorders, Pervasive; Child, Preschool; | 2011 |
Factors associated with the prescribing of olanzapine, quetiapine, and risperidone in patients with bipolar and related affective disorders.
Topics: Academic Medical Centers; Adult; Antipsychotic Agents; Benzodiazepines; Bipolar Disorder; Depressive | 2011 |
Association study of brain-derived neurotrophic factor gene polymorphisms and body weight change in schizophrenic patients under long-term atypical antipsychotic treatment.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Brain-Derived Neurotrophic Factor; Clozapine; Female; | 2011 |
Bone remodeling, bone mass and weight gain in patients with stabilized schizophrenia in real-life conditions treated with long-acting injectable risperidone.
Topics: Adult; Antipsychotic Agents; Bone and Bones; Bone Density; Bone Remodeling; Case-Control Studies; Co | 2011 |
Improved outcomes following a switch to olanzapine treatment from risperidone treatment in a 1-year naturalistic study of schizophrenia patients in Japan.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Drug Resistance; Female; Humans; Income; Japan; Male; | 2012 |
Risperidone induced weight gain leading to benign intracranial hypertension.
Topics: Antipsychotic Agents; Bipolar Disorder; Female; Humans; Obesity, Morbid; Pseudotumor Cerebri; Risper | 2011 |
Rate of weight gain and cardiometabolic abnormalities in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Biomarkers; Blood Pressure; Body Mass Index; Child; Female; Humans | 2012 |
Association study of NRXN3 polymorphisms with schizophrenia and risperidone-induced bodyweight gain in Chinese Han population.
Topics: Adult; Antipsychotic Agents; Asian People; DNA; Female; Genotype; Haplotypes; Humans; Linkage Disequ | 2013 |
Peripheral injection of risperidone, an atypical antipsychotic, alters the bodyweight gain of rats.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Dose-Response Relationship, Drug; Eating; Leptin; Mal | 2002 |
Triglyceride, cholesterol and weight changes among risperidone-treated youths. A retrospective study.
Topics: Adolescent; Affective Disorders, Psychotic; Antipsychotic Agents; Attention Deficit and Disruptive B | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
The effects of novel antipsychotics on glucose and lipid levels.
Topics: Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL | 2002 |
Topiramate plus risperidone for controlling weight gain and symptoms in preschool mania.
Topics: Bipolar Disorder; Child, Preschool; Drug Therapy, Combination; Female; Fructose; Humans; Risperidone | 2002 |
A case series of eight aggressive young children treated with risperidone.
Topics: Aggression; Antipsychotic Agents; Brain; Child; Child Behavior Disorders; Child, Preschool; Electroe | 2002 |
Antipsychotic drugs and diabetes.
Topics: Antipsychotic Agents; Causality; Dementia; Diabetes Mellitus; Humans; Obesity; Risperidone; Weight G | 2003 |
Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapine; Dibenzothiazepines; Female | 2003 |
Weight gain in patients with schizophrenia treated with risperidone, olanzapine, quetiapine or haloperidol: results of the EIRE study.
Topics: Adult; Adverse Drug Reaction Reporting Systems; Ambulatory Care; Antipsychotic Agents; Benzodiazepin | 2003 |
Peripheral injection of risperidone, an atypical antipsychotic, alters the body weight gains of rats.
Topics: Animals; Antipsychotic Agents; Disease Models, Animal; Injections, Subcutaneous; Rats; Risperidone; | 2003 |
Olanzapine versus risperidone: weight gain and elevation of serum triglyceride levels.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Cholesterol; Cohort Studies; Female; | 2003 |
A 3-year naturalistic study of 53 preschool children with pervasive developmental disorders treated with risperidone.
Topics: Antipsychotic Agents; Autistic Disorder; Child; Child Development Disorders, Pervasive; Child, Presc | 2003 |
Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Clozapine; Dibenzothiazepines; Drug The | 2003 |
Risperidone-induced long-term weight gain in a patient with schizophrenia.
Topics: Adult; Humans; Male; Obesity; Risperidone; Schizophrenia; Selective Serotonin Reuptake Inhibitors; W | 2004 |
Effectiveness of antipsychotic treatments for schizophrenia: interim 6-month analysis from a prospective observational study (IC-SOHO) comparing olanzapine, quetiapine, risperidone, and haloperidol.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cognition Disorders; Diagnostic and Statistical Manual | 2004 |
Development of an atherogenic metabolic risk factor profile associated with the use of atypical antipsychotics.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Biomarkers; Carrier State; Cholesterol, HDL; Coronary | 2004 |
Discontinuation of risperidone and reversibility of weight gain in children with disruptive behavior disorders.
Topics: Antipsychotic Agents; Child; Child Behavior Disorders; Clinical Trials as Topic; Female; Humans; Mal | 2004 |
Atypical antipsychotics and weight gain in Chinese patients: a comparison of olanzapine and risperidone.
Topics: Adult; Antipsychotic Agents; Asian People; Benzodiazepines; Female; Hong Kong; Humans; Male; Obesity | 2004 |
Effects of the classical antipsychotic haloperidol and atypical antipsychotic risperidone on weight gain, the oestrous cycle and uterine weight in female rats.
Topics: Animals; Antipsychotic Agents; Dose-Response Relationship, Drug; Eating; Estrous Cycle; Female; Halo | 2004 |
Weight gain and new onset diabetes associated with olanzapine and risperidone.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Diabetes Mellitus; Female; Humans; Mal | 2004 |
The effectiveness of risperidone in the treatment of three children with feeding disorders.
Topics: Antipsychotic Agents; Anxiety Disorders; Child; Child Behavior Disorders; Feeding and Eating Disorde | 2004 |
Newer antipsychotic drugs and obesity in children and adolescents. How should we assess drug-associated weight gain?
Topics: Adolescent; Age Factors; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Child; Child, Presc | 2005 |
[Effect of atypical antipsychotics on metabolism].
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Cholesterol, HDL; Glucose Tolerance Tes | 2004 |
Pharmacological treatment and other predictors of treatment outcomes in previously untreated patients with schizophrenia: results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study.
Topics: Administration, Oral; Adult; Antipsychotic Agents; Benzodiazepines; Cohort Studies; Demography; Depr | 2005 |
Management of atypical antipsychotic-induced weight gain in schizophrenic patients with topiramate.
Topics: Adult; Anti-Obesity Agents; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weight; Chi | 2005 |
[No association of -1438G/A polymorphism in promoter region of 5-HT2A receptor gene with antipsychotic agent-induced weight gain].
Topics: Adult; Antipsychotic Agents; Chlorpromazine; Female; Gene Frequency; Genotype; Humans; Male; Polymer | 2005 |
Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Clozapine; Double-Blind Method; Female; Haloperidol; H | 2005 |
Drug-induced weight gain.
Topics: Anticonvulsants; Antipsychotic Agents; Humans; Obesity; Psychotropic Drugs; Risperidone; Valproic Ac | 2005 |
[Possible connection between ghrelin, resistin and TNF-alpha levels and the metabolic syndrome caused by atypical antipsychotics].
Topics: Antipsychotic Agents; Benzodiazepines; Carbohydrate Metabolism; Case-Control Studies; Clozapine; Dib | 2005 |
Psychosis in multiple sclerosis associated with left temporal lobe lesions on serial MRI scans.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Delusions; Excitatory Amino Acid Antagonists; Female; | 2006 |
No effect of atypical antipsychotic drugs on weight gain and risk of developing type II diabetes or lipid abnormalities among nursing home elderly patients with Alzheimer's disease.
Topics: Aged; Aged, 80 and over; Alzheimer Disease; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Di | 2006 |
Cross-sectional comparison of fasting lipids in normoglycemic patients with schizophrenia during chronic treatment with olanzapine, risperidone, or typical antipsychotics.
Topics: Adult; Aged; Antipsychotic Agents; Benzodiazepines; Blood Glucose; Body Mass Index; Cross-Sectional | 2006 |
Distinct endocrine effects of chronic haloperidol or risperidone administration in male rats.
Topics: Adipose Tissue; Animals; Antipsychotic Agents; Appetite; Body Weight; Corticosterone; Diabetes Melli | 2006 |
Excessive weight gain after remission of depression in a schizophrenic patient treated with risperidone: case report.
Topics: Adult; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Bulimia; Depression; Diabetes | 2006 |
Reversal of antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole: A case report.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Dyslipidemias; Female; Humans; Hyperprolactinemia; Obesit | 2006 |
Serum BDNF levels and weight gain in schizophrenic patients on long-term treatment with antipsychotics.
Topics: Antipsychotic Agents; Brain-Derived Neurotrophic Factor; Chronic Disease; Clozapine; Female; Humans; | 2007 |
Weight gain associated with clozapine, olanzapine and risperidone in children and adolescents.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Body Weight; Child; Clozapine; Female; Humans; Ma | 2007 |
No effect of dietary fat on short-term weight gain in mice treated with atypical antipsychotic drugs.
Topics: Adipose Tissue; Administration, Oral; Animals; Antipsychotic Agents; Benzodiazepines; Body Compositi | 2007 |
Glucose and lipid metabolism of long-term risperidone monotherapy in patients with schizophrenia.
Topics: Adiponectin; Adult; Antipsychotic Agents; Body Composition; Body Mass Index; Cholesterol, HDL; Femal | 2007 |
Psychotic disorders, eating habits, and physical activity: who is ready for lifestyle changes?
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapine; Dose-Response | 2007 |
The practical search.
Topics: Aggression; Antipsychotic Agents; Autistic Disorder; Child; Child Behavior Disorders; Evidence-Based | 2007 |
Illuminating the molecular basis for some antipsychotic drug-induced metabolic burden.
Topics: AMP-Activated Protein Kinase Kinases; Antipsychotic Agents; Benzodiazepines; Dibenzothiazepines; Hum | 2007 |
Do differences in atypical antipsychotics matter in routine practice? Medication switch from olanzapine and risperidone to amisulpride.
Topics: Adolescent; Adult; Amisulpride; Antipsychotic Agents; Benzodiazepines; Drug Utilization; Dyskinesia, | 2007 |
Weight gain in newly diagnosed first-episode psychosis patients and healthy comparisons: one-year analysis.
Topics: Adult; Affective Disorders, Psychotic; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Dose- | 2007 |
Dose-dependent acute excessive weight gain and metabolic changes in a drug-naive patient on risperidone are reversible with discontinuation: a case report.
Topics: Adult; Antipsychotic Agents; Dose-Response Relationship, Drug; Female; Humans; Risperidone; Schizoph | 2007 |
Disruption of the neurokinin-3 receptor (NK3) in mice leads to cognitive deficits.
Topics: Age Factors; Animals; Antipsychotic Agents; Avoidance Learning; Behavior, Animal; Clozapine; Cogniti | 2007 |
Observed clinical and health services outcomes in pediatric inpatients treated with atypical antipsychotics: 1999-2003.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Brief Psychiatric Rating Scale; Child; Child, Pre | 2007 |
Orally disintegrating olanzapine induces less weight gain in adolescents than standard oral tablets.
Topics: Administration, Oral; Adolescent; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Body Weigh | 2007 |
Risperidone-induced polydipsia and polyphagia associated with galactorrhea, abdominal pain, and rapid weight gain in an adolescent Hispanic female.
Topics: Abdominal Pain; Adolescent; Bipolar Disorder; Drinking Behavior; Feeding Behavior; Female; Galactorr | 2007 |
'Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation'.
Topics: Antipsychotic Agents; Clinical Trials as Topic; Conflict of Interest; Data Interpretation, Statistic | 2008 |
Investigation into the influence of a high fat diet on antipsychotic-induced weight gain in female rats.
Topics: Abdominal Fat; Animals; Antipsychotic Agents; Benzodiazepines; Dietary Fats; Drinking Behavior; Feed | 2008 |
Weight gain due to long term antipsychotic treatment of persistent mental disorders.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Female; Follow-Up Studies; Humans; Is | 2008 |
Risperidone treatment of borderline personality disorder assessed by a borderline personality disorder-specific outcome measure: a pilot study.
Topics: Adult; Antipsychotic Agents; Borderline Personality Disorder; Dose-Response Relationship, Drug; Drug | 2008 |
Risperidone treatment of children and adolescents with chronic tic disorders: a preliminary report.
Topics: Adolescent; Antipsychotic Agents; Attention Deficit Disorder with Hyperactivity; Child; Chronic Dise | 1995 |
Weight gain associated with risperidone.
Topics: Adolescent; Antipsychotic Agents; Female; Humans; Male; Risperidone; Schizophrenia, Paranoid; Weight | 1996 |
Risperidone, weight gain, and bulimia nervosa.
Topics: Antipsychotic Agents; Bulimia; Child; Dose-Response Relationship, Drug; Female; Humans; Risk Factors | 1997 |
Weight gain with risperidone.
Topics: Antipsychotic Agents; Humans; Risperidone; Weight Gain | 1997 |
Risperidone in children and adolescents with pervasive developmental disorder: pilot trial and follow-up.
Topics: Adolescent; Anger; Child; Child Development Disorders, Pervasive; Dopamine Antagonists; Female; Huma | 1997 |
Diet and the atypical neuroleptics.
Topics: Antipsychotic Agents; Child; Feeding and Eating Disorders; Food-Drug Interactions; Humans; Male; Ris | 1998 |
Brief report: two-year control of behavioral symptoms with risperidone in two profoundly retarded adults with autism.
Topics: Adult; Autistic Disorder; Compulsive Behavior; Dopamine Antagonists; Female; Gynecomastia; Humans; I | 1999 |
Weight gain and antipsychotic medications.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Obesity; Olanzapine; Pirenzepine; Risperid | 1999 |
Weight gain: side effect of atypical neuroleptics?
Topics: Adolescent; Adult; Adverse Drug Reaction Reporting Systems; Antipsychotic Agents; Body Mass Index; C | 1999 |
Risperidone-induced hepatotoxicity in children and adolescents? A chart review study.
Topics: Adolescent; Alanine Transaminase; Antipsychotic Agents; Aspartate Aminotransferases; Child; Female; | 1999 |
Relative weight gain among antipsychotics.
Topics: Antipsychotic Agents; Benzodiazepines; Clozapine; Humans; Obesity; Olanzapine; Pirenzepine; Risperid | 1999 |
Risperidone in anorexia nervosa.
Topics: Adult; Anorexia Nervosa; Antipsychotic Agents; Child; Delusions; Dose-Response Relationship, Drug; F | 2000 |
Risperidone-associated weight gain in children and adolescents: a retrospective chart review.
Topics: Adolescent; Antipsychotic Agents; Body Mass Index; Child; Female; Humans; Male; Retrospective Studie | 2000 |
Weight gain with risperidone among patients with mental retardation: effect of calorie restriction.
Topics: Aggression; Antipsychotic Agents; Diet; Dose-Response Relationship, Drug; Energy Intake; Humans; Int | 2001 |
Weight gain over 4 months in schizophrenia patients: a comparison of olanzapine and risperidone.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Female; Follow-Up Studies; Humans; Ma | 2001 |
Weight gain and antipsychotic medication: differences between antipsychotic-free and treatment periods.
Topics: Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapine; Drug Administration Schedu | 2001 |
Weight gain associated with olanzapine and risperidone in adolescent patients: a comparative prospective study.
Topics: Adolescent; Antipsychotic Agents; Benzodiazepines; Female; Haloperidol; Humans; Male; Mental Disorde | 2002 |
Mechanisms of weight gain induced by antipsychotic drugs.
Topics: Animals; Antidepressive Agents, Second-Generation; Antipsychotic Agents; Appetite; Dopamine Antagoni | 2002 |
Extreme weight gain in a youth with schizophrenia: risk/benefit considerations.
Topics: Adolescent; Adult; Antipsychotic Agents; Benzodiazepines; Body Mass Index; Clozapine; Follow-Up Stud | 2002 |